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1 Introduction 
Pathogenic bacteria possess different virulence factors, e.g. to evade the immune 
system or to efficiently colonize a host. Bacterial toxins are mostly essential virulence 
factors of the respective bacterium.  
One of the first toxins, which were identified was the diphtheria toxin of Corynebacterium 
diphtheriae (Roux & Yersin, 1888). The identification of many other important toxins 
followed. Of particular interest are toxins functioning as biological weapons, like anthrax 
of Bacillus anthracis, but also toxins used in the pharmaceutical industry like botulinum 
toxin of Clostridium botulinum. Furthermore, inactivated bacterial toxins are commonly 
used as vaccines, stimulating the host’s immune system to develop immunity against the 
respective bacterium. 
This thesis has a focus on an A-B toxin, the cytotoxic necrotizing factor CNFY, which is 
expressed by the enteropathogen Yersinia pseudotuberculosis, a model organism 
widely applied in fundamental research. 
1.1 The genus Yersinia 
Yersiniae are gram-negative rod shaped bacteria, which facultatively grow in aerobic 
conditions and are psychrotolerant. They are able to grow at 4°C as well as 43°C with an 
optimum between 20 - 30°C. At moderate temperatures outside the host they are mostly 
motile and lose this feature inside the host at 37°C (Kapatral & Minnich, 1995). 
The genus Yersinia belongs to the group of Enterobacteriaceae and was first described 
by the Swiss tropical physician Alexandre Yersin in 1894. He was able to isolate the 
most known species Y. pestis out of plague-spots of human dead bodies (Treille & 
Yersin, 1894). In total, 18 species belong to the genus Yersinia (Savin et al., 2014), but 
only three of them are human pathogens, the above mentioned Y. pestis and two 
enteropathogenic species, namely Y. enterocolitica and Y. pseudotuberculosis (Carniel 
et al., 2006; Chen et al., 2010). Transmission of all human pathogenic Yersinia strains 
occurs by animals. These infections are referred to as zoonoses. Furthermore, isolates 
of these pathogens have in common a tropism for lymphatic tissue. Within these tissues 
the bacteria are able to replicate efficiently and escape or inhibit the innate immune 
response of the host (Grosdent et al., 2002; Heesemann, 1994; Naktin & Beavis, 1999).  
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Up to now plague is one of the most dangerous infectious diseases and still not 
eradicated. New infections with Y. pestis are reported regularly, e.g. epidemics in 
Madagascar or even in the United States of America due to persistance of the bacteria 
in rodents. Y. pestis is transmitted to the host by infected fleas, which serve as vectors. 
The bite induces the regurgitation of the contaminated stomach content of the flea into 
the bloodstream of the host (Hinnebusch, 1997). Rodents often show no symptoms of 
disease, whereas a Y. pestis infection in humans leads to bubonic or pneumonic plague. 
These diseases cause rapid death of the patient without antibiotic treatment (McCrumb 
et al., 1953; Quenee & Schneewind, 2009).  
In comparison, infections by the enteropathogenic strains, Y. enterocolitica or 
Y. pseudotuberculosis, are less dangerous. These bacteria are transmitted via 
contaminated food or water, e.g. raw meet or milk (Lynch et al., 2006). An infection with 
these species induce Yersiniosis, a variety of gut-associated diseases like enteritis and 
diarrhea or it can rarely cause autoimmune diseases like erythema nodosum or reactive 
arthritis (Lamps, 2003; Lamps et al., 2003). Yersiniosis is the third most abundant 
bacterial zoonotic infectious disease in Germany and the European Union (Rosner et al., 
2010). With an intact immune system of the host, these infections are self limiting and do 
not require antibiotic treatment (Abdel-Haq et al., 2000).  
Although these three human pathogenic species belong to the same genus, they vary 
significantly in the type of transmission (see above). The genetically higher degree of 
relationship is between Y. pseudotuberculosis and Y. pestis. It could be shown that 
Y. pestis evolved out of Y. pseudotuberculosis about 1,500 – 20,000 years ago 
(Achtman et al., 1999). Nevertheless, these two species show important differences in 
the progress and severity of disease. Responsible therefore are differences in the 
genome, mostly the extra chromosomal DNA.  
All human pathogenic strains harbour a very similar virulence plasmid with a size of 
around 70 kb, which is needed for infection. However, there are 13% of genes inactive in 
Y. pestis, of which most of them are important for a successful Y. pseudotuberculosis 
infection (Chain et al., 2004). For example the gene yadA (Yersinia adhesin A), encoded 
on the virulence plasmid, is needed for adhesion to and invasion into the eukaryotic cells 
by the enteropathogenic strains, whereas it is inactive in the Y. pestis strains (Neyt et al., 
1997). In addition to the virulence plasmid pYV, which is harboured by all pathogenic 
strains, Y. pestis carries two other plasmids, pFRA (100 kb) and pPLA (9.5 kb). These 
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two extrachromosomal elements are of high importance for the infection, because they 
are needed for the survival in the flea and the transmission via the blood of the host 
(Sebbane et al., 2009).  
The enteropathogenic species consist of many different serotypes. The two species 
show a weak sequence-identity of around 50% in the genome, and differ in their gene 
expression pattern (Brenner et al., 1976). The Y. enterocolitica strains are classified in 
biogroups based on biochemical features and in serogroups, depending on their O-
antigen immune reactivity (Brenner et al., 1976). Many of these serogroups are known to 
induce diseases in humans, but the most common serogroup in Germany with about 
90% of all Y. enterocolitica infections is the serogroup O:3/biotype 4 (Rosner et al., 
2010). The Y. pseudotuberculosis strains are categorized in 21 serogroups, whereas the 
majority of diseases are caused by the serogroups O:1 and O:3 (Dube, 2009). Several 
differences among the Y. pseudotuberculosis strains were described. A few isolates e.g. 
carry the intact gene for the cytotoxic necrotizing factor cnfY, whereas this gene is 
mutated in other sequenced Y. pseudotuberculosis strains (Lockman et al., 2002).  
Due to their ability to colonize and invade different hosts, enteropathogenic Yersinia 
species are used for fundamental research on the infection mechanism (e.g. in mice). 
The detailed path of infection of the enteric species is described below. 
1.2 Pathogenesis of enteropathogenic Yersinia strains 
The uptake of enteropathogenic Yersinia species takes place by ingestion of 
contaminated food or water. Raw or undercooked pork is the main source of infection, 
because many pigs are colonized by Y. enterocolitica without showing any symptoms of 
disease (Fosse et al., 2009; Fredriksson-Ahomaa et al., 2006). Additionally, the bacteria 
are able to grow at 4°C in the fridge. 
Infection with both enteric Yersinia species is considered as biphasic, divided into early 
and late infection phase. The early phase starts with the uptake of the bacteria in the 
human body, where an immediate shift in temperature and pH occurs, to which the 
bacteria need to adjust rapidly. These changes in the environment of the bacteria lead to 
the expression of stress adaption and virulence factors. The coding genes are located 
both on the chromosome and on the virulence plasmid pYV (Pepe et al., 1994). This 
expression is important for the bacteria to pass through the stomach with its acidic pH 
(Young et al., 1996). Subsequently, the bacteria reach the small intestine and the 
terminal ileum, where the Yersinia are able to adhere to specialized enterocytes, the 
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microfold cells (M-cells) and invade therein (see Figure 1.2.1). Up to this step the 
bacteria are motile, but lose this characteristic during the progress of infection.  
The M-cells belong to the follicle-associated epithelial layer (FAE) of the gut, which 
covers the Peyer’s patches (PP). These cells have a flat form and fewer, wider and less 
pronounced microvilli compared to the absorptive enterocytes of the gut (Grutzkau et al., 
1990). M-cells possess β1-integrins, which are important receptors for the adhesion, 
invasion and ultimately the induced transcytosis of Yersinia through the gut epithelial 
layer. They initiate the process of transcytosis, by recognizing antigens on their apical 
side, take them up in vesicles and transport them to their basolateral side into the PP 
(Neutra et al., 1999). With the transcytosis of the enteric Yersinia, the late infection 
phase starts. 
The bacteria are able to colonize the PP, which leads to a proinflammatory response 
characterized by the infiltration of phagocytes (Grutzkau et al., 1990) and the release of 
proinflammatory cytokines (see 1.3). To evade or protect themselves against the 
ongoing immune response, Yersinia possess different virulence factors, e.g. the Yersinia 
outer proteins (Yops) (see 1.4.2), which expression is associated with the late infection 
phase (Cornelis & Wolf-Watz, 1997; Revell & Miller, 2001).  
In the next step, the bacteria leave the PP and spread via the lymphatic system to the 
mesenteric lymph nodes (MLNs). From there they are able to spread to the systemic 
organs liver, spleen and kidneys. It is also believed, that the enteropathogenic Yersinia 
species can, in some cases, travel directly from the small intestine through the blood 
stream to the systemic organs like liver and spleen and bypass the MLNs (Autenrieth & 
Firsching, 1996). In the organs, Yersinia replicates mostly extracellularly, which leads to 
the formation of microcolonies and abscesses (Autenrieth & Firsching, 1996; Isberg & 
Van Nhieu, 1994). Additionally, there is evidence that some strains of the 
enteropathogenic species are able to survive and even replicate within the macrophages 
(Brzostek et al., 2003; Cavanough & Randall, 1959; Pujol & Bliska, 2005; Tsukano et al., 
1999). This would be another factor helping the bacteria to hide and thereby evade their 
elimination by the host’s immune system. 
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Figure 1.2.1: Infection route of enteropathogenic Yersinia species through the gut. 
The yersiniae are ingested by contaminated food or water, reach the small intestine and transcytose via M-
cells, localized in the terminal ileum. After the transcytosis mediated by β1-integrin receptors, the bacteria 
reach the Peyer’s patches, travel through the lymphatic system and reach the MLN. From there they 
spread to the systemic organs liver and spleen. It is assumed that some of the bacteria can bypass the 
MLNs and reach the systemic organs directly from the PP via the blood stream (Autenrieth & Firsching, 
1996). 
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1.3 Enteropathogenic Yersinia and the host’s immune response 
All enteropathogenic bacteria come into contact with the largest and most complex part 
of the host immune system, the intestinal immune system. It has evolved a local and 
systemic tolerance for the commensals, the oral tolerance, in which the M-cells play a 
key role (Strobel & Mowat, 1998). This differentiation between harmful pathogenic and 
harmless commensal bacteria is highly important. If the immune system overshoots 
constantly with commensal bacteria, inflammatory disorders like coeliac disease or 
Crohn’s disease may occur. If the immune system does not react properly in case of 
invading pathogens, an infection with severe disease symptoms can result. 
A characteristic for an enteropathogenic bacterium is its ability to invade into or 
transpass the gut epithelial barrier. By invading in the small intestine, the pathogenic 
bacteria come into contact with the largest proportion of immune cells in the gut. These 
cells belong to the gut-associated lymphoid tissue (GALT), which is divided into two 
parts, the lymphocytes in the epithelial layer and lamina propria (LP) and the 
lymphocytes in the PP. Enteropathogenic yersiniae are known to enter through the M-
cells in the terminal ileum and reach the PP as described. The PP are formed of large 
B cell follicles (60% B cells), intervening T cell areas (25% T cells), dendritic cells (DCs) 
(10%), and macrophages and polymorphonuclear leukocytes (PMNs) (together < 5%) 
(Jung et al., 2010). The entry of the yersiniae into the PP leads to the induction phase of 
the innate immune response of the host, as described in detail below (see Figure 1.3.1).  
At the early stage of an infection with enteropathogenic Yersinia species, the bacterial 
numbers decrease significantly, probably due to the fast influx of macrophages and 
neutrophils in answer to the penetration. This was especially shown after an i.v. injection, 
mimicking a systemic infection of the bacteria (Conlan, 1997). These cell types and also 
the DCs are very important during this step of the host’s immune response, because of 
their phagocytic behaviour and their release of proinflammatory cytokines. The release is 
triggered by the activation of the Toll-like receptors on these cell types upon contact with 
the pathogen. It was shown for enteropathogenic yersiniae, that the binding of the 
invasin to the β1-integrins of enterocytes can additionally trigger the release of 
proinflammatory cytokines (Kampik et al., 2000; Schulte et al., 1996). Whether other 
factors like LPS or YadA also contribute to the recruitment of the immune cells is still 
unclear. 
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Figure 1.3.1: Overview of the cells of the innate and adaptive immunity (Dranoff, 2004).  
The innate immunity forms the first line of defence against an invading bacterium. In contrast, the adaptive 
immunity is slower, but more specific.  
 
In the PP, DCs are mainly responsible for the antigen sampling. They take up the 
bacteria and act as antigen presenting cells (APCs) for T cells. However, also 
macrophages and especially PMNs are recruited to the PP and defend the host against 
the pathogen by phagocytizing the bacteria. Upon a Yersinia infection, the infiltrating 
immune cells as well as the enterocytes (Eckmann et al., 1995) have been shown to 
produce proinflammatory cytokines, especially IL-1 (Autenrieth & Firsching, 1996; 
Beuscher et al., 1992), leading to the recruitment and maturation of additional 
phagocytes. One day after an oral infection of mice, microabscesses and residing 
bacteria can be detected in the PP (Autenrieth et al., 1996; Hanski et al., 1989).  
In the next step, the bacteria exit the PP through the lymphatics or the blood and reach 
the MLNs, the largest lymph nodes of the human body, or the systemic organs (see 1.2), 
respectively. It has been suggested that some phagocytes may also be involved in the 
dissemination of yersiniae from the PP (Autenrieth et al., 1996). These cells are 
proposed to function as vehicles transporting the intracellular bacteria through the blood 
like trojan horses.  
Different cytokines, mainly produced by macrophages, e.g. IL-12 or IL-18 lead to the 
stimulation of NK cells and T cells and the antigen presentation of the APCs, which 
constitutes the cross point between the innate and adaptive immune response. It is 
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known that the concerted activities of the adaptive immune cells, T helper cells (CD4+), 
and cytotoxic T cells (CD8+), and the innate immune cells, the activated macrophages 
are required to control a Yersinia infection efficiently. T cells control the infection (1) with 
their ability to kill infected cells, (2) by helping macrophages to eliminate the internalized 
bacteria, and (3) by activation of B cells for antibody production (Autenrieth et al., 1992, 
1993a; Bohn & Autenrieth, 1996). But, particularly the T cell activated macrophages 
have been shown to kill enteric Yersinia species efficiently (Autenrieth & Heesemann, 
1992; Zhang & Bliska, 2005).  
Even though the enterophathogenic Yersinia species harbour defence mechanisms to 
evade the host immune system, infections in humans are mostly self-limiting after 
triggering the immune response, and end with a complete clearance of the bacteria. 
However, in small children, elderly persons, immunosuppressed patients or in conditions 
involving iron overload (Adamkiewicz et al., 1998; Chiu et al., 1986; Autenrieth et al., 
1993a, b), bacteria are able to evade the immune system by injecting different effector 
proteins into the immune cells and impairing the complement system with virulence 
factors (see 1.4). 
1.4 Virulence factors of enteropathogenic Yersinia 
The virulence factors of the enteropathogenic Yersinia species are encoded both on the 
chromosome as well as on the virulence plasmid pYV (Portnoy & Falkow, 1981). In 
recent years, it was possible to sequence and annotate whole genomes of different 
Yersinia strains. Thereby, new virulence genes and partially their mode of action in the 
host-pathogen interaction have been identified (Thomson et al., 2006). 
The virulence gene expression is tightly regulated and influenced by temperature, the pH 
or nutrients (Pepe et al., 1994). The regulation occurs on the transcriptional as well as on 
the post-transcriptional level and involves different regulators (Darwin & Miller, 1999; 
Gort & Miller, 2000; Young & Miller, 1997). 
The main pathogenicity factors for infection and resistance against the innate immune 
system of the host are encoded on the virulence plasmid (Revell & Miller, 2001). The 
gene products are categorized in four groups:  
1. Secreted antiphagocytic effector proteins (Yops)  
2. Ysc proteins of the type-III-secretion system (T3SS) involved in the production 
and secretion of the Yops 
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3. The Yersinia adhesin A (YadA), necessary for the bacteria’s adhesion and 
invasion to/into the eukaryotic cell 
4. The regulatory protein LcrF of Y. pseudotuberculosis and Y. pestis or VirF (98% 
sequence-identity) of Y. enterocolitica (Hoe et al., 1992) 
Without the virulence plasmid, the pathogenicity of the Yersinia species is massively 
diminished and the bacteria are no longer able to reach the systemic organs (Cornelis et 
al., 1998; Straley et al., 1993). 
In addition to the plasmid-encoded virulence factors, three other important factors are 
encoded on the chromosome: 
1. The attachment and invasion locus (ail), coding for a 17 kDa integral outer 
membrane protein 
2. The pH6 antigen, which forms a 16 kDa pilus like structure 
3. The invA gene, coding for the invasin 
The Ail protein has been shown to play four different roles in the Yersinia infection 
process. It is important for the serum resistance of the bacteria, the adhesion to and 
internalization into eukaryotic cells, the Yop translocation into the host cells and it is able 
to inhibit the inflammatory response of the host (Bartra et al., 2008; Felek & Krukonis, 
2009; Hinnebusch et al., 2011; Kolodziejek et al., 2007, 2010; Tsang et al., 2010). Ail is 
expressed anaerobically at 37°C in both enteropathogenic species. However, no 
difference in the virulence was observed in an isogenic ail mutant strain for the 
enteropathogenic species (Isberg, 1996; Wachtel & Miller, 1995). In contrast, an 
isogenic Y. pestis ail mutant strain was attenuated in virulence (Hinnebusch et al., 2011). 
The pH6 antigen was shown to promote adhesion to the host cell, the induction of 
hemagglutination, and possesses anti-phagocytic properties towards macrophages. 
Nevertheless, because of its expression profile at 37°C and low pH, it is believed that it 
supports survival of the bacteria in the phagolysosome during the late infection phase 
(Huang & Lindler, 2004; Yang & Isberg, 1997; Yang et al., 1996).  
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1.4.1 Invasins and adhesins 
The virulence factors inducing adhesion (adhesins) to and internalization (invasins) into 
the host cells are of high importance for the infection of enteropathogenic Yersinia 
strains. 
Yersiniae exploit the zipper mechanism to initiate their invasion into the host cell (see 
Figure 1.4.1) (Finlay & Cossart, 1997; Galan, 1994). The initial contact to the eukaryotic 
cell is ensured by adhesins. Two of them are mainly needed, YadA and especially InvA 
(see below). The adhesion activates signaling pathways in the host cell. Subsequently, 
cytoskeletal actin rearrangements are induced and thereby the internalization of the 
bacterium into membrane-bound vacuoles is initiated, forming the bacterial phagosome.  
 
Figure 1.4.1: Invasion of enteropathogenic Yersinia by InvA induced zipper mechanism.  
Schematic description of the zipper mechanism. Yersinia binds to the M-cell receptors (β1-integrins) in the 
intestine with invasin by high affinity binding. This leads to actin cytoskeleton rearrangements and the 
formation of membrane protrusions. The bacterium is taken up by the cell into a bacterial phagosome 
(Isberg, 1989). 
 
1.4.1.1 Invasin 
Invasin (InvA) is the most important invasion protein of the enteropathogenic Yersinia 
species. This protein is involved in both the adhesion to and the invasion into the M-cells 
of the gut epithelial layer (Dersch & Isberg, 2000). Its expression in non-invasive 
Escherichia coli enables these bacteria to invade into human epithelial cells (HEp-2) 
(Isberg & Falkow, 1985; Miller & Falkow, 1988). The invA gene expression in vitro is 
temperature-, pH-, and growth phase-dependent. Maximal expression is obtained at 
25°C during late stationary phase in nutrient rich medium with low osmolarity (Isberg et 
al., 1988; Pepe et al., 1994). 
invasin 
M-cell 
β1-integrin 
M-cell M-cell 
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This 108 kDa outer membrane protein consists of an N-terminal outer membrane 
anchoring domain and five β-barrel domains in Y. pseudotuberculosis (see Figure 1.4.2). 
The invasin binds to β1-integrins anchored in the host cell membrane and thereby leads 
to a clustering of these receptors. Responsible for the binding are the head domains D4 
and D5 (Clark et al., 1998; Tran Van Nhieu & Isberg, 1993). After binding, clustering of 
the integrins is induced through multimerization of invasin via domain D2 (Dersch & 
Isberg, 1999). This leads to the initiation of signaling cascades in the host cell, which 
trigger internalization (zipper mechanism) of the bacteria (see Figure 1.4.1) (Dersch & 
Isberg, 1999, 2000).  
 
Figure 1.4.2: The invasin (InvA) structure of Y. pseudotuberculosis. 
InvA consists of 5 domains, with domains D4 and 5 responsible for the β1-integrin binding. Domain 2 of 
Y. pseudotuberculosis leads to a multimerization of InvA, which in turn induces a clustering of the β1-
integrin receptors (Dersch & Isberg, 1999). 
 
1.4.1.2 YadA 
The virulence factor YadA is another important adhesin of enteropathogenic yersiniae. It 
binds to proteins of the extracellular matrix (ECM), e.g. laminin or collagen and thereby 
enables the bacterium to adhere to the host cell (Flügel et al., 1994; Heise & Dersch, 
2006; Tertti et al., 1992). 
The yadA gene encodes for an outer membrane protein, which is exclusively expressed 
at 37°C (Barocchi et al., 2005; Linke et al., 2006). Depending on the Yersinia species, it 
possesses an atomic mass of around 200 - 240 kDa. The trimeric protein has a „lollipop“ 
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like structure and covers the surface of the bacterium like a capsule (Hoiczyk et al., 
2000).  
Structure analyses revealed that YadA from Y. pseudotuberculosis carries an additional 
domain at its N-terminus, which is absent in Y. enterocolitica. This domain of YadA 
induces, besides adhesion, also the invasion of Y. pseudotuberculosis into the 
eukaryotic cell, by binding to the natural ligand of the α5β1-integrin receptors, fibronectin. 
Furthermore, YadA of Y. enterocolitica preferentially binds to collagen and laminin of the 
ECM (Heise & Dersch, 2006). 
 
Figure 1.4.3: The virulence factor YadA. 
A: Schematic illustration of the trimeric protein YadA, consisting of an anchor-, stalk-, neck-, and head-
domain (Linke et al., 2006). 
B: Electron microscopic picture of a bacterium with the capsule like arranged YadA proteins. Bar indicates 
100 nm (Hoiczyk et al., 2000). 
 
YadA of both species also induces an inflammatory response by triggering the 
expression of the proinflammatory cytokine interleukin 8 (IL-8) (Eitel et al., 2005; Schmid 
et al., 2004). An additional function of the protein is the protection of the bacterium 
against the immune system of the host. It binds components of the complement system, 
like the factor H, and inhibits thereby the opsonation of the bacterium preventing its 
elimination (Balligand et al., 1985; Biedzka-Sarek et al., 2008; Kirjavainen et al., 2008; 
Pilz et al., 1992). 
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1.4.2 The Yop virulon 
The T3SS forms a syringe like structure with a needle surface to inject effector proteins 
into host cells (Kudryashev et al., 2013). The genes encoding the T3SS are organized in 
different operons on the pYV by their function, whereas the translocated Yops are 
distributed all over the plasmid (Cornelis, 1998, 2002a; Pujol & Bliska, 2005). The 
expression of this system and therefore the injection of the effector proteins is dependent 
on temperature and Ca2+ ionic concentration, conditions present in the surroundings 
during infection. Moreover, it is activated by the transcriptional activator low calcium 
response F (LcrF), which in turn is repressed by the global virulence regulator Yersinia 
modulator A (YmoA) at conditions found outside the host (25°C). The seven translocated 
Yop proteins so far known are exotoxins, named YopE, YopH, YopJ/P, YopK/Q, YopM, 
YopO/YpkA and YopT. They help the bacterium to manipulate the host cell functions, 
e.g. the cytokine production or the actin dynamics, to prevent their elimination by the 
host immune system, mostly by preventing phagocytosis (see Figure 1.4.5) (Cornelis, 
2002a; Viboud & Bliska, 2005).  
The T3SS of Yersinia consists of three parts, (1) the pore forming complex, (2) the 
needle structure and (3) the basal body (see Figure 1.4.4). For the assembly of the basal 
body, multi-ring structures consisting of different Ysc proteins are integrated in the outer- 
and inner-membrane of the bacterium. At first, YscC oligomerises and forms the outer-
membrane ring, which stretches into the periplasm (Diepold et al., 2010; Koster et al., 
1997). In the next step, the inner-membrane ring is formed by YscD, which connects the 
inner- and outer-membrane rings (Diepold et al., 2010; Ross & Plano, 2011; Spreter et 
al., 2009). Subsequently, YscJ oligomerises and completes the inner-membrane ring 
(Yip et al., 2005). Furthermore, a cytosolic energy producing ATPase, YscN is recruited 
and surrounded by the proteins YscK and YscL (Blaylock et al., 2006). In the next step, 
YscQ assembles at the cytoplasmic site of the T3SS (Diepold et al., 2010). Finally, the 
export machinery is formed, containing the proteins YscRSTUV which are positioned in 
the inner-membrane ring.  
The secretion needle formed by the protein YscF is secreted through the basal body. 
YscI is positioned first and seems to allow the crossing of substrates through the inner 
membrane (Allaoui et al., 1995; Marlovits et al., 2006). YscF is translocated through the 
YscI channel and polymerizes to form the needle structure (Diepold et al., 2012). The 
length of the needle varies from ~41 nm in Y. pestis to ~58 nm in Y. enterocolitica and 
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possesses an inner diameter of ~2 - 3 nm (Hoiczyk & Blobel, 2001; Journet et al., 2003; 
Kubori et al., 2000). YscP appears to regulate the length of the secretion needle (Journet 
et al., 2003; Payne & Straley, 1999; Stainier et al., 2000). The substrate specificity of the 
needle seems to be determined by YscU, which possesses an inner-membrane 
anchoring- and a cytosolic-domain (Allaoui et al., 1994; Edqvist et al., 2003). YscP was 
shown to induce the autocleavage of YscU after completion of the needle assembly 
(Agrain et al., 2005; Lavander et al., 2003; Sorg et al., 2007). This step is needed to 
continue the secretion of the proteins for the formation of the pore complex and the 
proper secretion of the Yop proteins (Björnfot et al., 2009; Riordan & Schneewind, 
2008). 
 
The Yop effector proteins should ideally be released upon host cell contact, which can 
also be mimicked in vitro by depletion of calcium in the medium (Lee et al., 1998; Yother 
& Goguen, 1985). To prevent a premature release of the effectors, the needle is blocked 
for the effector Yop proteins by a complex consisting of YopN, TyeA, YscB and SycN, 
which is called the calcium plug (Forsberg et al., 1991). In the next step, LcrV is secreted 
and forms a needle tip (Mueller et al., 2005), at which the pore complex - consisting of 
YopD and YopB - is positioned. These two proteins (YopD/B) are able to insert 
Figure 1.4.4: The type III secretion system of Yersinia (Dewoody et al., 2013).  
Schematic model of the T3SS of Yersinia. Colours indicate the different structures and functions. Blue: 
components of the C- ring and ATPase in the bacterial cytoplasm; orange: proteins of the export 
apparatus; purple: scaffold proteins of membrane ring structures; green: rod and needle components; red: 
pore complex. 
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themselves into the host cell membrane to form a translocation pore (Hakansson et al., 
1993, 1996a; Neyt & Cornelis, 1999; Rosqvist et al., 1995). With the assembly of YopD 
and YopB, the complex T3SS is completed and able to inject the effector Yops into the 
host cell upon cell contact. Most of these effector proteins require their own chaperone 
for correct folding and guidance to the secretion needle, but are injected into the cytosol 
of the host cell on their own. 
Seven cytotoxic effector proteins are translocated into phagocytes, interfering with cell 
signaling pathways and preventing phagocytosis (Viboud & Bliska, 2005). YopE, YopO 
and YopT belong to the group of bacterial toxins interacting with Rho-GTPases (see 1.7) 
(Barbieri et al., 2002). YopE is mimicking the Guanine-exchange proteins (GAPs) of the 
small Rho-GTPases RhoA, Rac1 and Cdc42, leading to a continuous hydrolysis of GTP 
(Von Pawel-Rammingen et al., 2000). YpkA of Y. pseudotuberculosis and YopO, the 
homolog in Y. enterocolitica are serine/threonine kinases binding to RhoA and Rac1 
(Viboud & Bliska, 2005; Wong & Isberg, 2005). This binding leads to the 
autophosphorylation of the Yop, which then controls the eukaryotic cell rounding and 
blocks the phagocytosis of the bacterium (Galyov et al., 1993; Grosdent et al., 2002; 
Hakansson et al., 1996b). YopT forms a cysteine protease, which leads to the removal 
of the GTPases RhoA, Rac, and Cdc42 from the membrane of the cell (Shao et al., 
2003), causing the disruption of actin fibres, cell rounding, and inhibition of the bacterial 
internalization (Cornelis, 2002b; Viboud & Bliska, 2005). 
YopH is a tyrosine phosphatase that blocks actin cytoskeletal dynamics, thus leading to 
the inhibition of phagocytosis by immune cells (Grosdent et al., 2002). It was shown to 
dephosphorylate mostly proteins of the focal adhesion complex (Black & Bliska, 1997; 
Bliska et al., 1991; Grosdent et al., 2002; Guan & Dixon, 1990; Persson et al., 1997). 
YopJ of Y. pseudotuberculosis and the Y. enterocolitica homolog YopP, seem to be 
particularly important in the defence against the adaptive immune system of the host 
(Viboud & Bliska, 2005). YopP/J are cysteine proteases inhibiting different signaling 
pathways in the host cell by binding to the mitogen-activated protein kinase (MAPK) 
kinases (MEKs), the inhibitor κB kinase β (IKKβ), and the counterregulators of the Toll-
like receptor-4 triggered apoptotic pathway. These interactions lead to the inhibition of 
cytokine expression and the apoptotic cell death of macrophages and DCs (Erfurth et al., 
2004; Lemaitre et al., 2006; Monack et al., 1997; Mukherjee et al., 2006; Zhang & Bliska, 
2010; Zheng et al., 2011).  
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YopM is a leucine-rich protein with no enzymatic activity (Viboud & Bliska, 2005). This 
protein appears to act like an adaptor protein, forming complexes with the ribosomal 
protein S6 kinase 1 (RSK1) and the protein kinase C-like 2 (PRK2) (McDonald et al., 
2003). YopM travels to the nucleus of the host cell and is essential for Yersinia to persist 
in the systemic organs liver and spleen by blocking the innate immune response. It was 
shown to downregulate proinflammatory cytokines, e.g. IL-1β, IL-12 or TNF-α and 
causes the depletion of NK cells (Kerschen et al., 2004; Skrzypek et al., 1998). YopK of 
Y. pseudotuberculosis and the Y. enterocolitica homolog YopQ seem to regulate the 
translocation pore size by affecting the pore-forming proteins YopB and YopD 
(Holmstrom et al., 1997). Both proteins seem to influence the amount of delivered 
proteins, to prevent neutrophil death and further activation of inflammatory responses. 
The translocation of YopH, YopM and YopE appear to be most important for the 
protection of Yersinia against the immune response of the host (Kerschen et al., 2004; 
Logsdon & Mecsas, 2003; Trülzsch et al., 2004). 
 
Figure 1.4.5: Overview of the different effector Yops and their influence in the host signaling 
pathways (Viboud & Bliska, 2005).  
Yop proteins are injected into the host cell by the T3SS. YopE, YopT, and YopA/O target and manipulate 
the small Rho-GTPases blocking mostly phagocytosis. YopJ/P inhibits the Toll-like receptor 4 (TLR4) 
signaling pathways and thereby inhibits inflammatory responses and induces apoptosis in macrophages. 
YopH blocks phagocytosis by immune cells. YopM is able to enter the nucleus, thus interfering in gene 
expression. 
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1.5 The actin cytoskeleton 
The actin cytoskeleton is involved in many cellular functions like cell motility, cell 
adhesion or the cellular shape and polarity (Le Clainche & Carlier, 2008; Galletta & 
Cooper, 2009; Pollard & Borisy, 2003), but also in the defence against bacteria like in 
phagocytosis by macrophages or the migration of immune cells (Hoffmann & Schmidt, 
2004). 
The actin structure constantly rearranges, and this is achieved by fast polymerization 
and depolymerization of actin filaments. Thereby the actin alters between its monomeric 
form, the globular-actin (G-actin) and its multimeric form, the filamentous-actin (F-actin). 
G-actin is a 42 kDa protein forming tube-like structures (F-actin), consisting of two 
twisted strands (see Figure 1.5.1) (Winder & Ayscough, 2005). 
 
Figure 1.5.1: Actin polymerization and depolymerization dynamics.  
G-actin (ATPase) polymerizes at the plus end of the F-actin. At the minus end, the ATPase is activated and 
cleaves the ATP in ADP+P, resulting in the dissociation of the G-actin from the filament. This dynamics 
lead to rearrangements of the actin cytoskeleton. 
 
The G-actin is an ATPase and exists in two states, the ATP bound and the ADP bound 
state. If associated with ATP, it polymerizes at the plus end of the F-actin. At the minus 
end, the ATPase is activated and thereby the ATP is cleaved into ADP+P, which leads 
to the dissociation of the G-actin from the F-actin. This dynamic results in conformational 
changes of the actin cytoskeleton. Many signaling pathways and proteins are involved in 
the regulation of this process (Pollard & Borisy, 2003). Crucial are the small GTPases of 
the Rho-family (see 1.6). Many pathogenic bacteria are able to alter the actin 
cytoskeleton of the host cell by interacting with the dynamic to their advantage. This 
leads for example to the inhibition of their phagocytosis by macrophages, to the 
induction of their invasion by non-phagocytic cells or to the destruction of a barrier to 
reach the underlying tissue (Bhavsar et al., 2007; Gouin et al., 2005). 
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1.6 Small Rho-GTPases 
The Rho-GTPases belong to the Ras super-family and are small monomeric G-proteins 
with a size of 21 - 25 kDa. The rho gene was discovered in 1985 and named after its 
homology to ras, Ras homolog (Madaule & Axel, 1985). The Rho-GTPases are very 
homologous among each other and show an amino acid sequence-identity of about 40 -
 95% in their GTPase domain (Wennerberg & Der, 2004). Due to their differences in the 
sequence, the 23 so far known Rho-GTPases are categorized in six subfamilies, Rho, 
Rac, Cdc42, RhoBTB and RhoT/Miro (Bustelo et al., 2007). 
The Rho-GTPases are involved in many signaling pathways in the eukaryotic cell, like 
the regulation of the actin cytoskeleton, the gene expression, the cell cycle or the 
phagocytosis (Van Aelst & D’Souza-Schorey, 1997; Etienne-Manneville & Hall, 2002). 
The GTPases cycle from the active GTP-bound form to the inactive GDP-bound form is 
regulated and coordinated by three different protein classes (see Figure 1.6.1): 
1. Guanine-nucleotide-exchange factors (GEFs): these factors are responsible for 
the exchange of the GDP against the GTP (Symons & Settleman, 2000). 
2. GTPase-activation proteins (GAPs): these factors activate the GTPase, which 
leads to the hydrolysis of the bound GTP. 
3. Guanine-nucleotice-dissociation inhibitors (GDIs): these factors lead to the 
stabilization of the GDP-bound inactive form in the cytosol (Van Aelst & D’Souza-
Schorey, 1997; Nomanbhoy et al., 1999). 
The activation of the GTPases is triggered by extracellular signals like cytokines or by 
adhesion- or G-protein-associated receptors (Rossman et al., 2005). They possess 
isoprenylated cysteins at their C-terminus, with which they are able to bind membrane-
anchored lipids and subsequently interact with their effectors. In the inactive state, the 
Rho-GTPases are coupled with the GDIs at their isoprenylated cysteins 
(DerMardirossian et al., 2004). Morphologically, the activation of the Rho-GTPases leads 
to the formation of different cell fibres: RhoA induces the formation of stress fibres, Rac1 
of lamellipodia and Cdc42 of filopodia (see Figure 1.6.1) (Ahmadian et al., 2002). 
Additionally, it was shown that Cdc42 leads to the activation of Rac, which in turn leads 
to the activation of Rho (Nobes & Hall, 1995). Thereby, the Rho-GTPases are affecting 
each others activity. 
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Figure 1.6.1: The GTPase cycle of Cdc42, Rac1 and RhoA and their influence on the actin 
cytoskeleton. 
The activation of Cdc42, Rac1, and RhoA leads to the formation of filopodia, lamellipodia, and stress fibres, 
respectively. The GTPases cycle from the inactive form (GDP-associated) to the active form (GTP-
associated). This transition is accomplished by the GEF proteins, which are exchanging the GDP against 
GTP. Upon activation of the GTPase by the GAP proteins, the GTP is cleaved in GDP+P, leading to an 
inactive state. This state is stabilized by the GDI proteins in the cytosol. 
 
Many bacterial virulence factors are known to interact in the cycle of the most 
investigated GTPases, Rho, Rac and Cdc42 (Symons & Settleman, 2000). These 
factors help the bacterium for example to control the actin cytoskeletal rearrangements 
for their invasion process into the cell (Barbieri et al., 2002). Enteric yersiniae are able to 
interfere in the Rho-GTPase cycles at different steps, e.g. Y. pseudotuberculosis is 
interfering in the cycle of Rac1 during the β1-integrin induced phagocytosis (Alrutz et al., 
2001). Thereby the binding of InvA leads to a local activation of Rac1 (Del Pozo et al., 
2002; Wong & Isberg, 2005). In contrast, RhoA was observed to inhibit an InvA-induced 
bacterial invasion (Black & Bliska, 2000; Leeuwen et al., 1997; Tosello-Trampont et al., 
2003). Thus, RhoA must be blocked to enable an efficient invasin-induced bacterial 
invasion by Rac1 activation (Wong et al., 2006). However, InvA influences the GTPases 
indirectly by the activation of β1-integrin signaling pathways, whereas most GTPase-
interfering toxins act directly. 
1.7 Bacterial toxins interacting with Rho-GTPases 
Because of its diverse functions in bacterial defence, the actin cytoskeleton is a frequent 
target of bacterial toxins. Toxins modulating the actin cytoskeleton can be categorized 
into four groups, (1) toxins that covalently modify actin, (2) toxins that modulate the 
cytoskeleton as adenylate cyclases, (3) toxins that modulate the nucleotide state of the 
Rho-GTPases and (4) toxins that covalently modify GTPases (Barbieri et al., 2002). The 
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third group is subdivided into two subgroups, the activators and inhibitors. The first two 
groups are directly influencing the actin cytoskeleton, whereas the toxins of group 3 and 
4 are acting indirectly by interfering in the small Rho-GTPase cycle (Barbieri et al., 2002; 
Boquet & Lemichez, 2003). Figure 1.7.1 shows a summary of different bacterial toxins 
and their mode of action with the Rho-GTPases. 
 
Figure 1.7.1: Different Rho-GTPase modifying toxins. 
This scheme shows the regulating influence of the toxins in the different steps of the GTPase cycle. 
Included are the cytotoxic necrotizing factors of E. coli and Y. pseudotuberculosis (Boquet & Lemichez, 
2003). 
 
Bacterial toxins mostly lead to the inactivation of the Rho-GTPases by either covalently 
modifying the GTPase itself or by the imitation of GAP proteins, leading to a constitutive 
GTPase activity (Fiorentini et al., 2003). Inactivating toxins are for example YopE of the 
enteric Yersinia species, which imitates Rho-GTPase inactivating Rho GAPs (Black & 
Bliska, 2000; Fu & Galan, 1999), YopT of Y. pseudotuberculosis, which lead to the 
dissociation of the GTPase from the membrane (Shao et al., 2002) or the C3 toxin of 
Clostridium botulinum, which leads to an ADP-ribosylation of RhoA, B and C, thus 
inducing a strong interaction of the GTPase with the GDI. This in turn results in a 
blockage of the GTPase recruitment and subsequently to the inhibition of its activation 
(Aktories & Hall, 1989; Vogelsgesang et al., 2007). 
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In comparison, only a small group of toxins lead to a constitutive or non-constitutive 
activation of the Rho-GTPases by inhibiting the GTPase activity or the GAPs. Activating 
toxins are for example the dermonecrotic toxin (DNT) of Bordetella (Masuda et al., 2000) 
or the cytotoxic necrotizing factors (CNFs) of Y. pseudotuberculosis (Hoffmann et al., 
2004; Knust & Schmidt, 2010; Lockman et al., 2002) or E. coli (Fiorentini et al., 1997), 
which all lead to the constitutive activation of the Rho-GTPases (see 1.7.1). 
1.7.1 Cytotoxic necrotizing factors 
In 1984, the first CNF-producing E. coli strain was isolated from enteritis patients. The 
toxin caused dermonecrotic lesions and multinucleation plus enlargement of eukaryotic 
cells (Caprioli et al., 1984). Three CNFs of E. coli (CNF1-3) have been described so far, 
mostly produced by extraintestinal pathogenic strains. Additionally, a CNF beyond the 
species E. coli was identified in the Y. pseudotuberculosis wild-type strain YPIII 
(Lockman et al., 2002). 
These toxins were all shown to induce actin cytoskeletal rearrangements and 
multinucleation in different eukaryotic cells due to an inhibition of cytokinesis and 
ongoing cell cycle progression (Falzano et al., 1993a; Huelsenbeck et al., 2009). 
Furthermore, they possess the identical superior structure and consist of three functional 
domains: (1) the N-terminal host-cell binding domain, (2) the central translocation 
domain, and (3) the C-terminal catalysis domain (see Figure 1.7.3). Due to their 
structure, CNFs are categorized into the group of A-B toxins (Fabbri et al., 1999; 
Fiorentini et al., 1997). 
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Figure 1.7.2: Receptor-mediated endocytosis of the CNFs into the eukaryotic cell. 
The CNF binds to its receptor on the eukaryotic cell and is endocytosed into an endosome. The toxin 
containing endosome becomes acidic, leading to a conformational change of the CNF. Thereby, the 
translocation domain is integrated into the endosomal membrane, which leads to the cleavage and 
secretion of the catalytical domain into the cytosol. In there, this domain can deamidate the GTPases 
(Knust & Schmidt, 2010). 
 
Bacterial A-B toxins follow the mechanism of the receptor-mediated endocytosis induced 
by the binding of the N-terminal domain. Two different processes and subsequent 
catalytic reactions of bacterial A-B toxins in eukaryotic cells can be distinguished: (1) The 
toxins evade the degradative pathway and reach the Golgi apparatus (Falnes & 
Sandvig, 2000) or (2) the toxin containing endosomes become acidic, induce a 
conformational change of the toxins, leading to the autocatalytical cleavage of the 
catalytic domain and its subsequent secretion into the cytosol (Fabbri et al., 1999; 
Lemichez et al., 1997). The CNFs use the second mechanism whereby the cleaved 
catalytic domain interacts with the Rho-GTPase (Contamin et al., 2000; Knust & 
Schmidt, 2010) (see Figure 1.7.2).  
The CNFs are toxins interfering with the Rho-GTPase cycle by a constitutive activation 
of Rho, Rac or Cdc42. This permanent activation is accomplished by the deamidation of 
a conserved glutamine (61/63) to glutamate in the catalytic center of the GTPase. 
Subsequently, the GAP catalyzed hydrolysis of the bound GTP is inhibited, leading to a 
permanent activated state of the GTPase (Rittinger et al., 1997). 
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CNF1 is the best characterized toxin of the CNF toxin family. It is a 108 kDa sized 
protein, mainly produced by uropathogenic E. coli strains (UPEC), which cause 
extraintestinal infections (Blanco et al., 1992; Landraud et al., 2000). Moreover, it could 
be detected in E. coli K1 strains, which cause neonatal meningitis (Bonacorsi et al., 
2000). CNF1 leads to the constitutive activation of the Rho-GTPase subfamilies RhoA, 
Rac1, and Cdc42. 
 
 
The cnf1 gene is encoded on the chromosome on a pathogenicity island (Blum et al., 
1995) and is secreted and transfered to the host cell by outer membrane vesicles 
(OMVs) (Davis et al., 2006; Kouokam et al., 2006). The receptor-mediated endocytosis 
of CNF1 seems to be independent of clathrin and lipid rafts (sphingolipid/cholestrol rich 
microdomains) (Blumenthal et al., 2007; Contamin et al., 2000), but it was shown that 
binding to the 67 kDa laminin receptor induces the internalization of CNF1-expressing 
E. coli into human brain microvascular endothelial cells (HBMEC) (Kim et al., 2005). 
This toxin was demonstrated to induce the formation of actin stress fibres, filopodia and 
lamellipodia (Fiorentini et al., 1997), caused by the 55 kDa catalytical domain, which is 
essential for the biological activity of CNF1 (Schmidt et al., 1998). The crystallized 
catalytical domain shows a unique fold with a β-sheet surrounded by α-helices and loops 
(Buetow et al., 2001). Different functions for CNF1 have been demonstrated, e.g. the 
induction of phagocytosis by non-phagocytic cells, the inhibition of phagocytosis by 
phagocytic cells (Falzano et al., 1993b; Hofman et al., 2000; Visvikis et al., 2011) or the 
impairment of the barrier function of epithelial layers (Gerhard et al., 1998; Hopkins et al., 
2003). 
Figure 1.7.3: Structure of the cytotoxic necrotizing factor of E. coli CNF1 (Aktories, 2011). 
The toxin belongs to the group of A-B toxins and consists of three domains, the binding, 
translocation and catalysis domain. With the binding domain, CNF1 binds to its receptor on the 
eukaryotic cell and subsequently gets endocytosed. After a change of the pH, the translocation 
domain inserts into the endosomal membrane and leads to the secretion of the catalysis domain into 
the cytosol. 
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1.7.1.1 CNFY 
Some Y. pseudotuberculosis strains of the serogroup O:3, e.g. the pathogenic isolate 
YPIII, have been shown to produce a CNF called CNFY (Lockman et al., 2002). Due to 
mutations and deletions over the complete cnfY gene, the toxin is not expressed or 
inactive in many sequenced Y. pseudotuberculosis strains of the serogroup O:3 
(Lockman et al., 2002). This is also true for the Y. pestis strain CO92, which contains a 
sequence (Parkhill et al., 2001) with 99% sequence-identity to cnfY of 
Y. pseudotuberculsosis. However, the gene in Y. pestis harbours a deletion at the C-
terminus in the catalytical domain (see Figure 1.7.4) (Lockman et al., 2002). So far no 
Y. enterocolitica strain was described to harbour the toxin gene in its genome. 
The CNFY toxin is homolog to the CNF1 toxin of E. coli, with a sequence-identitiy of 
around 65% over the whole gene (Lockman et al., 2002). The cnfY gene is encoded on 
the chromosome of Y. pseudotuberculosis and flanked by a transposase and an 
oxidoreductase, indicating that the gene was acquired from another bacterium, like 
E. coli. The produced toxin has a size of about 115 kDa and leads to the formation of 
multinucleated giant HeLa cells, like its homolog CNF1 (Lockman et al., 2002).  
However, CNFY seems to address a different receptor in comparison to CNF1 as the 
preincubation of cells with inactive CNF1 does not block CNFY activity completely 
(Blumenthal et al., 2007). Moreover, antibodies against CNF1, which prevented 
multinucleation by CNF1 expressing E. coli lysates, could not prevent the CNFY activity in 
the eukaryotic cells (Lockman et al., 2002). However, it was demonstrated that CNFY 
binds to heparan sulfate proteoglycan, a co-receptor of CNF1 (Blumenthal et al., 2007).  
Subsequently, after binding to its receptor CNFY is taken up by receptor-mediated 
endocytosis into endosomes like CNF1, as the internalization of the toxin is inhibited by 
blocking the acidification of the early endosome (Blumenthal et al., 2007). In the cytosol 
of the eukaryotic cell, the catalytically active domain of CNFY functions similarly to the 
domain of CNF1 as the three recombinantly purified GTPases RhoA, Rac1, and Cdc42 
were also shown to serve as substrates for CNFY. Nevertheless, CNFY preferentially 
deamidates/activates RhoA over Rac or Cdc42 in human epithelial cells leading 
predominantly to the formation of actin stress fibres and of multinuclear giant cells 
(Hoffmann et al., 2004).  
So far, beyond elucidating the molecular mechanism of the toxin (primarily by 
intoxication of epithelial cells) in reference to its ability to activate the Rho-GTPase 
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RhoA, no further research has been performed on CNFY. However, different effects on 
the cells were attributed to the constitutively activation of RhoA by CNFY. For instance, it 
was demonstrated by incubating cells with CNFY that the RhoA activation is exclusively 
responsible for inhibition of cytokinesis (Huelsenbeck et al., 2009), which was described 
before as a consequence of CNF intoxication (Falzano et al., 1993a). Furthermore, 
CNFY was demonstrated to (1) decrease the endothelial barrier function (Baumer et al., 
2008), (2) to increase cell-matrix adhesion and subsequent cell spreading (May et al., 
2012), (3) to induce apoptosis in prostate cancer cells (Augspach et al., 2013), and (4) to 
induce immunity of mice against a subsequent Y. pseudotuberculosis infection when 
applied subcutaneously (Mou et al., 2012). 
 
Figure 1.7.4: Comparison of the CNFY sequences of Y. pseudotuberculosis YPIII and Y. pestis CO92 
(Lockman et al., 2002). 
The dotted lines indicate deletions in the CNFY gene of Y. pestis CO92 and the boxes indicate sequences 
that show a sequence-identity of >99%. Left and right are indicated the putative transposase and the 
putative oxidoreductase, respectively. 
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1.8 Aim of this study 
As mentioned above, the clinical isolate Y. pseudotuberculosis YPIII harbours the 
toxin gene cnfY, which has a sequence-identity to the cnf1 of uropathogenic E. coli 
K1 strains of about 65% (Lockman et al., 2002). Incubation of eukaryotic cells with 
CNFs results in a constitutive activation of the small Rho-GTPases Rho, Rac, and 
Cdc42, whereby CNFY predominantly activates RhoA (Flatau et al., 1997; Hoffmann 
et al., 2004). This activation leads to rearrangements of the actin cytoskeleton, and 
the formation of giant, multinucleated cells (Falzano et al., 2006; Huelsenbeck et al., 
2009).  
Previous studies focused on the molecular mechanism of the CNFY toxin were 
primarily focused on epithelial cells. However, little was known about the role of this 
toxin during pathogenesis of Y. pseudotuberculosis and the consequences of the 
constitutive activation of the Rho-GTPases in the infection process. Hence, the aim 
of this study was to investigate the molecular function of CNFY and its impact on the 
virulence of Y. pseudotuberculosis. 
To address this aim, the expression conditions of cnfY in vitro as well as in vivo in the 
mouse model, the secretion conditions of CNFY, and the molecular function of CNFY 
regarding the activation of the Rho-GTPases and the influence on the morphology of 
intoxicated eukaryotic cells should be investigated. The main focus was on 
deciphering the role of CNFY during the infection process. For this purpose, the 
impact of CNFY on the bacterial colonization ability in the different tissues, the 
histology of the infected tissues, and the immune response should be assessed.  
Additionally, the interplay and cooperation of CNFY with the T3SS and the Yop 
effector proteins in vitro and during the infection in mice should be examined. 
Moreover, it should be investigated whether CNFY plays an additional role in the 
host-pathogen interaction beside the amplification of crucial virulence factor 
functions. Furthermore, long-term effects on the immune system after infection with 
avirulent/low virulent Y. pseudotuberculosis mutant strains should be analyzed.  
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2 Material and methods 
2.1 Material 
2.1.1 Equipment and material 
Equipment and material of the following companies were used: BD Biosciences, 
Biochrom, Biometra, Bio-Rad, Brand, Consort, Eppendorf, Gilson, Greiner, Heraeus, 
Heidolph, Hirschmann EM, Ibidi, Infors AG, Integra Biosciences, Janke & Kunkel IKA-
Labortechnik, Laboport, Marienfeld, Millipore, Microflex Corporation, PeqLab, Roth, 
Sarstedt, Sartorius, Schott, Sigma Aldrich, Sorvall, TPP, Thermo Scientific, Oregon 
Scientific, VWR International, Whatman Schleicher & Schüll GmbH and Zeiss. Special 
equipment or materials used are mentioned in the text. 
2.1.2 Chemicals and buffers 
Chemicals and buffers of the following companies were used: Applichem, BD 
Biosciences, Biochrom, BioLegend, BioMoll, BioXCell, Difco, eBioscience, Fermentas, 
Fischer Scientific, Fluka, GIBCO, Invitrogen, Jackson ImmunoResearch, J.T. Baker, Life 
Technologies, Merck, Metabion, New England Biolabs Inc. (NEB), PAA, Pierce, Perkin 
Elmer, PeqLab, Promega, PromoCell, Qiagen, Roche, Roth, Sigma Aldrich, Serva, T. H. 
Geyer and Zeiss. Special chemicals used are mentioned in the text. If not noted 
otherwise all buffers and solutions were prepared with distilled water. Sterilization was 
accomplished by autoclaving for 20 min. at 121°C and 1 bar. Temperature sensitive 
substances were instead filtered using a pore size of 0.2 µm. 
Table 2.1: Buffers and solutions 
Buffer/solution Chemicals and concentrations 
3 x gel buffer 3 M Tris, 1 M HCl, 0.3% SDS 
Acetate buffer 0.5 M NaCl, 0.1 M ammonium acetate; pH 4 
Aceto-SDS solution 87.5% acetone, 0.25% SDS 
Binding buffer J774A.1 & HEp-2 RPMI 1640 + GlutaMax-I + 0.4% BSA + 20 mM 
HEPES pH 7.0  
Binding buffer RAW264.7 IMDM + 0.4% BSA + 20 mM HEPES pH 7.0  
Coomassie staining solution 20% isopropanol, 10% acetic acid, 
0.05% CoomassieTM Brilliant Blue G250 
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Coupling buffer (antibody 
purification) 
0.5 M NaCl, 0.1 M NaHCO3; pH 8.3 
Elution buffer 1 50 mM Tris-HCl, 100 mM NaCl, 150 mM imidazole 
Elution buffer 2 50 mM Tris-HCl, 100 mM NaCl, 250 mM imidazole 
Elution buffer (antibody 
purification) 0.2 M glycine, 0.15 M NaCl; pH 2.2 
Erythrolysis buffer 7.8 mM NH4Cl, 10 mM KHCO3, 100 µM EDTA 
FACS buffer PBS + 0.2% BSA 
Lysis buffer (protein purification) 50 m M Tris-HCl, 300 mM NaCl, 10 mM imidazole 
Neutralizing buffer 0.5 M NaCl, 0.1 M Tris-HCl; pH 8 
ONPG solution 4 mg/ml ONPG 
PBS (10x) 80 g/l NaCl, 2 g/l KCl, 14.4 g/l Na2HPO4, 2.4 g/l 
KH2PO3; pH 7.4  
SDS running buffer 33 mM Tris-HCl pH 8.3, 192 mM glycine, 0.1% SDS 
SDS sample buffer 3 g/l Tris pH 8.3, 14.4 g/l glycine, 0.1% SDS 
SDS running gel buffer 500 mM Tris-HCl, 4% SDS, pH 6.8 
SDS stacking gel buffer 1.5 M Tris-HCl, 4% SDS, pH 8.8 
TAE buffer (Tris-acetate-EDTA) 
(1x) 40 mM Tris-acetate, 2 mM EDTA, pH 8.0 
TBST buffer 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% 
Tween-20 
TBSTB buffer 3% BSA in TBST 
TBSTM buffer 5% skim milk powder in TBST 
TFB1 buffer 30 mM potassium acetate, 10 mM CaCl2, 50 mM 
MnCl2, 100 mM RbCl, 15% glycerin, pH 5.8 
TFB2 buffer 10 mM MOPS, 75 mM CaCl2, 10 mM RbCl, 15% 
glycerin, pH 6.5 
Transblot buffer 25 mM Tris, 192 mM glycine, 20% MetOH 
Transformation buffer  272 mM sucrose, 15% glycerol, sterile filtrated 
Washing buffer 50 mM Tris-HCl, 300 mM NaCl, 20 mM imidazole 
Z-buffer 100 mM sodium phosphate buffer pH 7, 
1 mM Mg2SO4  
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2.1.3 Media and supplements 
Media used in this study are listed in Table 2.2. If not noted otherwise all media were 
prepared with distilled water. For selective media sterile antibiotics were added (see 
Table 2.3). 
Table 2.2: Media 
Media Chemicals and concentrations 
BHI broth (brain-heart infusion) 37 g/l BHI 
CRMOX 40 g/l Tryptic Soy agar, 80 ml/l 0.25 M di-sodium 
oxalate, 80 ml/l 0.25 M magnesium chloride, 
10 ml/l 20% galactose,5 ml/ congo red 
Caco-2 medium MEM + 10% FCS 
DYT broth (Double Yeast 
Tryptone) complex medium 
(Miller, 1992) 
10 g/l yeast extract, 5 g/l NaCl, 16 g/l tryptone 
Freezing medium for eukaryotic 
cells 90% FCS + 10% DMSO  
HEp-2 medium RPMI 1640 + 1% GlutaMax-I + 7.5% NCS 
J774A.1 medium RPMI 1640 + 1% GlutaMax-I + 5% FCS 
LB broth (Sambrook et al., 1989) 5 g/l yeast extract, 5 g/l NaCl, 10 g/l tryptone 
LB solid medium LB-medium + 18 g/l agar 
MMA (minimal medium A) 
(Sambrook et al., 1989) 
10.5 g/l K2HPO4, 4.5 g/l KH2PO4, 1 g/l (NH4)2SO4, 
0.5 g/l sodiumcitrate 
Raw264.7 medium Iscove Basal medium with stable glutamine (IMDM) + 
10% FCS 
SOC medium (super optimal 
broth) complex medium 
5 g/l yeast extract, 0.5 g/l NaCl, 10 ml/l 1M MgCl2, 
20 g/l tryptone, 2.5 ml/l 1M KCl, 10 ml/l MgSO4 
Yersinia medium Yersinia selective agar base and Yersinia selective 
supplement (Oxoid) 
 
Table 2.3: Supplements and inhibitors 
Supplement/inhibitor & 
function End concentration 
Concentration stock 
solution & manufacturer 
Carbenicillin (antibiotic) 100 µg/ml 100 mg/ml in H2O (Roth) 
Chloramphenicol 
(antibiotic) 30 µg/ml 
30 mg/ml in 70% EtOH 
(Roth) 
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CNFY (cytotoxic necrotizing 
factor of YPIII) 1 - 25 nM 1 - 5 mg/ml (this study) 
CT04 (C3 Transferase; 
Rho Inhibitor I) 0.5 - 1 µg/ml 0.1 µg/µl (Cytoskeleton) 
Cytochalasin-D (inhibitor) 5 µg/ml 5 mg/ml in DMSO (Sigma) 
FCS (fetal calf serum; 
growth factor) 10%- 5% 100% (Biochrom) 
Gentamycin (antibiotic) 50 µg/ml 50 mg/ml (Sigma) 
HEPES (buffer) 10 mM 1 M (Biochrom) 
Kanamycin (antibiotic) 50 µg/ml 50 mg/ml in H2O (Merck) 
NCS (newborn calf serum; 
growth factor) 7.5% 100% 
Probenecid (inhibitor) 1.5 mM 150 mM (Sigma) 
TcdBF (Toxin B serotype F; 
Rac1/2/3 inhibitor) 85 - 250 ng/ml 
850 µg/ml (H. Genth, 
Institute for Toxicology, 
Medical School Hannover) 
2.1.4 Enzymes and antibodies 
Enzymes used in this study are listed in Table 2.4 and were applied with the provided 
buffers. Antibodies used for western blotting or flow cytometry are listed in Table 2.5.  
Table 2.4: Enzymes 
Manufacturer Enzyme 
Bioline MangoTaq™ DNA polymerase 
Finnzymes Phusion® High-Fidelity DNA Polymerase 
NEB Antarctic phosphatase 
Benzonase 
LongAmp Taq DNA polymerase 
Restriction enzymes 
Taq DNA polymerase 
T4-DNA ligase 
Sigma Aldrich Trypsin-EDTA 
Cytochalasin-D 
Qiagen RNaseA 
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Table 2.5: Antibodies 
Manufacturer Antibody (dilution and buffer) 
Antibodies for western blotting 
Ake Forsberg Anti-Yop all (TBSTB) 
Cell Signaling Anti-Cdc42 (1:1,000 in TBSTB) 
Anti-mouse-HRP (1:5,000 in TBSTB/TBSTM) 
Anti-Pan-Actin (1:1,000 in TBSTB) 
Anti-rabbiT HRP (1:5,000 in TBSTB/TBSTM) 
Anti-Rac1/2/3 (1:1,000 in TBSTB) 
Anti-RhoA (1:1,000 in TBSTB) 
David’s Biotechnology Anti-CNFY (1:1,000 in TBSTB) 
Sigma Anti-polyHistidin (1:2,000 in TBSTM) 
Antibodies for Flow Cytometry* 
BD Biosciences Anti-CD3-Biotin 
Anti-CD3-PE 
Anti-Ly6G-PE-Cy7 
Streptavidin-FITC 
BioLegend Anti-CD11c-PE-Cy7 
Anti-CD19-FITC 
Anti-CD25-APC 
Anti-CD49b-Biotin 
Anti-Ly6C-APC 
BioXCell Anti-mouse CD16/CD32 
eBioscience Anti-CD3-APC 
Anti-CD3-PE-Cy7 
Anti-CD4-PerCP-Cy5.5 
Anti-CD4-APC-eF780 
Anti-CD8-eFluor450 
Anti-CD335-PerCP-Cy5.5 (NKp46) 
Anti-CD11b-Pacific Blue 
Anti-CD11c-APC 
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Anti-CD19-Biotin 
Anti-CD45R-PerCP-Cy5.5 (B220) 
Anti-CD11c-APCeFluor780 
Anti-F4/80-PE 
Anti-Gr1-A700 
Anti-NKp46-PE 
Streptavidin-PerCP-Cy5.5 
*all antibodies were titrated for optimal staining conditions 
2.1.5 Commercial kits 
In Table 2.6 are listed all kits used in this study. Kits were employed according to the 
manufacturer’s protocol, unless differently stated. 
Table 2.6: Commercial kits 
Manufacturer Kit Application 
Cell Biolabs Cdc42 and Rac Activation 
Assay 
Pull down of active Rac and Cdc42 
GTPases 
Invitrogen Live/dead Fixable Blue Dead 
Cell Stain Kit 
Live/dead staining of cells for flow 
cytometry analysis, UV excitation 
Life 
Technologies 
LiveBLAzer-FRET B⁄G 
Loading Kit 
Yop delivery assay 
Millipore Rho Activation Assay Kit 
MILLIPLEX MAP Mouse 
Cytokine/Chemokine 
Magnetic Bead Panel - 
Premixed 32 Plex - 
Immunology Multiplex Assay 
Kit 
Pull down of active Rho GTPases 
Measurement of cytokine level 
Perkin Elmer Western Lightning ECL II Kit Detection of HRP conjugated secondary 
antibodies (western blot) 
Pierce Coomassie (Bradford) 
Protein Assay Kit 
Detection and quantification of total 
protein amount 
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Qiagen QIAquickTM Gel Extraction 
Kit 
QIAquickTM PCR Purification 
Kit 
QIAprepTM Spin Miniprep Kit 
Gel extraction of PCR products and 
plasmids 
Purification of PCR products 
 
Isolation and purification of plasmids 
2.1.6 Oligonucleotides and plasmids 
2.1.7 Oligonucleotides 
Metabion performed the synthesis of all used oligonucleotides (see Table 2.7). Each 
primer stock solution was 100 µM and was diluted for PCR reactions to 10 µM. 
Underlined nucleotides mark integrated restriction sites or overlapping regions as 
indicated. Plasmids used in this study are listed in Table 2.8. 
Table 2.7: Oligonucleotides 
Name Sequence 5’ - 3’ Description 
I661 GTGTAGGCTGGAGCTGCTTC sense for synthesis of kan-cassette of 
pKD3/4 
I662 CATATGAATATCCTCCTTAGTTC
C 
anti-sense for synthesis of kan-cassette 
of pKD3/4 
I984 TAAGAAACCATTATTATCATGAC sequencing primer for pFU vector 
system, binds in P1-site 
I987 TCTAGGGCGGCGGATTTG sequencing primer for pFU vector 
system, binds in P2-site 
II306 GCACTGGATCCTAGTATCTGGA
ATAGACAACGAAAG 
sense for 5’UTR of yopE 
II371 CGGACTAGTGATGGGCAAATT
GAAGCAC 
sense for upstream region of lcrQ 
II372 CGGGCATGCGCCCACTGGTAA
TGCAGG 
anti-sense for downstream region of lcrQ 
II794 GGGGCTAGCATGAAAAATCAAT
GGCAA 
sense for CNFY overexpression (NheI) 
II795 GGGCTCGAGTTAAAAGTCTTTT
TGTAA 
anti-sense for CNFY overexpression 
(XhoI) 
II894 ACATAATGTATTCTAATAAAAAC
ATTC 
sense for cnfY sequencing 
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II895 TAAATGATAATTTTGGTTTTACT
GGTG 
anti-sense for cnfY sequencing 
II896 GGGGGGGATCCTATTGACAAA
CAAAATGAAGCAAGATAG 
sense for promoterregion of cnfY 
(BamHI)  
II898 GGGGGGTCGACTTAGCCATTG
ATTTTTCATAAACACTCC 
anti-sense for promoterregion of cnfY 
(SalI) 
III710 CCGGGGAGCTCGACAAACAAA
ATGAAGCAAGATAGTTTTACAT
G 
sense for cnfY mutagenesis, upstream 
region (SacI) 
III711 CCGGGGAGCTCTTTTTGGCGA
TGCCACCTACCC 
sense 900 bp upstream of cnfY (SacI) 
III712 CCGGGGAGCTCATTTTCTGGC
GGGGTGTGACCA 
anti-sense for cnfY mutagenesis, 
downstream region (SacI) 
III713 CCGGGGAGCTCCTACGCCATG
TTTCCGAAACCCAG 
anti-sense 1000 bp downstream of cnfY 
(SacI) 
III714 GGAACTAAGGAGGATATTCATA
TGTAATGTTTTACAAAAAGACTT
TTAAATCTTAAGTCTC 
sense for cnfY mutagenesis (downstream 
region) with homologous kan region 
III715 GAAGCAGCTCCAGCCTACACA
AACACTCCTTTTATTGACGATG
CACAATG 
anti-sense for cnfY mutagenesis 
(upstream region) with homologous kan 
region 
III727 CCGGGGGATCCATGAAAAATC
AATGGCAACATCAATATTT 
test for cnfY loss 
III680 TCTCCACCCAAGCGGCCG anti-sense kan region, testing for 
genomic integration 
III681 CGATTCGCAGCGCATCGC sense kan region, testing for genomic 
integration 
IV16 GGGGGGCGGCCGCTTAAAAGT
CTTTTTGTAAAAC 
anti-sense for cnfY complementation 
(NotI) 
IV48 GTAAAGATGAATATGAATTCTC
TATTGATGC 
sense sequencing cnfY  
IV49 CCTCAAGCGCAATTTTTATACC anti-sense sequencing cnfY 
IV474 CCCCCGCGGCCGCTTAGTGGT
GATGGTGATGATGAAAGTCTTT
TTGTAAAA CATTAAACAC 
anti-sense for C-terminal His tag of cnfY 
(NotI) 
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V439 AGACAGCGGCCGCTCAGCTAC
TTAGCATGCTGAGTAAACTTGG
TCTGACAGT 
anti-sense test for TEM integration 
V553 CCGGGGAGCTCAGATGGGTTT
TAATATATCTTGACTGAAT 
sense for yopE mutagenesis, upstream 
region (SacI) 
V554 GAAGCAGCTCCAGCCTACACTT
CTCCTACGCTGCTAGATCC 
anti-sense for yopE mutagenesis 
(upstream region) with homologous kan 
region  
V555 GGAACTAAGGAGGATATTCATA
TGTATTGATAAAAACAAGGGGA
TAGTGTT 
sense for yopE mutagenesis 
(downstream region) with homologous 
kan region  
V556 CCGGGGAGCTCAATGTACCTG
TGAGCCATCG 
Anti-sense for yopE mutagenesis, 
downstream region (SacI)  
V557 CACCGGTCGCAGGATCAA sense 1000 bp upstream of yopE  
V558 TCTGTTGAGCATTCCACACT anti-sense 1000 bp downstream of yopE 
 
Table 2.8: Plasmids 
Plasmid Characteristics Source/reference 
pAKH3 pGO704, sacB+, AmpR (Nagel et al., 
2001) 
pCP20 pSC101ts, flp, AmpR, CmR (Datsenko & 
Wanner, 2000) 
pET28a T7 promoter based expression vector, KanR Novagen 
pFU54 promoterless luxCDABE, pSC101* ori, AmpR (Uliczka et al., 
2011) 
pFU58 promoterless gfpmut3.1, pSC101* ori, AmpR (Uliczka et al., 
2011) 
pFU68 promoterless lacZ, pSC101* ori, AmpR (Uliczka et al., 
2011)  
pFU166 gapA-luxCDABE, colE1 ori, AmpR (Uliczka et al., 
2011) 
pFU228 gapA-dsRed2, colE1 ori, CmR (Uliczka et al., 
2011) 
pFU234 ifp+, pSC101* ori, KanR (Uliczka et al., 
2011) 
pKD3/4 Kanamycin cassette template, KanR (Datsenko & 
Wanner, 2000) 
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pSR47s-E-
TEM2 
YopE-TEM1; KanR (Harmon et al., 
2010) 
pJNS01 pET28a, cnfY, KanR (Schweer et al., 
2013), this study 
pJNS02 PcnfY-luxCDABE, pSC101* ori, AmpR (Schweer et al., 
2013) 
pJNS03 PcnfY-gfpmut3.1, pSC101* ori, AmpR (Schweer et al., 
2013), this study 
pJNS04 PcnfY-lacZ, pSC101* ori, AmpR (Schweer et al., 
2013) 
pJNS05 pAKH3, cnfY::kanR, sacB+, AmpR (Schweer et al., 
2013), this study 
pJNS09 pFU234, AmpR (Schweer et al., 
2013), this study 
pJNS10 pJNS09, cnfY+, pSC101* ori, AmpR (Schweer et al., 
2013), this study 
pJNS11 pJNS09, pSC101* ori, AmpR (Schweer et al., 
2013), this study 
pJNS12 pJNS09, cnfY+, C-terminal 6xHis, pSC101* ori, 
AmpR 
(Schweer et al., 
2013), this study 
pJNS13 pAKH3, yopE::kanR, sacB+, AmpR (Schweer et al., 
2013), this study 
2.1.8 Bacterial strains and cell lines 
All bacterial strains and eukaryotic cell lines used in this study are listed in Table 2.9 and 
Table 2.10, respectively. 
Table 2.9: Bacterial strains 
Bacterial strain Description Reference 
Escherichia coli K-12 
DH10β F- endA1 recA1 galE15 galK16 nupG rpsL  
ΔlacX74 Φ80lacZΔM15 araD139Δ(ara,leu)7697 
mcrA Δ(mrr-hsdRMS-mcrBC)λ-   
(Casadaban & 
Cohen, 1980) 
BL21 λDE3 F- ompT gal dcm lon hsdSB(rB2 mB2) gal λDE3 (Studier & 
Moffatt, 1986) 
CC118 λpir F- ∆(ara-leu)7697 ∆(lacZ)74 ∆(phoA)20 araD139 
galE galK thi rpsE rpoB arfEam recA1 
(Manoil & 
Beckwith, 1986) 
Material and methods 
 
 37 
S17-1 λpir recA thi pro hsdR-M+(RP4-2 Tc::Mu-Km::Tn7), 
λpir 
(Simon et al., 
1983) 
Yersinia pseudotuberculosis 
YPIII pIB1, wild-type (Bolin et al., 
1982) 
YP12 pIB1- (Bolin et al., 
1982) 
YP101 YPIII ∆yscS (Schweer et al., 
2013), Steinmann 
YP147 pIB1, ΔcnfY, KanR (Schweer et al., 
2013), this study 
YP149 YPIII phoPQIP32953 (Schweer et al., 
2013) 
YP150 YP147, pIB1- This study 
YP173 YPIII ETEM, amino acids 1 to 100 of 
YopE+TEM1 
(Schweer et al., 
2013) 
YP174 YPIII ΔyscS ETEM, amino acids 1 to 100 of 
YopE+TEM1 
(Schweer et al., 
2013) 
YP188 YP149 ∆cnfY, KanR  (Schweer et al., 
2013), this study 
YP216 YP147, KanS This study 
YP217 YP147 ETEM, amino acids 1 to 100 of 
YopE+TEM1 
(Schweer et al., 
2013), this study 
YP275 pIB1, ∆yopE, KanR (Schweer et al., 
2013), this study 
YP298 YP101, ΔcnfY, KanR This study 
 
Table 2.10: Cell lines 
Cell line Description Reference 
Caco-2 Human colonic Adenocarcinoma cell line (Fogh & Trempe, 1975) 
HEp-2 Human Larynx carcinoma cell line (Toolan, 1954) 
J774A.1 Murine monocytes/macrophages cell line (Ralph & Nakoinz, 
1975) 
RAW 264.7 Murine macrophages leukemia cell line (Ralph & Nakoinz, 
1977) 
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2.1.9 Software and databases 
Software applied in this study was Graph Pad PRISM 5.0 (Graphpad Software, Inc.), 
FlowJo (Tree Star Inc.), and FACSDivaTM (BD Bioscience). Databases used in this study 
were the National Center for Biotechnology Information (NCBI; www.ncbi.nlm.gov), and 
uniprot (www.uniprot.de). 
2.2 Methods 
All microbiological, molecular, biochemical and cell biological methods used in this study 
are listed in the following passages. Used materials are summarized in chapter 2.1 or 
either mentioned in the text. 
2.2.1 Microbiological methods 
2.2.1.1 Sterilization 
Sterilization of solutions and media was accomplished by autoclaving for 20 min at 
121°C and 1 bar. Temperature sensitive substances were filtered, using a filter pore size 
of 0.2 µm (Filtropure S 0.2, Sarstedt). Glassware was dry heat sterilized at 180°C. Heat 
labile equipment and workbenches were disinfected with 70% ethanol or 7% Pursept®. 
2.2.1.2 Growth conditions 
Y. pseudotuberculosis was cultured under aerobic conditions at 25°C, whereas cultures 
of E. coli were incubated at 37°C if not noted otherwise. Cultivation took place either on 
agar plates (Heraeus incubator) or in liquid culture (Infors incubation shaker) at 200 rpm 
in test tubes or Erlenmeyer flasks. Supplements, if required for the experiment, are listed 
in Table 2.3. If not noted otherwise, bacteria were grown in LB broth or on LB agar 
plates. Specially used media were: Yersinia-agar plates, BHI, SOC, DYT, MMA and 
RPMI. 
2.2.1.3 Determination of cell density 
The cell density of bacterial cultures was measured via the optical density (OD600) at 
600 nm wavelength with a spectrophotometer (Ultraspec 3100 pro, Ambersham 
Biosciences). A bacterial culture with an OD600 of 1 correlates with a cell density of 
approx. 1 x 109 bacteria/ml (Sambrook et al., 1989). Reference for the measurement 
was the corresponding growth medium. 
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2.2.1.4 Storage of bacteria 
For short- or middle-term storage periods the bacteria were grown on agar plates and 
stored at 4°C. Long-term storage was accomplished in the corresponding culture 
medium with 30% glycerol at -80°C. Therefore, overnight grown bacteria (1.25 ml) were 
mixed with 0.75 ml of 80% sterile glycerol. 
2.2.1.5 Curing of the virulence plasmid of Y. pseudotuberculosis 
To remove the virulence plasmid pIB1 from Y. pseudotuberculosis strains, the curing 
method of Riley & Toma (1989) was used. The method is based on the detection of the 
virulence associated calcium-dependency and Congo-red absorption of the pIB1 
carrying Yersinia. Therefore, the bacteria were grown on CRMOX plates for 24 h at 37°C 
to built up selection pressure on the plasmid-cured bacteria (pIB1-). Bacteria colonies 
without the plasmid appeared bright and big, whereas bacteria still carrying the plasmid 
formed small red colonies. To verify the loss, bacteria were tested by colony-PCR 
against a plasmid-encoded gene. 
2.2.1.6 Yop secretion assay 
The Yop secretion assay was performed as described previously (Cornelis et al., 1987). 
Bacteria were grown overnight at 25°C in LB medium, diluted 1:50 in fresh LB medium 
and grown at 25°C to an OD600 of about 0.4 - 0.5. The cultures were shifted to 37°C for 
3 - 4 h in the absence or presence of 20 mM Mg2+ and 20 mM sodiumoxalate, a Ca2+ 
chelator. The OD600 of the different strains was adjusted to the strain with the lowest 
OD600 (18 ml). After harvesting the bacteria by a centrifugation step (10 min, 4°C, 27,000 
x g), the supernatant was sterilized with a 0.2 µm filter. To precipitate the proteins of the 
supernatant, 2 ml of 100% trichloroacetic acid (TCA) were added and incubated for 
30 min on ice. The denatured proteins were harvested by centrifugation (10 min, 4°C, 
27,000 x g). After discarding the supernatant, the pellet was resuspended in 2 ml Aceto-
SDS and incubated for 20 min on ice. Subsequently, the mixture was centrifuged 
(10 min, 4°C, 27,000 x g) and the pellet washed with 500 µl aceton. After another 
centrifugation step (10 min, 4°C, 27,000 x g) the pellet was dried and resuspended in 
50 µl 3 x SDS sample buffer. The samples were boiled for 5 min at 95°C, separated on 
12% SDS polyacrylamide gels and visualized by Coomassie brilliant blue staining (see 
2.2.4.4). 
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2.2.2 Cell biological methods 
2.2.2.1 Cultivation and passage of eukaryotic cells 
The cultivation conditions of eukaryotic cells were 37°C with 5% CO2 in a cell incubator. 
The cells, if not noted otherwise, were cultured in 75 cm2 cell culture flasks with 20 ml 
medium and passaged every 2 - 3 days. 
2.2.2.1.1 Cultivation and passage of HEp-2 and Caco-2 cells 
Cultivation of the human epithelial cell line HEp-2 was performed in RPMI medium 
supplemented with 7.5% NCS. Caco-2 cells were cultured in DMEM medium 
supplemented with 10% FCS and 10 mM HEPES. To detach the adherent cells off the 
culture flask bottom, the cells were washed once with 5 - 10 ml PBS and subsequently 
treated with 2 ml trypsin-EDTA for 5 min at 37°C. The trypsin reaction was stopped by 
addition of 5 x the volume of culture medium. After resuspension, the cells were diluted 
1:10 with fresh medium and transferred into a new flask. 
2.2.2.1.2 Cultivation and passage of J774A.1 and RAW264.7 
The adherent murine macrophage cell lines J774A.1 and Raw264.7 were cultured in 
RPMI or IMDM (respectively) and both supplemented with 10% FCS. For the passage, 
cells were washed once with PBS and scraped off the bottom of the culture flask. After 
resuspending the cells in 10 ml fresh culture medium, cells were diluted 1:20 with 
medium and transferred into fresh flasks. 
2.2.2.2 Determination of cell count  
For the determination of the cell amount per ml cell suspension, cells were diluted 1:10 
in trypan-blue to exclude the dead cells from the count. Trypan-blue is not able to 
penetrate the cytoplasmic membrane, hence the dye invades selectively dead cells, 
which appear blue under the light microscope. The average cell number of 4 squares of 
a Neubauer counting chamber was determined and multiplied by 104. Calculation took 
account of used dilutions prior to cell counting. 
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2.2.2.3 Freezing and thawing of eukaryotic cells 
For freezing/storage, eukaryotic cells were cultured in 75 cm2 cell culture flasks to a 
subconfluent level. Cells were detached from the surface as described in 2.2.2.1.1 and 
2.2.2.1.2. After centrifugation (5 min, 25°C, 172 x g), the pellet was resuspended in 1 ml 
freezing medium and transferred into cryotubes. Subsequently, the cells were cooled 
down slowly to -80°C and long-term stored in liquid nitrogen at -170°C. 
For thawing, the cryotubes were incubated shortly at 37°C and afterwords the cells were 
taken up in 9 ml fresh medium followed by centrifugation (5 min, 25°C, 172 x g). After 
resuspending the pellet in 20 ml fresh culture medium, the cells were transferred into a 
75 cm2 cell culture flask and cultivated at 37°C with 5% CO2. 
2.2.2.4 Incubation of eukaryotic cells with CNFY 
The incubation of eukaryotic cells with CNFY took place in the respective culture medium 
(concentration 1, 10 or 25 nM). For this purpose, cells were seeded one day prior to 
toxin treatment and washed once with PBS before addition of CNFY. Incubation took 
place for 30 min - 24 h in a cell incubator. 
2.2.2.5 Multinucleation assay 
The multinucleation assay is based on the ability of CNFY to interfere in the cell cycle of 
the eukaryotic cell, leading to the formation of multinucleated giant cells. Hence, 
multinucleation assays were performed to determine the activity or in case of a ΔcnfY 
mutant strain, the loss of CNFY. In order to test this, eukaryotic cells were incubated over 
48 h with lysates of whole bacterial cell extracts and visualized afterwards. 
To prepare bacteria lysates, different Yersinia strains were grown at 37°C overnight in 
BHI medium to get a high CNFY expression. After measuring the OD600 of the cultures 
the OD600 were adjusted to the strain with the lowest cell density to 50 ml. Bacteria were 
harvested by a centrifugation step (10 min, 4°C, 27,000 x g) and subsequently the pellet 
resuspended in 5 ml PBS containing 1 tablet Mini, EDTA-free Protease Inhibitor Cocktail 
(Roche) per 10 ml and 100 µg/ml gentamycin. Cells were lyzed using a French press 
(Thermo Scientific) and 18,000 psi pressure. After another centrifugation step (60 min, 
4°C, 27,000 x g) the supernatant was sterilized using a filter with a pore size of 0.2 µm. 
The lysates were diluted 1:10, 1:50, 1:250 and 1:1,250 with culture medium and given 
onto the cells for 48 h. After the incubation, the actin cytoskeleton and nuclei were 
stained (2.2.2.6). 
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2.2.2.6 Visualization of the actin cytoskeleton 
The actin cytoskeleton was stained to determine the impact of CNFY on the 
polymerization dynamic after different incubation times. For this purpose, cells were 
treated with FITC conjugated phalloidin. 
Therefore, cells were seeded one day prior to treatment with a density of 1.7 x 
104 cells/well in a microslide 8 well plate (ibidi). Cells were washed once with PBS and 
treated for 24 h with recombinant CNFY or 48 h with bacteria lysate. After incubation, the 
cells were washed three times with PBS and fixed with 4% Paraformaldehyde (PFA) for 
10 min at room temperature. Subsequently, the cells were washed three times with PBS 
(each time 5 min) and permealized using 0.1% Triton X-100 (in PBS) for 5 min at room 
temperature. After the following washing steps (3 x 5 min), cells were stained for 1 - 3 h 
at room temperature in the dark, using Phalloidin-FITC (0.5 µg/ml in PBS). Cells were 
then washed (3 x 5 min) and the nuclei stained with DAPI (1 µg/ml in 1 x TBST) for 
3 min at room temperature in the dark. After 3 additional washing steps (3 x 5 min), the 
cells were visualized using a fluorescence microscope (Axiovert II with Axiocam HR, 
Zeiss, Germany) and the AxioVision program (Zeiss, Germany) or stored at 4°C in the 
dark. 
2.2.2.7 Rho/Rac/Cdc42 activation assay 
To determine whether there is a concentration dependency of CNFY or an impact of 
YopE on the activation of the three small Rho-GTPases, RhoA, Rac1 and Cdc42 
activation assays were carried out. To test the activation of Rac1 and Cdc42 a 
Rac1/Cdc42 Activation Assay Combo Kit of Cell Biolabs was used, whereas the 
activation of RhoA was tested using the Rho Activation Assay Kit 17-294 of Millipore, 
following the manufacturer instructions. 
For the assays, the murine macrophage cell lines J774A.1 or RAW264.7 or the human 
epithelial cell line HEp-2 were seeded two days prior to treatment on 1 well plates 
(Fischer Scientific) with a concentration of 2 x 106 cells/well. At least 20 h before toxin 
treatment, cells were washed once in PBS and further incubated in starving medium 
(without FCS). 
For evaluating activation levels’ dependency on CNFY, cells were washed once with 
PBS and incubated with different concentrations of the recombinant CNFY toxin (1 nM, 
10 nM, and 25 nM) for 3 h at 37°C in starving medium. 
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To test the impact of YopE on the activation of the three Rho-GTPases, the murine 
macrophages RAW264.7 were infected after toxin treatment (25 nM) with either YPIII 
(wild-type) or YP275 (∆yopE). To this purpose, yersiniae were grown overnight at 37°C, 
washed once with PBS and adjusted to an OD600 of 1. For infection, the cells were 
washed once with PBS and the bacteria, diluted in the starving medium to an MOI of 
100, were given onto the cells. Infection took place for 20 min at 37°C.  
The activation assay is based on the use of Rhotekin RBD or PAK PBD agarose beads. 
When active (GTP-bound form), RhoA is specifically binding to the Rho-binding domain 
(RBD) of Rhotekin, whereas active Rac1 and Cdc42 specifically bind to the p21-binding 
domain (PBD) of the p21-activated protein kinase (PAK) to control downstream signaling 
cascades. Figure 2.2.1 scematically shows the principle of the Rac1/Cdc42 Activation 
Assay Combo Kit. The experiment was carried out according to the manufacturers 
protocols as shortly described below. 
Cells were lyzed using the supplemented buffer of the kits. Subsequently protein loading 
controls were taken and the remaining lysates were incubated with Rhotekin RBD or 
PAK PBD agarose beads to isolate the active forms of RhoA, Rac1 or Cdc42. Isolated 
active forms of the GTPases and protein loading controls were then loaded onto SDS-
PAGE and detected with specific antibodies via western blot (2.2.4.5). 
 
Figure 2.2.1: Principle of the Rho GTPase activation assay. 
RhoA/Rac1/Cdc42 Activation Assay Combo Kit (Cell Biolabs, San Diego, CA, USA). 
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2.2.2.8 TEER (Trans Epithelial Electrical Resistance) measurement 
To test a possible influence of the toxin CNFY on the intestinal epithelial cell monolyer, 
the transwell system of Corning Life Sciences was used. Therefore, the Transwell® (see 
Figure 2.2.2) with 3.0 µm Pore Polycarbonate Membrane Insert was moisted at least 1 h 
before seeding of the cells. In order to do this, 800 µl medium was given to the 
basolateral side and 100 µl to the apical side of the insert. 
 
Figure 2.2.2: Scheme of the Transwell® culture chamber. 
 
The Caco-2 cells were seeded apical (2.2.2.1.1 & 2.2.2.2) with a concentration of 1,5 x 
105 cells/insert in 100 µl (in total 200 µl). A change of the medium (apical & basolateral) 
was performed every second day. The cells were seeded 21 - 29 days before the 
treatment to ensure the formation of a confluent monolayer. In order to test the 
confluency, the TEER was measured repeatedly with an epithelial Voltohmmeter (World 
Precision Instruments Inc.). 
The Caco-2 monolayer was treated basolateral with the recombinant toxin or apically 
infected with Yersinia strains. For the toxin treatment, CNFY (10 nM) was given to the 
basolateral side of the membrane in fresh medium. The TEER was measured before 
treatment and subsequently every second hour. For the infection, bacteria were grown 
overnight at 25°C and adjusted to an OD600 of 0.5. Approximately 1 x 106 bacteria/well 
were given apical onto the monolayer in binding buffer. The TEER was measured before 
infection and was subsequently determined every hour.  
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2.2.2.9 Yop delivery assay in vitro 
The Yop delivery assay was carried out to detect differences in the Yop translocation 
pattern into eukaryotic cells due to CNFY activity. The Yop delivery was measured with 
three different techniques (see below). Visualization and quantification of Yop 
translocated cells were carried out with the LiveBLAzer-FRET B⁄G Loading Kit from Life 
Technologies (Bla-reporter assay), whereas the detection of the translocated Yop 
proteins in the cells was carried out with antibodies against the proteins.  
The general principle of the bla-reporter assay is based on the translocation of β-
lactamase fusion proteins into the eukaryotic cell (see Figure 2.2.3). In this study, a 
yopE-bla fusion construct was used which is translocated with the T3SS. Hence, 
eukaryotic cells were infected with different Y. pseudotuberculosis strains harbouring the 
gene for the fusion-protein. After an infection/translocation period of 1 h, the cells were 
stained with the dye CCF4-AM. The dye gets trapped due to the activity of esterases in 
the living cells, which appear green fluorescent after excitation with 409 nm wavelength. 
If the fusion-protein is translocated, the β-lactamase is able to cleave the dye, leading to 
blue fluorescent cells after excitation with 409 nm wavelength. 
 
 
Figure 2.2.3: Principle of the bla-reporter assay. 
The dye CCF4-AM is trapped in the cell by cytoplasmic esterases. After excitation with 409 nm wavelength, 
all living cells appear green fluorescent. All cells with translocated β-lactamase (YopE- β-lactamase in this 
study) appear blue fluorescent due to the cleavage of the dye. 
 
CCF4-AM 
FRET%
CCF4 
409 nm 520 nm 
CCF4 
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447 nm 520 nm 
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2.2.2.9.1 Microscopy of Yop delivery 
The microscopic Yop delivery assay was performed as described previously (Marketon 
et al., 2005). Therefore, 5 x 104 cells/well (µ-slide, ibidi) of HEp-2, Caco-2, RAW264.7 or 
J774A.1 cells were seeded one day prior to infection. 
At the day of infection, the cells were washed once with PBS and pretreated with 25 nM 
of the recombinant CNFY (3 µg/ml), exoenzyme C3 transferase from Clostridium 
botulinum (CT04, Cytoskeleton. Inc) (0.5 µg/ml, 1 µg/ml), Clostridium difficile toxin 
TcdBF (85 ng/ml, 250 ng/ml) (Huelsenbeck et al., 2007a) or the same amount of PBS in 
serum free medium for 2 - 3 h at 37°C. 
For infection, overnight cultures of the strains YPIII, YP173, YP174 or YP217 were 
washed once with PBS and adjusted to an OD600 of 1. The infection dose was at MOI of 
10 and was carried out for 1 h at 37°C. To facilitate the interaction between eukaryotic 
cells and bacteria, the yersiniae were centrifuged onto the cells (5 min, RT, 172 x g). 
After infection the cells were washed three times and dyed with CCF4-AM using the 
LiveBLAzer-FRET B⁄G Loading Kit from Life Technologies for 90 min at RT, according to 
the manufacturers protocol. The Yop translocation was visualized with a fluorescence 
microscope (Axiovert II with Axiocam HR, Zeiss, Germany), using the AxioVision 
program (Zeiss, Germany). 
2.2.2.9.2 Flow cytometry of Yop delivery 
To determine a possible influence of CNFY on the Yop delivery rate into 
Y. pseudotuberculosis infected eukaryotic cells, a Yop delivery assay with subsequent 
flow cytometry analysis was performed. Hence, eukaryotic cells were infected with 
Y. pseudotuberculosis strains harbouring a yopE-bla fusion.  
For quantification of the amount of cells translocated with the yop proteins, infected and 
stained cells were acquired with a LSR Fortessa cell analyzer (BD Bioscience). 
Therefore, 1 x 106 HEp-2 or J774A.1 cells/well (6-well plate, TPP) were seeded one day 
prior to infection.  
At the day of infection, the cells were washed once with PBS and preincubated with the 
toxin CNFY (25 nM/ 3 µg/ml) or an equal amount of PBS for 3 h at 37°C. For infection, 
overnight cultures (37°C) of the strains YPIII, YP173, YP174 or YP217 were washed 
once with PBS and adjusted to an OD600 of 1. The infection dose was an MOI of 10 and 
was carried out in binding buffer for 1 h at 37°C. To facilitate the interaction between 
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eukaryotic cells and bacteria, the yersiniae were centrifuged onto the cells (5 min, RT, 
172 x g). Subsequently, the cells were washed once with PBS and detached from the 
cell culture plate. Therefore, HEp-2 cells were treated with 500 µl trypsin-EDTA for 
5 min. The reaction was stopped by the addition of 4.5 ml medium containing 
7.5% NCS. J774A.1 macrophages were detached by scraping the cells off the tissue 
culture plate. After detachement, the cells were resuspended in 1 ml medium and 
centrifuged for 5 min at 400 x g. The supernatant was removed completely and the cell 
pellet resuspended in 200 µl of the CCF4-AM staining solution (according to the 
manufacturers protocol) and transfered into a non-coated 96-well microtiter plate. 
Throughout the staining period (90 min), the cells were shaken with a microplate shaker 
(PMS-1000, Grant bio) at 400 rpm. Subsequently, the cells were transferred into 
Matrix™ Blank and Alphanumeric Storage Tubes (Thermo Scientific) and acquired with 
the flow cytometer. Acquired data were then analyzed with FlowJo software (Treestar). 
2.2.2.9.3 Western blot of Yop delivery 
To compare the translocated Yop proteins in the eukaryotic cells after infection with YPIII 
(wt) or the yopE mutant strain (YP275), a specific antibody against all Yop proteins was 
used for western blot analysis. Therefore, 2 x 105 RAW264.7 cells/well were seeded one 
day prior to infection onto 24-well tissue culture plates. 
At the day of infection, the cells were washed once with PBS and incubated with 25 nM 
recombinant CNFY or the equal amount of PBS for 3 h at 37°C. For infection, overnight 
cultures (37°C) of YPIII, YP275 and YP101 were washed once with PBS and adjusted to 
an OD600 of 1. The eukaryotic cells were infected with an MOI of 100 in binding buffer. 
To facilitate the interaction between eukaryotic cells and bacteria, the Yersinia were 
centrifuged onto the cells (5 min, RT, 172 x g). One hour post infection (37°C), the cells 
were washed twice with PBS and incubated for another hour with gentamycin containing 
binding buffer (50 µg/ml). After elimination of the extracellular bacteria, the cells were 
washed three times with PBS and resuspended in 100 µl 3 x SDS sample buffer. The 
lyzed cells were heated for 5 min at 95°C and 10 µl loaded onto a 12% SDS 
polyacrylamide gel. After separation on the gel, proteins were blotted onto a 
nitrocellulose membrane and the intracellular Yops were visualized with an antiserum 
directed against all secreted Yops (α-all Yop) (see 2.2.4.5). Subsequently, the 
membrane was stripped and reprobed with a pan-actin antibody as loading control.  
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2.2.3 Molecular biological methods 
2.2.3.1 Measuring of DNA concentration 
The measurement of the DNA concentration and purity was performed photometric with 
a NanoDrop spectrophotometer (PeqLab), using the optical density of the solution 
(OD260, OD280). Here, an OD260 of 1 corresponds to a dsDNA concentration of 50 µg/ml. 
To eliminate potential impurities, the ratio of OD260 to OD280 was calculated. A value of 
1.8 represents a solution with high purity, whereas DNA solutions contaminated with 
proteins possess significant lower OD260/OD280 values. 
2.2.3.2 Polymerase chain reaction (PCR) 
The PCR was used to amplify specific DNA fragments with heat stable DNA 
polymerases (e.g. Taq) and was carried out after Innis & Gelfand (1990). The annealing 
temperature is dependent on the used oligonucleotides (length, sequence) and was 
calculated (see Suggs et al., 1981) and tested by a gradient PCR. The elongation time 
and temperature are dependent on the used polymerase and the size of the DNA 
fragment, which needs to be amplified.  
Because of its proof reading activity, the Phusion® High-Fidelity DNA polymerase was 
mainly used to amplify DNA. The screening of positive clones was accomplished by the 
MangoTaq™ polymerase, which contains a coloured loading dye for gel electrophoresis. 
The LongAmp® Taq DNA polymerase was preferentially used to amplify long DNA 
fragments. PCR reaction compounds were mixed according to the manufacturers 
protocol in 20 - 25 µl aliquots. Fragments were amplified in a T3000 Thermocycler 
(PeqLab), an Eppendorf Master cycler or an Eppendorf gradient cycler. 
2.2.3.3 Agarose gel electrophoresis 
The agarose gel electrophoresis is used for separation of DNA fragments according to 
their molecular weights and was carried out in horizontal electrophoresis chambers after 
Sambrook et al. (1989). The agarose gels contained 0.8 - 2% agarose, which was 
heated in 1 x TAE buffer. The same buffer was used as running buffer in the chamber. 
DNA samples were mixed with 6 x loading dye, applied onto the gel and seperated 
electrophoretically at 90 - 110 V for 45 - 60 min. Using ethidiumbromide, the DNA was 
stained for 10 - 20 min, detected with UV light, and documented with the camera of the 
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gel documentation system (Gel DocTM, Bio-Rad). Molecular weigths were detected on 
the basis of the DNA size standard Gene Ruler DNA Ladder Mix (see Figure 2.2.4).  
 
Figure 2.2.4: Gene Ruler DNA Ladder Mix (Thermo Scientific). 
 
2.2.3.4 Plasmid DNA isolation 
5 - 7 ml LB medium supplemented with antibiotics were inoculated with solid colonies of 
E. coli and incubated with agitation overnight at 37°C. The plasmid isolation was 
performed with the „QIAprep®Spin Miniprep Kit“ (QIAGEN) according to the 
manufacturers protocol. Isolated plasmids were eluted with 50 µl H2Odest. 
2.2.3.5 Genomic DNA isolation 
For preparation of genomic DNA of Yersinia, bacteria were grown overnight at 25°C. 
200 µl of the culture was mixed with 200 µl phenol/chloroform and centrifuged for 2 min 
(14,000 x g). The supernatant was transfered into a new tube and the DNA precipitated 
with 4 volumes of 100% ethanol. After centrifugation for 20 min (14,000 x g), the DNA 
was washed twice in 70% ethanol and the dried pellet resuspended in EB buffer. The 
concentration of the precipated genomic DNA was determined and adjusted to 
100 ng/µl. The DNA was stored at 4°C and used for DNA amplification. 
2.2.3.6 DNA extraction 
For the isolation of DNA fragments out of agarose gels, the „MinElute Gel Extraction Kit“ 
(QIAGEN) was used. The band was cut out of the gel under UV light and eluted 
according to the manufacturers protocol. The DNA was eluted in 50 µl H2Odest. 
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2.2.3.7 Purification of PCR fragments 
For purification of PCR fragments, the „QiAquick PCR Purification Kit” (QIAGEN) was 
used. The purification was carried out according to the manufacturers protocol and for 
elution of the fragments 50 µl H2Odest was used. 
2.2.3.8 Restriction digestion of DNA 
For the restriction of plasmid DNA or PCR products, different restriction enzymes were 
used. These endonucleases possess the feature to target dsDNA at specific recognition 
sites. This reaction normally leads to the formation of „sticky ends“, needed for the 
insertion of DNA fragments, which were treated with the same enzymes. The digestion 
was done according to the manufacturers protocol (New England Biolabs) with the 
appropriate buffer and if necessary 1 - 10 units of the enzymes were used depending on 
the reaction mix. The restriction took place for 3 - 12 h at 37°C. Heat inactivation was 
performed for 20 min at 65°C, when suitable. Subsequently, the digested DNA was 
loaded and extracted of an agarose gel. 
2.2.3.9 Dephosphorylation 
To prevent religation of the digested plasmid, the DNA fragments were treated with the 
antarctic phosphatase prior to ligation. In this reaction the 5’ end of the restriction site is 
dephosphorylated with 1 - 3 µl of the phosphatase in the reaction mix for 1 h at 37°C. 
2.2.3.10 Ligation 
A ligation is used to insertion a DNA fragment into a plasmid. Hence both the fragment 
and the plasmid were digested with the same restriction endonucleases. Ligation was 
proceeded according to manufacturers protocol with 1 - 3 µl T4-DNA-ligase and the 
appropriate buffer for 3 h at room temperature or overnight at 4°C in the dark. The ligase 
is catalyzing the formation of phosphodiester bonds. 
2.2.3.11 DNA sequencing 
Sequencing of constructed plasmids or PCR products was performed by the Department 
of Genome Analysis at the Helmholtz Centre for Infection Research. 
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2.2.3.12 Construction of plasmids 
2.2.3.12.1 Construction of CNFY overexpressing plasmid 
For the overexpression and purification of the toxin CNFY, the plasmid pJNS01 (cnfYhis6) 
was constructed. Therefore, the gene cnfY (ypk_2615) from the genomic DNA of 
Y. pseudotuberculosis YPIII was cloned into the commercial vector pET28a (Novagen). 
The gene cnfY was amplified with the primers II794/II795 and integrated into the 
XhoI/NheI sites of pET28a (see Table 2.8), which harbours a His tag sited at the N-
terminus of cnfY. Clones were selected on LB agar plates containing kanamycin and 
tested by sequencing and test restriction digest (for general cloning procedure see 
chapters above). 
2.2.3.12.2 Construction of mutagenesis plasmids 
To achieve the genomic replacement of specific genes, mutagenesis plasmids were 
constructed. For the construction of the plasmid pJNS05 (containing cnfY::KanR 
mutation) and the plasmid pJNS13 (containing yopE::KanR), first the kanamycin 
resistance gene was amplified, using the kan primers (I661/I662) and plasmid 
pACYC177 as template. Next, Y. pseudotuberculosis YPIII genomic DNA or virulence 
plasmid DNA was used as a template to amplify 500-bp regions flanking the target gene 
cnfY or yopE up- and down- stream. The upstream fragment of cnfY or yopE was 
amplified using the primers III710/715 or V553/V554, respectively. The reverse primers 
contained 20 nucleotides at the 5’-end, which are homologous to the start of the 
kanamycin resistance gene. The downstream fragment of cnfY or yopE was amplified 
with the primers III712/III714 or V555/V556, respectively. The forward primers contained 
20 nucleotides at the 3’-end, which are homologous to the end of the kanamycin 
resistance gene.  
A fusion-PCR reaction was performed with the corresponding forward primer and the 
reverse primer using the upstream and downstream PCR products of the target genes 
and the kanamycin gene fragment as templates. The fragments were digested using 
SacI and cloned into the suicide vector pAKH3. The transformants were selected on LB 
agar plates containing kanamycin and tested by sequencing and tesT restriction (for 
general cloning procedure see chapters above). 
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2.2.3.12.3 Construction of reporter gene fusion plasmids 
For the construction of the cnfY promoter fusion with gfpmut3.1, the DNA upstream of 
cnfY (525 bp) was amplified from the genomic DNA of Y. pseudotuberculosis YPIII with 
the primers II896/II898. The fragment was integrated into the BamHI/SalI restriction site 
of pFU58. The transformants (pJNS03) were selected on LB agar plates supplemented 
with carbenicilin and tested by sequencing and restriction (for general cloning procedure 
see chapters above). 
2.2.3.12.4 Others 
For the complementation of the strain YP147 (∆cnfY), the plasmid pJNS10 was 
constructed. This plasmid contains the cnfY gene under control of its own promoter.  
For the construction, the vector pFU234 of the pFU series (Uliczka et al., 2011) was 
used. First, the antibiotic resistance cassette was exchanged from kanamycin to 
carbenicilin, using the restriction sites XhoI and SacI to obtain the vector pJNS09. Next, 
a PCR fragment was amplified (PcnfY-cnfY) with the primers II896/IV16 from the 
chromosomal DNA of Y. pseudotuberculosis YPIII. The fragment was integrated into the 
BamHI/NotI sites of pJNS09. The transformants were selected on LB agar plates 
containing carbenicilin. To confirm the positive clones, the inserted fragment was 
sequenced and restricted. As a control for the complementation experiments a vector 
containg only the ori SC101* and the antibiotic resistance cassette was constructed. 
Hence, the vector pJNS09 was restricted with the enzyme AatII and religated to obtain 
the plasmid pJNS11. 
For easy western blot detection of the CNFY toxin without an appropriate antibody 
against CNFY, the cnfY gene with a C-terminal His tag was constructed. Therefore, the 
fragment PcnfY-cnfYhis6 was amplified from the chromosomal DNA of 
Y. pseudotuberculosis YPIII using the primers II896/IV474 and integrated into the 
BamHI/NotI of pJNS09. The transformants were selected on LB agar plates containing 
carbenicillin. To confirm the positive clones, the inserted fragment was sequenced and 
restricted (for general cloning procedure see chapters above). 
2.2.3.13 Construction of mutant strains 
Different mutant strains were generated to identify functions of the deleted genes. For 
the construction procedure of the mutagenesis plasmids see 2.2.3.12.2. Mutants were 
genereated by homologous recombination as described previously (Nagel et al., 2001). 
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For construction of the mutant strains YP147, YP188 and YP298, the plasmid pJNS05 
was integrated via conjugation into the cnfY locus of YPIII, YP147 and YP101, 
respectively. The mutant strain YP275 was generated using the plasmid pJNS13. 
Chromosomal integration of the fragments was selected by plating on Yersinia agar 
plates supplemented with kanamycin and carbenicillin. Excision of the plasmid including 
the cnfY or yopE allele was obtained by plating of the strain on 10% sucrose and was 
analyzed by PCR and DNA sequencing. To verify the deletion of cnfY or yopE, different 
PCR reactions were carried out, using the primer pairs II371/II372, III711/III713, 
III727/II895, III711/III680 and III713/III681 for ∆cnfY and V557/V558, V553/III680 and 
V556/III681 for ∆yopE. To further test a new constructed ΔcnfY mutant, a multinucleation 
assay (2.2.2.5) and/or a western blot (2.2.4.5) against CNFY were performed. To further 
test the ΔyopE mutant, a western blot (2.2.4.5) against all Yop proteins was performed. 
The strain YP217 was constructed by chromosomal integration of the YopE-β-lactamase 
(ETEM) fusion plasmid pSR47s-E-TEM1 into the yopE locus. Because the plasmid 
pSR47s-E-TEM1 also harbours a kanamycin resistance cassette, the resistance 
cassette of the YP147 strain needed to be removed first. In order to do so, the vector 
pCP20 was transformed electricallay into the strain. The transformants were inoculated 
in BHI medium and grown overnight at 37°C to remove the kan gene. At the next day, 
the overnight culture was diluted 1:10 in BHI and incubated for 1 h at 42°C to remove the 
remaining vector. Subsequently, the bacteria were plated on LB agar plates. The clones 
were tested for growth on kanamycin and carbenicillin. The bacteria not able to grow on 
the two antibiotics formed the mutant YP216. The following integration of yopE-TEM1 
was obtained through conjugation of E. coli K-12 strain S17λpir pSR47s-E-TEM1 with 
the Y. pseudotuberculosis strain as described previously (Harmon et al., 2010). To verify 
the mutant a PCR was carried out with the primers V439/II306. 
To obtain the mutant strain YP150, the YP147 was cured of the virulence plasmid pYV 
(see 2.2.1.5). The mutant was verified by PCR using the primers II371/II372. 
For construction of the other mutant strains used in this study, see Schweer et al., 2013. 
2.2.3.14 Production of electrocompetent Yersinia 
For the production of electrocompetent Yersinia, 20 ml BHI medium were inoculated 
1:50 with an overnight culture and grown at 25°C to exponential growth phase (OD600 
0.5 - 0.8). After centrifugation for 15 min at 4°C (2,755 x g), the bacteria pellet was 
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resuspended in 2 ml ice-cold H2Odest and subsequently centrifuged for 2 min at 4°C 
(7,500 x g). The bacteria were resuspended in 2 ml ice-cold transformation buffer, 
centrifuged for 2 min at 4°C (7,500 x g), resuspended in 120 µl transformation buffer, 
and directly used for transformation (2.2.3.16). 
2.2.3.15 Production of chemocompetent E. coli 
Chemocompetent E. coli were produced using the rubidium chloride method. Hence, 
200 ml LB medium were inoculated 1:100 with an overnight culture and supplemented 
with 4 ml MgSO4 (20 mM). The culture was grown at 37°C to exponential growth phase 
(OD600 0.5 - 0.8). Subsequently, the cells were centrifuged for 8 min at 4°C (2,755 x g) 
and the pellet resuspended in 80 ml TFB1 buffer. The suspension was incubated for 
10 min on ice and centrifuged again for 8 min at 4°C (2,755 x g). Next, the pellet was 
resuspended in 8 ml ice-cold TFB2 buffer. After an incubation period of 45 min on ice, 
100 µl aliquots of bacteria were transferred into tubes and stored at -40°C. 
2.2.3.16 Electro transformation in Yersinia 
For transformation of plasmid DNA in Yersinia, 40 µl electrocompetent cells were mixed 
wit 2 - 6 µl plasmid-DNA and transfered into a cold 2 mm cuvette (PeqLab). The 
electroporation was accomplished at 2.5 kV, 25 µF and 200 W with an elctroporator 
(GenePulser II, Bio-Rad). The bacteria were immediately taken up in 1 ml SOC medium 
without antibiotic for phenotypic expression (2 h, 25°C, 550 rpm). Next, the bacteria were 
grown on LB agar plates supplemented with antibiotics for selection of transformants for 
two days at 25°C. 
2.2.3.17 Chemical transformation in E. coli 
For the chemical transformation of plasmid DNA in E. coli, 100 µl aliquots of competent 
cells were thawed on ice and subsequently mixed with 1 - 15 µl plasmid-DNA or a 
ligation mix. After an incubation period of 30 min on ice, a heat shock at 42°C for 2 min 
and an incubation for 2 min at 4°C on ice, the bacteria were diluted in 500 µl LB medium. 
The cells were incubated at 37°C for 60 min at 550 rpm for phenotypic expression. The 
selection of the transformants was accomplished on LB agar plates supplemented with 
antibiotics. 
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2.2.4 Biochemical methods 
2.2.4.1 Preparation of whole cell extracts 
For the preparation of whole cell extracts, the OD600 was measured to calculate the 
correct buffer amount (see below) and 1 ml of the bacterial culture centrifuged for 5 min 
at 14,000 x g. The pellet was resuspended in 3 x SDS sample buffer (150 µl = OD600 3) 
and heated at 95°C for 5 min. Subsequently, the samples were treated with 0.2 µl 
benzonase (5 - 5.8 U) for 1 h at 37°C and loaded onto a SDS polyacrylamid gel or 
stored at -20°C. 
2.2.4.2 Protein precipitation (TCA) 
To precipitate the proteins of the supernatant of a bacterial culture, TCA was used for 
denaturation. Therefore, the Yersinia were grown 3 h, 7 h or overnight at 37°C or 25°C 
and subsequently the OD600 was determined and adjusted to 45 ml with an OD600 of 1. 
After harvesting the bacteria by a centrifugation step (10 min, 4°C, 27,000 x g), the 
supernatant was sterilized with a 0.2 µm filter. To precipitate the proteins of the 
supernatant, 5 ml of 100% TCA was added. Incubation took place for 30 min on ice and 
the denatured proteins were harvested by centrifugation (10 min, 4°C, 27,000 x g). After 
discarding the supernatant, the pellet was resuspended in 4 ml Aceto-SDS and 
incubated for 20 min on ice. Subsequently, the mixture was centrifuged again (10 min, 
4°C, 27,000 x g) and the pellet washed with 500 µl aceton. After another centrifugation 
step (10 min, 4°C, 27,000 x g) the pellet was dried and resuspended in 50 µl 3 x SDS 
sample buffer. After heating for 5 min at 95°C, the samples were separated on 10% SDS 
polyacrylamide gels. A western blot was carried out with antibodies against CNFY or a 
His tag to make the secreted proteins visible. 
2.2.4.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
The SDS-PAGE was performed as described previously (Laemmli, 1970). This method 
consists of a denaturating discontinuous electrophoresis separating proteins according 
to their molecular weight. The SDS and β-mercaptoethanol containing sample buffer 
denatures the native proteins by destroying non-covalent bondings and disulfide bridges. 
The different pH-values of the stacking- and running-gel lead to a discontinuous 
electrophoresis. 
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Figure 2.2.5: PageRulerTM Prestained Protein Ladder (Fermentas). 
 
The samples were heated, prior to loading, for 5 min at 95°C and centrifuged for 5 min at 
14,000 x g. 5 - 25 µl of the samples and 5 µl of the PageRulerTM Prestained Protein 
Ladder (see Figure 2.2.5) were used. The electrophoresis of the 10 - 15% gels was 
carried out at 130 V with SDS running buffer for 60 - 90 min. Gels were either stained in 
Coomassie staining solution (2.2.4.4) or blotted onto a polyvinylidene fluoride (PVDF) 
membrane (2.2.4.5). 
Table 2.11: Composition of 0.75 mm SDS-gels (Sambrook et al., 1989) 
 
  
Component 10% running 
gel (2x) 
12% running 
gel (2x) 
15% running 
gel (2x) 
Stacking gel 
(4x) 
H2Odest 4.2 ml 3.5 ml 2.5 ml 6.5 ml 
30% 
Acryl/bisacrylamide 
3.3 ml 4.0 ml 5 ml 1.1 ml 
Running gel buffer 2.5 ml 2.5 ml 2.5 ml - 
Stacking gel buffer - - - 2.5 ml 
TEMED 25 µl 25 µl 25 µl 25 µl 
APS (10%) 100 µl 100 µl 100 µl 100 µl 
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2.2.4.4 Coomassie staining 
The Coomassie staining method was used to stain all proteins separated by a SDS 
polyacrylamide gel (Diezel et al., 1972). After electrophoresis, the gels were stained with 
agitation for 1 h at RT in the Coomassie staining solution. The destaining was carried out 
by agitation for 2 x 30 min in 10% acetic acid at RT. 
2.2.4.5 Western blot 
To specifically detect proteins, western blot analysis were carried out as described 
previously (Towbin et al., 1979). Therefore, proteins were separated with a SDS-PAGE 
and transfered electrophoretic onto an Immobion PVDF membrane (Millipore). The 
membrane was activated previously for 10 - 15 sec in methanol. Subsequently, the 
activated membrane and the gel were enclosed in between two equlibrated (transblot 
buffer) sponges and Whatman paper and adjusted in the blotting chamber. The 
assembly was carried out according to the manufacturer’s protocol (Mini-protean II 
western blot system, Bio-Rad). After transferring the proteins for 1 h at 100 V in 
precooled transblot buffer, the membrane was blocked, to avoid unspecific binding, for 
1 h at RT or overnight at 4°C. Therefore, the membrane was agitated in TBSTB or 
TBSTM. After blocking, the membrane was incubated under agitation with the primary 
antibody for immuno-detection (diluted in TBSTB/TBSTM, see Table 2.5) of a specific 
protein for 1 - 5 h at RT or overnight at 4°C, according to the manufacturer’s protocol. 
Subsequently, the membrane was wasched three times in TBST for 10 min under 
agitation. The secondary antibody conjugated to horseradish peroxidase (HRP), was 
added to the membrane (diluted in TBSTB/TBSTM) and incubated for 1 h at RT or 
overnight at 4°C under agitation. After three washing steps, for 10 min in TBST, the blot 
was developed using the Western Lightning ECL II Kit (Perkin Elmer) and documented 
with the chemi documentation system (Bio-Rad). 
2.2.4.6 Stripping of the membrane 
To remove antibodies from a membrane to detect additional proteins on it, the 
membrane was stripped. Therefore, the membrane was washed once in TBST after 
developing and stripped under agitation at RT for 5 - 15 min in Restore Plus Western 
Blot Stripping Buffer (Thermo Scientific) according to the manufacturer’s protocol. After 
stripping the membrane, it was washed three times for 10 min in TBST and blocked 
again. Subsequently, new antibody probing on the membrane could be performed. 
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2.2.4.7 Purification of CNFY-His6 
For overexpression of CNFY, E. coli strain BL21λDE3 was transformed with the cnfY 
expression plasmid pJNS01. The bacteria were grown at 37°C in 500 ml LB medium 
supplemented with kanamycin, to an OD600 of 0.6. Subsequently, the Plac-driven 
expression was induced upon addition of 250 µM IPTG. Further incubation took place at 
17°C overnight at 200 rpm. After harvesting the bacteria by centrifugation (10 min, 4°C, 
27,000 x g), the pellet was resuspended in 20 ml lysis buffer. Subsequently, the bacteria 
were lyzed with a French press (18,000 psi) and centrifuged for 90 min with 27,000 x g 
at 4°C. The supernatant was sterilized using a 0.2 µm filter.  
The purification was performed by an affinity chromatography with 1.5 ml Ni-NTA 
agarose (Qiagen). Therefore, the agarose was transferred into a gravity chromatography 
column (Bio-Rad) and washed once with washing buffer. The sterile supernatant was 
inserted into the column to let the His tag conjugated CNFY bind. Subsequently, the 
supernatant with unbound proteins run out of the column and the agarose was washed 
with three column volumes of washing buffer. To elute the bound protein, 8 ml elution 
buffer 1 followed by 8 ml elution buffer 2 were added to the column and collected in 
8 fractions. Samples of each fraction were loaded onto a SDS-PAGE and detected with 
Coomassie staining solution (2.2.4.4). Fractions containing the recombinant protein were 
pooled. 
To get rid of the imidazol contained in the elution buffers, a buffer exchange against PBS 
was performed, using an Amicon (Millipore), which excludes proteins smaller than 
100 kDa. The Amicon was used according to the manufacturer’s protocol and the protein 
washed three times with each 10 ml PBS. After exchanging the buffer and concentrating 
the protein to 1.5 ml 10 µl of the protein was mixed with 5 µl of 3 x SDS sample buffer 
and boiled at 95°C for 5 min. The sample was loaded on 2 SDS polyacrylamide gels 
(5 µl/gel) and one gel was stained with Coomassie staining solution, the other used for 
western blot analysis with a anti His primary antibody (see 2.2.4.5). 
To measure the concentration of the purified toxin, a Bradford assay was performed with 
the Coomassie Reagent Protein Assay Kit (Pierce), according to the manufacturer’s 
protocol. Therefore, the protein was measured undiluted and diluted 1:10 and 1:100 in 
duplicates. 250 µl of the Coomassie reagent was added to each sample and incubated 
for 10 min at RT. The absorption was measured in an iMark Microplate Absorbance 
Reader (Bio-Rad) at wavelength 595 nm. Subsequently, the protein was aliquoted and 
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frozen at -20°C. To test the activity of the recombinant toxin a multinucleation assay was 
performed (see 2.2.2.5). 
2.2.4.8 Polyclonal antibodies against CNFY of Y. pseudotuberculosis 
Polyclonal antibodies against CNFY were generated in a rabbit (Davids Biotechnology) 
by injection of 0.2 - 0.6 mg purified recombinant CNFY (see 2.2.4.7). The toxin was heat 
inactivated for 30 min at 70°C prior to injection. For purification, the serum was 
specifically purified by affinity chromatography (see below). As a negative control for the 
polyclonal antibodies, pre-immune serum of the rabbit was used.  
2.2.4.8.1 Specific purification of polyclonal CNFY antibody 
To specifically purify the CNFY antibody of the rabbit serum, an affinity chromatography 
with CnBr activated sepharose 4B was performed. Therefore, approximately 1.5 mg of 
the recombinant CNFY protein (see 2.2.4.7) were diluted in 4 ml PBS. Subsequently, the 
PBS was exchanged with an Amicon (>100 kDa) against 4 ml coupling buffer and stored 
at 4°C before addition to the activated sepharose. 
To activate the CnBr sepharose, 0.5 g were taken up in 10 ml 1 mM HCl and transferred 
onto a filter on a suction filter. The sepharose was washed on the filter first for 15 min 
with 200 ml 1 mM HCl and second with 10 ml coupling buffer. Subsequently, the 
sepharose was transferred into a 50 ml falcon tube with 5 ml coupling buffer. 
To couple the prepared protein to the activated sepharose, the protein was given to the 
sepharose and incubated under agitation for 2 h at RT. After incubation, the mixture was 
transferred onto a polypropylene column and the sepharose was sedimented. The flow 
through was collected and prepared for a SDS-PAGE with 3 x SDS sample buffer (see 
2.2.4.3). Uncoupled protein was removed by washing the sepharose with 2.5 ml 
coupling buffer. Using 1 M freshly prepared ethanolamine (pH 8) the remaining binding 
sites of the sepharose were blocked under agitation for 2 h at RT. Therefore, the column 
was filled completely with ethanolamine and sealed with parafilm. Subsequently, the 
sepharose was washed 3 times with 2.5 ml acetate buffer, 3 times with 2.5 ml 
neutralizing buffer and 3 times with 2.5 ml PBS. 
To couple the antibodies with the antigen, 10 ml serum (see 2.2.4.8) were given to the 
coupled sepharose onto the polypropylene column. The column was sealed with 
parafilm and the sepharose incubated with the serum under agitation overnight at 4°C. 
The flow through was collected and prepared for a SDS-PAGE with 3 x SDS sample 
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buffer (see 2.2.4.3). To remove uncoupled antibodies, the sepharose was washed 10 
times with 10 ml PBS and once with 10 ml 0.1 M glycine (pH 3) to remove the weakly 
coupled antibodies. 
To elute the CNFY antibody, the sepharose was treated 5 times with 1.5 ml elution buffer 
to obtain 5 elution fractions. Each fraction was neutralized by the addition of 0.6 ml 1 M 
Tris-HCl (pH 8). SDS samples of each fraction were prepared with 3 x SDS sample 
buffer and the remaining aliquots were stored at -20°C. A SDS-PAGE with following 
Coomassie staining of the collected samples (see 2.2.4.3 & 2.2.4.4) was carried out. 
Additionally, to test the specificity of the purified antibody in the different elution fractions 
western blot analyses (see 2.2.4.5) were performed. 
2.2.4.9 Expression analysis of PcnfY::lacZ β-galactosidase assay 
For expression analyses of the cnfY gene the vector pJNS04 was used. This vector 
harbours a transcriptional fusion of the cnfY promoter region and the lacZ gene. The β-
galactosidase cleaves the substrate ONPG, which leads to the formation of nitrophenol. 
The yellow colour of the substance was measured using an ELISA-reader (OD420), to 
calculate the specific enzyme activity. 
The measurement of three independent cultures in triplicate was performed as 
described previously (Nagel et al., 2001). Therefore, the bacteria were grown overnight 
at 25°C or 37°C. Subsequently, the culture was used to inoculate fresh medium 1:50 to 
let the bacteria grow to exponential or early stationary phase. 
The OD600 of all samples of the three growth phases was determined. Next, 200 µl of the 
1:10 diluted samples were transferred into glas tubes (duplicate). Lysis of the bacteria 
was performed by adding 0.1% SDS-solution, two drops of chloroform and incubation for 
10 min at RT. After addition of 1.8 ml Z-buffer, the reaction was started with 400 µl 
ONPG. When the samples turned yellow, the reaction was stopped by a change in pH 
with 1 ml Na2CO3 (1 M). The stopping time was noted and each sample was measured 
in duplicate. 
The activities were calculated as follows: β-galactosidase activity OD420 • 6.75 OD600-1 • 
Δt (min)-1 • vol (ml)-1. (6.75: extinction coefficient of cleaved ONPG in [µmol/min/mg 
protein]) 
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2.2.5 Mouse experiments 
Female BALB/c mice between 6- and 8-weeks old were purchased from Janvier (Saint 
Berthevin Cedex, France) and housed under specific pathogen-free conditions 
according to GV-SOLAS (German Recommendations of the Society for Laboratory 
Animal Science) and FELASA (Federation of Laboratory Animal Science Associations) 
recommendations in the animal facility of the Helmholtz Centre for Infection Research, 
Braunschweig. The animal protocol was approved by the „Niedersächsisches 
Landesamt für Verbraucherschutz und Lebensmittelsicherheit“: animal licensing 
committee permission no. 33.9.42502-04-055/09 and 33.9.42502-04-12/0907. Animals 
were handled with appropriate care and welfare, and all efforts were made to minimize 
suffering. 
2.2.5.1 Oral infection 
The infection of mice with Y. pseudotuberculosis was performed orally to mimic the 
natural route of infection.  After starving the mice overnight, the bacteria were introduced 
directly into the stomach of the mouse, using a syringe with a gavage needle.  
Therefore, the bacteria were grown overnight in 50 ml LB liquid culture at 25°C. 
Subsequently, 20 ml bacterial culture was mixed with 30 ml PBS to wash the bacteria 
and centrifuged 10 min with 2,755 x g at RT. The pellet was resuspended in 50 ml PBS 
and centrifuged again for 10 min with 2,755 x g at RT. After resuspension of the bacterial 
pellet in 10 ml PBS, the OD600 was measured and adjusted to the required OD600. For 
infection 200 µl of the bacterial suspension was used.  
In order to determine the infection dose, 1:10 serial dilutions of the bacteria were plated 
on LB agar plates and the colony forming units (CFU) were counted. 
2.2.5.2 In vivo expression analysis 
To determine the expression level of the cnfY gene in vivo, the plasmids pJNS02 or 
pJNS03 were used. Both plasmids harbour a transcriptional fusion of the cnfY promoter 
region with a reporter system (PcnfY::luxCDABE & PcnfY::gfpmut3.1, respectively).  
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2.2.5.2.1 In vivo imaging system (IVIS) 
To detect the cnfY gene expression during the course of infection, the 
Y. pseudotuberculosis wild-type strain YPIII, harbouring the vector pJNS02 or the empty 
vector pFU54, were used. About 2 x 108 luminescent bacteria were used for oral 
infection (see 2.2.5.1). The expression was monitored over a period of 5 days. For 
imaging, the mice were anesthesized with isoflurane and the bacterial infection was 
followed daily using the IVIS Lumina system (Xenogen). 
To ensure maintenance of the plasmid during the course of infection, an organ burden 
experiment was performed (see 2.2.5.5). Therefore, the bacteria were isolated from the 
small intestine, colon, caecum, MLNs, spleen and liver and tested for the presence of 
the plasmid five days post infection by plating on LB agar plates with or without 
antibiotics. 
2.2.5.2.2 Cryosections 
To detect the cnfY gene expression on single cell level in the different organs, 
cryosections have been prepared. Therefore, the Y. pseudotuberculosis wild-type strain 
YPIII, harbouring the vectors pJNS03 and pFU228 (PgapA::dsRed2), were used. With this 
system it was possible to detect all bacteria under the microscope with DsRed and the 
ones expressing the cnfY gene with GFP. About 2 x 108 bacteria were used for oral 
infection (see 2.2.5.1). After five days the mice were sacrificed by CO2 asphyxiation. For 
cryosections, the small intestine, colon, caecum, MLNs, spleen and liver were frozen in 
Tissue-Tek OCT freezing medium (Sakura Finetek) on dry ice. Sections of 6 - 10 mm 
were prepared using a Zeiss cryostat Hyrax C50, mounted on SuperFrost Plus slides 
(Thermo Scientific) and stored at -20°C. The samples were air-dried at RT in the dark, 
fixed for 10 min in ice-cold acetone and washed twice with PBS.  
Nuclei in the fixed tissue were stained with 49,6-diamidino-2-phenylindole (DAPI). 
Therefore, a drop of Roti-Mount FluorCare MIT DAPI (Roth) was used per sample. The 
sample was coated with a cover slip, which was fixed with nail polish and stored at 4°C 
or directly used for microscopy. The visualization was performed with a fluorescence 
microscope (Axiovert II with Axiocam HR, Zeiss, Germany) using the AxioVision 
program (Zeiss, Germany). 
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2.2.5.3 Histology 
For histological analysis of the infected organs, mice were infected orally with 
approximately 2 x 108 bacteria (see 2.2.5.1) for 3 or 6 days. After sacrificing the mice via 
CO2 asphyxiation, the MLNs, spleen, liver, ileum, caecum and colon were prepared 
according to standard histology procedures. The organs were fixed in 4% neutrally 
buffered formaldehyde for 24 to 48 h, embedded in paraffin and 3 µm sections stained 
with hematoxylin-eosin (H & E). Organs of three to four mice per group were blindly 
analyzed by a histopathologist. Sections were evaluated by light microscopy blinded to 
the experimental groups. Dr. Marina Pils of the Mouse Pathology unit of the Helmholtz 
Centre for Infection Research performed the embedding, staining and microscopy. 
2.2.5.4 Survival 
Survival experiments were carried out to test the virulence of different 
Y. pseudotuberculosis strains. Therefore, groups of 10 mice were infected orally with 
approximately 2 x 109 bacteria of each strain. The infected mice were monitored every 
day for 14 days to record the survival rate, the body weight and health status. With a 
weight loss over 20%, in comparison to the baseline weight, mice were sacrificed and 
recorded as dead. 
2.2.5.5 Organ burden 
Organ burden experiments were performed to determine the bacterial load in the 
different organs affected in the infection route. Groups of 7 - 10 animals were orally 
infected with approximately 2 x 108 bacteria of different Y. pseudotuberculosis strains 
(YPIII, YP147 (ΔcnfY), YP12 (pYV-), YP150 (pYV- ΔcnfY), YP101 (ΔyscS) or YP298 
(ΔyscS ΔcnfY)). At specific time points after infection, mice were euthanized by CO2 
asphyxiation. The Peyer’s patches (PP), small intestine, caecum, MLNs, liver and spleen 
were prepared (for Flow cytometry + Organ burden experiments of spleen, MLNs and 
PP, see 2.2.5.6). The ileum and caecum were first rinsed in PBS and then incubated in 
PBS supplemented with gentamycin (50 µg/ml) for 30 min on ice to kill the extracellular 
bacteria. In order to remove the gentamycin, the small intestine and caecum were 
washed with PBS. Subsequently, all organs were weighed, transferred into falcon tubes 
with 2 - 5 ml PBS and homogenized in PBS at 30,000 rpm for 30 sec, using a Polytron 
PT 2100 homogenizer (Kinematica, Switzerland). To determine the bacterial load of the 
organs 50 µl of serial 1:10 dilutions of the homogenates were plated on LB agar plates 
Material and methods 
 
 64 
with and without antibiotics. The CFU were determined and calculated as CFU per 
g organ/tissue. 
2.2.5.6 Flow cytometry (measurement of immune response) 
To analyze the immune response triggered upon infection with different 
Y. pseudotuberculosis strains (wild-type strain YPIII in comparison to YP147 (ΔcnfY), 
YP12 (pYV-), YP101 (ΔyscS), YP150 (pYV- ΔcnfY) or YP298 (ΔyscS ΔcnfY)), an 
antibody staining with subsequent flow cytometry analysis was performed. Therefore, 
groups of 5 - 8 mice were orally infected with approximately 2 x 108 bacteria. 3 or 28 
days after infection mice were euthanized with CO2 asphyxiation and PP, MLNs and 
spleen were isolated.  
2.2.5.6.1 Preparation of single cell suspensions 
After preparing the organs, the spleen weight was determined. Single cell suspensions 
were generated in PBS by pressing the spleen cells through a 100 µm cell strainer 
(Falcon) and the MLNs and PP through a 30 µm cell strainer with the stamp of a syringe. 
For isolation of spleen cells, the cell strainer was moistened with 1 ml FACS buffer and 
washed twice with 4 ml PBS. The cell strainer for MLNs and PP were moistened with 
0.5 ml FACS buffer and washed twice with 1 ml FACS buffer. Organ burden samples 
were transferred into 15 ml falcon tubes (3 ml for spleen) or U-bottom tubes (100 µl PP 
sample + 900 µl PBS & 200 µl MLNs sample + 800 µl PBS) for homogenizing and 
plating (2.2.5.5). The remaining splenocytes for flow cytometry were treated with 1 ml 
erythrolysis buffer for 3 min at RT to eliminate the erythrocytes. By adding 10 ml FACS 
buffer, the lysis was stopped.  
All samples were centrifuged for 8 min with 400 x g at 4°C. Subsequently, the cell pellets 
were resuspended in 1 ml FACS buffer. The spleen samples were transferred onto a 
30 µm cell strainer, which was subsequently washed with 1 ml FACS buffer.  
Next, the cell number was determined. Therefore, 20 µl of the cell suspension was 
diluted 1:25 with propidium iodide (PI). The cell counting was performed with an Accuri 
C6 flow cytometer (BD Bioscience). Amounts of 1 - 2.5 x 106 cells were transferred into 
Matrix™ Blank and Alphanumeric Storage Tube (Thermo Scientific). 
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2.2.5.6.2 Staining of immune cells 
The aliquoted cell samples were washed twice by addition of 750 µl PBS and 
centrifugation for 3 min with 400 x g at 4°C. Subsequently, the supernatant was removed 
and the cell pellet resuspended in 200 µl Live/dead staining solution (Invitrogen; 
Live/dead Fixable Blue Dead Cell Stain Kit, UV excitation) to exclude dead cells from the 
analysis. After staining in the dark for 30 min on ice, the cells were washed once with 
750 µl FACS-buffer. The supernatant was removed after centrifugation (3 min; 400 x g; 
4°C) and blocking of FcγR and IgG was performed by addition of 50 µl CD16/CD32 
(BioXCell; anti-mouse CD16/CD32) and ratIgG (Jackson ImmunoResearch; ChromPure 
Rat IgG, whole molecule) antibodies for 15 min on ice. By addition of 50 µl of the 
antibody mix (in FACS buffer) the cellular surface markers of either lymphoid or myeloid 
cells were stained for 15 min on ice in the dark. The following antibodies were used: 
CD3-APC, CD4-PerCP-Cy5.5, CD8-eFluor450, CD335-PerCP-Cy5.5, CD11b-
PacificBlue, CD19-Biotin, CD45R-PerCP-Cy5.5, F4/80-PE, CD11c-APCeFluor780, 
CD19-FITC, CD49b-Biotin and Ly6C-APC. All antibodies were titrated for optimal 
staining conditions. The stained cells were washed twice with 750 µl FACS-buffer and 
subsequent centrifugation (3 min; 400 x g; 4°C).  
Further, biotin-conjugated antibodies were treated with 100 µl streptavidin-FITC for 
15 min on ice. After washing the samples twice with 750 µl FACS-buffer (3 min; 400 x g; 
4°C) the cells were fixed by the addition of 200 µl Fix/Perm buffer (Foxp3 Staining Buffer 
Set; eBioscience) for 30 min on ice in the dark. Subsequently, 800 µl Perm buffer were 
added and the cells were centrifuged for 5 min with 450 x g at 4°C. The supernatant was 
removed and the cells resuspended in 150 µl FACS-buffer. Next, the cells were stored at 
4°C or directly loaded into a LSR Fortessa cell analyzer (BD Bioscience). The acquired 
data were analyzed with FlowJo software (Treestar). 
2.2.5.7 Yop delivery assay during mouse infection 
To detect differences in the Yop translocation rates during mouse infection with or 
without CNFY, Yop delivery assays were performed. Therefore, groups of 5 to 8 mice 
were infected orally (see 2.2.5.1) with approximately 2 x 109 bacteria of strain YPIII-
ETEM (YP173) and the isogenic cnfY mutant YP147-ETEM (YP217). As negative 
controls for Yop translocation, groups of 2 mice were infected with the same amount of 
wild-type YPIII or YP101-ETEM (YP174) bacteria. After three days, the mice were 
sacrificed via CO2 asphyxiation. The lymphatic organs PP, MLNs and spleen were 
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isolated, single cell suspensions were prepared, samples for organ burden were taken, 
erythrocytes of the spleen eliminated and cells counted (see 2.2.5.6.1).  
For the flow cytometry analysis, 1 x 106 cells were transferred into Matrix™ Blank and 
Alphanumeric Storage Tubes (Thermo Scientific) and centrifuged for 3 min with 400 x g, 
15.4 r and 4°C. The supernatant was removed and FcγR blocked using CD16/CD32 
antibody diluted in FACS buffer for 15 min at 4°C. By the addition of a biotin-conjugated 
antibody against CD19, the immune cells were stained first for 15 min at 4°C. 
Subsequently, the antibody solutions (in FACS buffer) for different surface marker for the 
innate immune cell panel or T cell panel were added. The staining incubation time was 
20 min at 4°C with the following antibodies: Streptavidin-PerCP-Cy5.5, CD11c-APC, 
CD11c-PE-Cy7, Gr1-A700, CD3-PE, CD4-APC-Cy7, CD3-PE-Cy7, NKp46-PE and 
CD25-APC. The samples were washed twice with 750 µl FACS buffer, with a 
centrifugation step of 3 min with 400 x g, and 4°C in between. 
To label the Yop translocated cells, the LiveBLAzer-FRET B/G Loading Kit (Life 
Technologies) was used with 1 µg/ml CCF4-AM for 1 hour at RT in the presence of 
1.5 mM probenecid (Sigma) and 50 µg/ml gentamycin, according to the manufacturer’s 
protocol. The cell subsets were defined as: B cells (CD19+ CD3-), T cells (CD19- CD3+), 
NK cells (CD19- CD3- NKp46+), neutrophils (CD19- CD3- CD49b- Ly6G+ CD11b+), 
macrophages/monocytes (CD19- CD3- CD49b- Ly6G- CD11b+) and DCs (CD19- CD3- 
CD49b- Ly-6G- B220- F4/80- CD11c+). A LSR Fortessa cell analyzer (BD Bioscience) 
was used to acquire the data. Data were analyzed with FlowJo software (Treestar) using 
unstained cells, YPIII infected and YP174 infected cells as negative controls.  
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2.2.5.8 Measurement of secreted cytokines 
To measure the cytokine release in uninfected, YPIII- or YP147-infected mice, serum 
samples were prepared. Therefore, mice were infected orally with approximately 2 x 108 
bacteria (see 2.2.5.1) for 3 days.  
2.2.5.8.1 Serum preparation 
After sacrificing the mice via CO2 asphyxiation, heart blood was taken immediately with 
an insulin syringe. The blood samples were incubated for 30 min - 3 h at RT. After 
clotting of the blood, samples were centrifuged at RT for 8 min with 2,300 x g. 
Subsequently, the supernatant was transfered into new Eppendorf tubes, centrifuged 
and transferred again into new Eppendorf tubes. The prepared serum samples were 
stored at -80°C. 
2.2.5.8.2 Luminex 
To measure the cytokine concentrations in the serum, the MILLIPLEX MAP Mouse 
Cytokine/Chemokine Magnetic Bead Panel - Premixed 32 Plex - Immunology Multiplex 
Assay Kit from Millipore was used. The following cytokines were analyzed: Eotaxin, G-
CSF, GM-CSF, IFN-γ, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17, IL-1α, IL-1β, IL-
2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, KC-like, LIF, LIX, M-CSF, MCP-1, MIG, MIP-1α, 
MIP-1β, MIP-2, RANTES, TNF-α and VEGF.  
Therefore, the prepared serum samples were thawed on ice and processed for the 
measurement. The assay was performed according to the manufacturers protocol using 
the Luminex® detection system for the readout. This system is able to quantify multiple 
cytokine levels simultaneously. 
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3 Results 
The wild-type strain YPIII of Y. pseudotuberculosis produces the cytotoxic necrotizing 
factor cnfY, which displays a sequence identity of about 65% (Lockman et al., 2002) to 
its homolog cnf1 of uropathogenic E. coli or E. coli K1 strains (Caprioli et al., 1984). 
These toxins constitutively activate small Rho-GTPases, thereby inducing 
rearrangements of the actin cytoskeleton and thus the formation of stress fibres, 
filopodia or lamellipodia. Upon intoxication with CNFs, the eukaryotic cells become rigid 
and lose their ability to divide. This leads to the formation of multinucleated giant cells 
(Caprioli et al., 1984; Lockman et al., 2002). Previous studies with CNFY indicated that 
an intoxication of epithelial, as well as of neuronal cells, selectively activated the small 
Rho-GTPase RhoA (Hoffmann et al., 2004). 
So far, only little is known about the expression of cnfY and the impact of the toxin-
induced Rho-GTPase activation on the virulence of Y. pseudotuberculosis. These points 
are addressed below. 
3.1 Expression and secretion pattern of cnfY/CNFY 
A functional cnfY gene is encoded by a few pathogenic Y. pseudotuberculosis isolates. 
Many Yersinia strains harbour mutations over the whole gene, including the Y. pestis 
strain CO92 (Lockman et al., 2002). Expression of cnfY was tested in the wild-type strain 
Y. pseudotuberculosis YPIII. 
3.1.1 The CNFY toxin is highly expressed and secreted under host-
relevant conditions 
For the in vitro expression analysis of the cnfY gene, a transcriptional promoter fusion of 
cnfY with the lacZ (β-galactosidase) gene was used (pJNS04). The cnfY expression was 
measured at three different growth phases, the exponential (3 h), the early stationary 
(7 h), and the late stationary phase (14 h) at 25°C and 37°C (see Figure 3.1.1). A low 
cnfY expression could be detected at 25°C, but the highest expression level was in the 
late stationary phase at 37°C, which best resembles conditions in the host.  
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Figure 3.1.1: The highest expression of cnfY in vitro was detected at 37°C in the late stationary 
growth phase.  
Y. pseudotuberucosis YPIII, harbouring the plasmid pJNS04 (PcnfY::lacZ), was grown in LB medium at 25°C 
or 37°C to exponential (3 h), early stationary (7 h) and late stationary (14 h) growth phase. The β-
galactosidase activity was determined from three independent cultures in triplicate.  
 
Subsequently, the secretion level of the toxin was examined. Therefore, 
Y. pseudotuberculosis YPIII was incubated at 25°C or 37°C to the exponential (3 h), the 
early stationary (7 h) and the late stationary (14 h) growth phase. Next, the sterilized 
supernatants were precipitated and analyzed on a western blot, using a CNFY specific 
antiserum (see Figure 3.1.2). The secretion of CNFY resembles the expression pattern 
of cnfY with the highest secretion detectable at 37°C in the late stationary phase. 
 
Figure 3.1.2: The highest secretion level of CNFY in vitro was detected at 37°C in the late stationary 
growth phase. 
Y. pseudotuberculosis YPIII and YP147 (∆cnfY) were grown in LB medium at 25°C or 37°C to exponential 
(3 h), early stationary (7 h) and late stationary (14 h) growth phase. The supernatant was sterilized and 
precipitated. CNFY was detected by western blot analysis with a specific CNFY (~115 kDa) antibody.  
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Subsequently, the nutrient-dependent expression of cnfY was tested. To this purpose, 
bacteria were grown to the late stationary phase at 37°C in different minimal- and 
complex-culture media (see Figure 3.1.3, other tested conditions not shown). The 
expression of cnfY was significantly higher in the complex media, especially in brain-
heart-infusion (BHI) in comparison to the minimal-media MMA and RPMI in which the 
expression was as low as at 25°C in LB medium.  
In summary, the expression of cnfY is growth phase-, temperature-, and nutrient-
dependent, suggesting a predominant expression during late stages of the infection. 
 
Figure 3.1.3: The cnfY expression is dependent on nutrient availability. 
Y. pseudotuberucosis YPIII, harbouring the plasmid pJNS04 (PcnfY::lacZ), was grown in complex (LB or 
BHI) or in minimal (MMA or RPMI) media at 37°C to the late stationary (14 h) growth phase. The β-
galactosidase activity was determined from three independent cultures in triplicate. The asterisks indicate 
significant differences of β-galactosidase activities at the tested conditions calculated with an unpaired 
Student’s t-test. The expression in different media differed significantly from expression in LB medium, *** 
(P<0.001). 
 
3.1.2 The cnfY gene expression is controlled by virulence regulators 
Due to the similarities in the expression conditions with the other known virulence genes, 
different regulatory factors have been tested for their influence on the cnfY expression or 
secretion. Hence, mutant strains lacking different virulence regulators have been used to 
measure the cnfY expression at the most relevant conditions at 37°C in the exponential, 
early stationary, and late stationary growth phases.  
Previous data already showed an influence of the Yersinia modulator A (YmoA) as a 
repressor of CNFY at 25°C (J. Schweer, Master-thesis). YmoA has been shown before 
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as being important for controlling the expression of late virulence genes, like the Yop 
effector proteins, by inhibiting the transcription of lcrF (Böhme et al., 2012). However, 
previous data also showed no cnfY expression dependency on the presence of the 
virulence plasmid, coding for lcrF (J. Schweer, Master-thesis).  
Furthermore, the secretion of CNFY in a mutant strain lacking the virulence plasmid was 
examined. Y. pseudotuberculosis YPIII, the mutant YP12 pYV-, and the cnfY mutant 
strain were incubated at 37°C overnight. Next, the sterilized supernatants were 
precipitated and analyzed on a western blot, using a CNFY specific antiserum for the 
toxin-detection (see Figure 3.1.4). No virulence plasmid-dependent secretion of CNFY 
could be detected. Taken together, these data suggest that the cnfY expression is 
repressed by YmoA like the Yop proteins, but independently from the plasmid encoded 
transcriptional activator LcrF. Additionally, CNFY is not secreted via the type three 
secretion system (T3SS). 
 
 
 
 
 
 
 
Additional regulators of known virulence genes were tested, the ferric uptake regulator 
(Fur) and the cyclic AMP receptor protein (Crp). Hence, Y. pseudotuberculosis strains 
YPIII, YP89 (∆crp), and YP105 (∆fur), all harbouring the plasmid pJNS04 (PcnfY::lacZ), 
were incubated at 37°C to exponential (3 h), early stationary (7 h), and late stationary 
(14 h) growth phase. Figure 3.1.5 shows the expression of cnfY in the fur- and the crp-
mutant strains. The deletion of the iron assimilation regulator Fur seems to have no 
impact on the expression of cnfY (also at 25°C, data not shown), whereas Crp appears 
to upregulate the expression of cnfY at 37°C, specifically in the late stationary phase. 
Crp is known to have an influence on the carbon storage regulator (Csr) system, which 
is in turn involved in the expression of InvA (Heroven et al., 2012). Taken together, cnfY 
Figure 3.1.4: The CNFY secretion is independently from the virulence 
plasmid pYV.  
Y. pseudotuberculosis YPIII, YP12 pYV-, and YP147 (∆cnfY) were grown 
overnight in LB medium at 37°C. The supernatant was sterilized and 
precipitated. CNFY was detected by western blot analysis with a specific CNFY 
(~115 kDa) antibody. 
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is regulated by factors, which are also involved in the regulation of different virulence 
factors, e.g. the invA gene.  
 
Figure 3.1.5: The cnfY expression is dependent on Crp, but not on Fur at 37°C. 
Y. pseudotuberucosis YPIII, YP89 (∆crp) and YP105 (∆fur), harbouring the plasmid pJNS04 (PcnfY::lacZ), 
were grown in LB medium at 37°C to exponential (3 h), early stationary (7 h), and late stationary (14 h) 
growth phase. The β-galactosidase activity was determined from three independent cultures in triplicate. 
The asterisks indicate significant differences of β-galactosidase activities at the tested conditions calculated 
with an unpaired Student’s t-test. The expression in a crp mutant differed significantly from expression in 
the wild-type with **(P<0.01) and *** (P<0.001). 
 
3.1.3 The cnfY gene is highly expressed in vivo during the whole 
infection route 
Due to the high expression level of cnfY in vitro, a transcriptional cnfY promoter fusion 
with the luciferase operon (PcnfY::luxCDABE) was used to detect the cnfY expression in 
the mouse model. The expression of the toxin during the course of infection was 
followed to determine time points and organs at/in which cnfY is expressed and possibly 
important for the infection.  
To this purpose, groups of 3 - 5 BALB/c mice were infected orally with 3  x 108 bacteria  
of Y. pseudotuberculosis YPIII, carrying the PcnfY::luxCDABE promoter fusion plasmid 
(pJNS02). The luciferase activity due to cnfY expression was measured using the in vivo 
imaging system (IVIS), which measures the bioluminescent signal. The expression was 
followed during the course of infection over six days (see Figure 3.1.6). As a negative 
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control for the basal expression level of the luciferase, mice were infected with bacteria 
harbouring an empty vector (pFU54), carrying the luciferase operon without the cnfY 
promoter. In these mice, no bioluminescent signal was detected (data not shown). 
 
Figure 3.1.6: The highest cnfY expression in vivo was detectable two days post infection.  
Groups of 3 - 5 BALB/c mice were infected orally with 3 x 108 bacteria of Y. pseudotuberculosis YPIII, 
harbouring the plasmid pJNS02 (PcnfY::luxCDABE). At indicated time points, the mice were anesthesized 
and the bioluminescence was detected with a CCD camera of the in vivo imaging system (IVIS) on the 
ventral site. Mice were infected with three independent bacterial cultures. The figure is representative for 
two independent experiments. 
 
The overall expression level of cnfY in vivo during the entire course of infection was very 
strong. Already one hour after infection, a small bioluminescent signal was visible in the 
abdominal part of the anesthesized mice. The highest expression was detectable after 
two days in the gut and gut-related tissues. The toxin was expressed during infection up 
to six days. However, due to the overall high expression, it was impossible to 
differentiate between the different tissues (see Figure 3.1.6).  
In order to test the expression of cnfY at a single cell level in the organs, cryosections 
were prepared. Hence, groups of 3 BALB/c mice were infected for three or five days with 
approximately 2 x 108 Y. pseudotuberculosis wild-type bacteria, carrying two plasmids, 
coding for a constitutive PgapA::dsred2 reporter construct (pFU228) and a compatible 
PcnfY::gfpmut3.1 transcriptional fusion (pJNS03). The small intestine, caecum, colon, 
mesenteric lymph nodes (MLNs), spleen, and liver were analyzed. The infected tissues 
were screened for bacterial microcolonies under the fluorescent microscope by the 
expression of dsred2 and subsequently tested for gfpmut3.1-expression. Figure 3.1.7 
shows the colonization and the expression of cnfY in the Peyer’s patches (PP), caecum, 
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MLNs, spleen, and liver five days post infection. The cnfY gene is equally expressed in 
all tested organs, leading to the conclusion that CNFY is needed throughout the whole 
infection route. 
In summary, cnfY is highly expressed in vivo during the entire infection and shows no 
organ dependency in its expression. 
 
Figure 3.1.7: The cnfY expression is not organ-specific.  
Groups of 3 BALB/c mice were infected orally with 2 x 108 bacteria of Y. pseudotuberculosis YPIII, 
harbouring the plasmids pJNS03 (PcnfY::gfpmut3.1) and pFU228 (PgapA::dsRed2). Five days post infection, the 
mice were sacrificed and the small intestine, caecum, MLNs, spleen, and liver isolated. Cryosections 
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(6 µm) have been prepared and analyzed by fluorescence microscopy. Sections were screened for 
bacteria expressing the reporter protein DsRed2 and subsequently analyzed for cnfY expression by 
monitoring GFPmut3.1 fluorescence. White bars indicate 20 µm. 
 
3.2 CNFY activates the small Rho-GTPases and alters the cell 
morphology 
The E. coli homolog of CNFY, CNF1 was shown to lead to the activation of the three 
small Rho-GTPases Rac1, Cdc42 and RhoA, whereas CNFY was shown to preferably 
activate the small Rho-GTPase RhoA in epithelial cells (Hoffmann et al., 2004).  
Given the high expression and secretion of the toxin (see 3.1) in Y. pseudotuberculosis 
YPIII, the CNFY function was further analyzed to investigate if the produced toxin was 
also active. To test the activity of the toxin directly produced by YPIII, the bacteria were 
grown overnight at 37°C to induce the highest expression and secretion of the toxin. 
Sterilized supernatants of bacterial lysates of the strains YPIII and YP147 (∆cnfY) were 
given onto human epithelial cells (HEp-2) and incubated for 48 hours. The polymerized 
actin cytoskeleton and the nuclei of the cells were stained with FITC-conjugated 
pholloidin and DAPI, respectively and visualized via fluorescent microscopy. 
Multinucleation and formation of giant cells, which is exclusively attributed to the CNFY 
activity showed that CNFY is active (see Figure 3.2.1, complementation experiments not 
shown). 
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Figure 3.2.1: Incubation of epithelial cells with sterilized Y. pseudotuberculosis YPIII lysate leads to 
the formation of multinucleated giant cells.  
Y. pseudotuberculosis YPIII and YP147 (∆cnfY) were grown overnight at 37°C. The bacterial whole cell 
extract was lyzed, centrifuged and the sterilized supernatant incubated on human epithelial HEp-2 cells for 
48 h. The nuclei were stained with DAPI (blue) and the F-actin with FITC-conjugated phalloidin. White bars 
indicate 20 µm. 
 
Due to the high expression of cnfY in vivo, it was hypothesized that CNFY could play a 
relevant role for the virulence of Y. pseudotuberculosis wild-type YPIII, most likely by 
interfering with the immune cells and preventing the bacteria-elimination. To test the 
effect of CNFY on cultured cells, the recombinant toxin was purified. Because the innate 
immune cells form the first line of defence against a Yersinia infection, the effect of CNFY 
on murine macrophages was tested. The macrophage cell line J774A.1 with or without 
the induction of maturation to fully active macrophages by phorbol myristate acetate 
(PMA/ 48 h) was intoxicated with CNFY (10 nM) for 24 hours (see Figure 3.2.2). The 
polymerized actin cytoskeleton and nuclei of the cells were stained and visualized by 
fluorescent microscopy. 
YP147 ( cnfY) untreated YPIII
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Figure 3.2.2: CNFY induces the formation of filopodia, lamellipodia and stress fibres of mature and 
immature murine macrophages.  
Unstimulated (-PMA) or stimulated (+ PMA/48 h) murine macrophages J774A.1 were treated with 10 nM 
recombinant CNFY or the same amount of PBS for 24 h. Nuclei were stained with DAPI (blue), F-actin with 
FITC-conjugated phalloidin. Arrows show membrane ruffles, filopodia and stress fibres induced by CNFY 
intoxication. White bars indicate 20 µm. 
 
No difference in the effect of CNFY on immature or mature macrophages regarding the 
cellular shape could be observed. However, the cells formed filopodia, lamellipodia and 
stress fibres, indicating the activation of the three Rho-GTPases Rac1, Cdc42 and 
RhoA. Subsequent Rho-GTPase activation assays of the three GTPases in the 
macrophages J774A.1 and the epithelial cells HEp-2 showed that CNFY, incubated for 
three hours on the cells, induces the activation of the tested GTPases (see Figure 3.2.3). 
The activation pattern as well as the whole GTPase contents varied, depending on the 
concentration of the toxin.  
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Figure 3.2.3: CNFY intoxication leads to the activation of the three small Rho-GTPases RhoA, Rac1 
and Cdc42 in murine macrophages and human epithelial cells.  
J774A.1 macrophages and HEp-2 epithelial cells were treated with 1, 10 or 25 nM recombinant CNFY or 
the same amount of PBS for 3 h. Cells were lyzed and aliquots taken for western blot analysis of total 
protein contents. The rest of the samples was used to isolate the activated GTPases Rac1-/Cdc42-GTP or 
RhoA-GTP using PAK1- or rhotekin-coupled beads, respectively. Using specific antibodies against RhoA 
(24 kDa), Rac1 (21 kDa) and Cdc42 (25 kDa), the activated and total protein contents of the lysates could 
be detected. As a loading control actin (45 kDa) was detected with a specific antibody. 
 
The lowest concentration of 1 nM CNFY was sufficient to activate especially RhoA, but 
also Rac1 and Cdc42 in the macrophages, whereas the HEp-2 cells do not seem to be 
as susceptible to the CNFY treatment as macrophages. For the HEp-2 cells, a distinct 
activation of RhoA and Cdc42 is only detectable at concentrations of 10 nM and 25 nM. 
However, the basal activation level of Rac1 seems to be quite high in both cell lines. A 
RhoA shift due to the deamidation of a conserved glutamine is already clearly visible 
with 1 nM toxin in the HEp-2 cells, whereas it is not detectable even at higher CNFY 
concentrations in the treated J774A.1 cells. Additionally, Rac1 but predominantly Cdc42 
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seem to be degraded with higher CNFY concentrations in the HEp-2 cells, which was 
shown before for RhoA upon CNF1 treatment (Doye et al., 2002).  
Taken together, CNFY treatment at these specific conditions leads to the activation of the 
three Rho-GTPases RhoA, Rac1 and Cdc42 in the tested cell lines. Very low 
concentrations are sufficient to activate the GTPases in J774A.1 cells, whereas higher 
concentrations of CNFY are needed to achieve an equal activation level in HEp-2 cells. 
3.3 Impact of CNFY on the virulence of Y. pseudotuberculosis 
Due to the overall high expression of cnfY and the impact on the cell morphology and 
Rho-GTPase activation state, it was essential to determine a possible impact of CNFY 
during the course of infection in the mouse model. To this purpose, a cnfY mutant strain 
was constructed by exchanging the functional cnfY gene against the kanamycin 
resistance gene. 
3.3.1 CNFY is crucial for the virulence of Y. pseudotuberculosis 
To evaluate the contribution of CNFY during infection with Y. pseudotuberculosis YPIII, a 
mouse survival experiment was conducted. Groups of 10 BALB/c mice were infected 
orally with Y. pseudotuberculosis wild-type or the cnfY mutant strain YP147 both 
harbouring either a complementation plasmid carrying the cnfY gene under control of its 
own promoter (pJNS10) or the empty vector (pJNS11).  
A lethal infection dosis (2 x 109 bacteria/mouse) was used and mice were monitored 
day-to-day for a period of 14 days for their body weight and general appearance, e.g. 
rough fur. Mice with less than 80% of their start-up weight were recorded as dead and 
the date of death was noted. Figure 3.3.1 shows the survival (A) and the body weight 
curves (B) of the mice. 
The wild-type strain infected mice developed severe symptoms of disease with a fast 
weight reduction and succumbed within six days post infection. Oppositely, all mice 
infected with the cnfY mutant strain survived and displayed only mild symptoms of 
disease until day five or six when they started recovering and regaining weight. The 
effect of the cnfY loss could be reverted by introducing the complementation plasmid 
pJNS10 (PcnfY::cnfY, ori SC101*). Even a minimal reduction in the average survival time 
of the mice, approximately by one day (not significant), was detected probably because 
of a slight overexpression of the toxin.  
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Figure 3.3.1: The cnfY mutant strain is avirulent in a mouse survival experiment, yet causes body 
weight reductions of mice up to five days post infection.  
Groups of 10 BALB/c mice were infected orally with 2 x 109 bacteria of Y. pseudotuberculosis YPIII pJNS11 
(empty vector), YP147 (∆cnfY) pJNS11 (empty vector), YPIII pJNS10 (cnfY+; complementation plasmid) or 
YP147 (∆cnfY) pJNS10 (cnfY+; complementation plasmid). Two independent experiments were performed. 
(A) Survival of infected mice was monitored for 14 days. (B) Body weight of infected mice was recorded for 
14 days. Mice with a weight reduction over 20% were sacrificed and noted as dead. 
 
Due to a defect in the allele of phoP, Y. pseudotuberculosis YPIII is not able to replicate 
in macrophages, unlike other Y. pseudotuberculosis strains (Grabenstein et al., 2004). 
To rule out the possibility that the effect of CNFY on the virulence might only be visible in 
a phoP-deficient derivative with an overall lower pathogenicity, the defective phoP allele 
was exchanged against the functional phoP of Y. pseudotuberculosis IP32953 enabling 
the YPIII strain to replicate within macrophages. Groups of 10 BALB/c mice were 
infected orally with 2 x 109 bacteria of the phoP+ YPIII strain (YP149) and the phoP+ 
YPIII strain without cnfY (YP188). Survival and body weight of the mice were recorded 
as described above. All mice infected with the phoP+ strain died within five days post 
infection, whereas 80% of the mice infected with the corresponding cnfY mutant strain 
survived and regained weight six days post infection (see Figure 3.3.2).  
In summary, the activity of CNFY is highly important for the pathogenicity of 
Y. pseudotuberculosis YPIII, independently of the presence of a functional phoP. Loss of 
CNFY renders the Y. pseudotuberculosis YPIII strain avirulent. 
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Figure 3.3.2: The introduction of a functional phoP+ into Y. pseudotuberculosis YPIII does not 
change the impact of CNFY on virulence significantly.  
Groups of 10 BALB/c mice were infected orally with 2 x 109 bacteria of Y. pseudotuberculosis YP149 
(phoP+) or YP188 (phoP+ ∆cnfY). (A) Survival of infected mice was monitored for 14 days. (B) Body weight 
of infected mice was recorded for 14 days. Mice with a weight reduction over 20% were sacrificed and 
noted as dead. 
 
3.3.1.1 CNFY is crucial for efficient colonization of mesenteric lymph nodes 
and the systemic organs 
CNFY seems to be crucial for the virulence of Y. pseudotuberculosis, as described 
above. To determine the stages during the infection in which CNFY might be particularly 
relevant, oral infection experiments have been performed to detect the bacterial loads in 
the different organs during the infection process. Hence, groups of 5 BALB/c mice were 
infected orally with 2 x 108 bacteria and sacrificed after different time points (1 - 7 days). 
Small intestine, caecum, PP, MLNs, spleen, and liver were isolated, homogenized and 
dilutions of the homogenates were plated to determine the bacterial numbers per gram 
tissue.  
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Figure 3.3.3: The loss of cnfY leads to clearance of Yersinia in MLNs, spleen and liver in the later 
infection phase.  
Groups of 5 BALB/c mice were infected orally with 2 x 108 bacteria of Y. pseudotuberculosis YPIII or 
YP147 (∆cnfY). At 1 - 7 days post infection, mice were sacrificed and the organs (small intestine, PP, 
caecum, MLNs, spleen, and liver) isolated. Homogenized organs were plated and the bacterial load (CFU) 
per gram tissue determined. The figure displays results of two independent experiments. For statistical 
analysis, a Mann-Whitney test was applied to determine significant differences in bacterial colonization of 
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the organs between YPIII- and YP147 (∆cnfY)-infected mice. Asterisks indicate the significances, with * 
(P<0.05), ** (P<0.01) and *** (P<0.001). 
 
Figure 3.3.3 depicts the bacterial loads at different infection periods in the organs. No 
difference in the colonization ability in caecum and PP between the two strains was 
detected. Surprisingly, at day five to seven a slightly higher amount of the cnfY mutant 
bacteria could be reisolated from the small intestine. This was probably due to 
shortening of the gut (a sign of inflammation; see below). The cnfY mutant strain is able 
to colonize the MLNs up to two days post infection, however after three days, the mutant 
strain seems to be cleared out of this tissue, whereas the wild-type strain is able to 
replicate therein. The clearance of the mutant strain out of the MLNs is even more 
pronounced four to seven days post infection. Clearance of the cnfY mutant is also 
visible in the systemic organs spleen and liver, starting at day four or five post infection. 
These data suggest that CNFY might be more important in the late infection phase for 
the colonization of the MLNs, spleen, and liver. With the loss of CNFY, 
Y. pseudotuberculosis YPIII is no longer able to colonize the host sufficiently to induce a 
severe infection. 
In addition to the differences in colonization of the systemic organs spleen and liver, 
these organs displayed macroscopic differences such as size and colour during 
infection. The spleen of mice infected with the wild-type strain shrinked and displayed a 
pale red colour, whereas the spleens of the mice infected with the cnfY mutant strain 
enlarged (see Figure 3.3.4 A) and were intensely red coloured over time (data not 
shown). Also the livers of mice infected with the strain YPIII were less red and shrinked, 
whereas the livers of the mice infected with the cnfY mutant were deep red, but showed 
no difference in their weights (see Figure 3.3.4 B). Additionally, the gut lengths of the 
mice infected with the two strains differed significantly. The small intestine of mice 
infected with the wild-type strain was significantly shorter after six to seven days post 
infection, a sign of severe inflammation as the intestinal length correlates to inflammation 
(see Figure 3.3.4 C). This indicates that CNFY is not only affecting the colonization of the 
systemic organs by YPIII, but also induces a different intestinal inflammation despite 
similar bacterial amounts. 
In summary, CNFY seems to induce severe inflammation in the gut and leads to the 
shrinking of the systemic organs spleen and liver, in which CNFY seems to be important 
for the bacterial colonization. 
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Figure 3.3.4: CNFY induces shrinkage of spleen and liver and shortening of the gut length of 
infected mice.  
Groups of 5 BALB/c mice were infected orally with 2 x 108 bacteria of Y. pseudotuberculosis YPIII or 
YP147 (∆cnfY). Mice were sacrificed and the organs (small intestine, spleen, and liver) isolated. Figure A 
and B display results of two independent experiments, figure C of one experiment. (A) Spleen and (B) liver 
weights were monitored each day up to seven days post infection. (C) Lengths of intestines were 
determined 6 and 7 days after infection. For statistical analysis, a Mann-Whitney test was applied to 
determine significant differences between the tissues of YPIII- and YP147 (∆cnfY)-infected mice. Asterisks 
indicate the significances, with ** (P<0.01) and *** (P<0.001). 
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3.3.2 CNFY leads to highly inflamed tissues 
As mentioned above, the infection with Y. pseudotuberculosis wild-type or the cnfY 
mutant leads to differences in the overall appearance of the isolated organs. To analyze 
the impact on the different tissues, histopathological analysis of the small intestine, 
caecum, colon, MLNs, spleen, and liver was performed. Groups of 3 BALB/c mice were 
infected orally with 2 x 108 bacteria for three or six days, the organs were isolated and 
embedded in formaldehyd. The sections were stained with hematoxylin-eosin (H & E) 
and blindly evaluated. The histopathological analysis was performed by Dr. Marina C. 
Pils of the „Mouse Pathology, Animal Experimental Unit“ of the Helmholtz Centre for 
Infection Research.  
The overall inflammation of the examined tissues of YPIII infected mice was significantly 
higher in comparison to the tissue of the mice infected with the cnfY mutant strain. The 
inflammatory response was especially evident in the gut and the spleens of the animals. 
The intestinal inflammation was most pronounced in the ileum and the caecum in both 
groups. 
Figure 3.3.5 shows microscopic pictures of the small intestine and the spleen of YPIII- 
and YP147 (ΔcnfY)-infected or untreated mice six days post infection. The ileum of the 
mice infected with the wild-type strain was overall severely inflamed with disrupted villi 
and a thickened lamina propria (see Figure 3.3.5 A/ B). However, the inflammation of the 
ileum of YP147 (ΔcnfY)-infected mice was locally restricted with the formation of 
multifocal lesions characterized by the presence of inflammatory cells from the muscular 
layer up to the epithelial cells (see Figure 3.3.5 A/B). The inflammation in these spots led 
to an enlargement of the villi length, due to epithelial cell hyperplasia (increased 
proliferation), but did not affect the flanking tissue. 
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Figure 3.3.5: CNFY leads to a highly inflamed intestine and necrosis in the spleen.  
Groups of 3 BALB/c mice were infected orally with 2 x 108 bacteria of Y. pseudotuberculosis YPIII or 
YP147 (∆cnfY). Mice were sacrificed six days post infection, organs (ileum and spleen) isolated and 
sections stained with H & E. (A) Representative light microscopic picture of an ileum of YPIII- and YP147 
(∆cnfY)-infected animals. YPIII induces diffuse invasion of inflammatory cells into the lamina propria. 
YP147 (∆cnfY) induces invasion of inflammatory cells into the lamina propria at occasional inflammatory 
areas. Black bar represents 200 µm. Boxes indicate magnified areas shown in figure B. (B) Representative 
light microscopic pictures of an ileum of an uninfected mouse, the magnified ileum of a YPIII-infected 
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mouse, and the magnified ileum of a YP147 (∆cnfY)-infected mouse, showing an occasional inflammatory 
area. The circle indicates focal invasion of inflammatory cells. Black bar represents 50 µm. (C) 
Representative light microscopic picture of a spleen of an uninfected mouse, of a YPIII-infected mouse with 
splenic atrophy and a bacterial microcolony surrounded by necrosis, and of a YP147 (∆cnfY)-infected 
mouse, showing hyperplasia of the white pulp and activated lymphoid follicle. Bar represents 50 µm. Arrow 
indicates bacterial foci. W: white pulp (dashed line); N: necrosis; H: hyperplasia; R: red pulp; M: muscularis 
mucosa. 
 
In the spleens of mice infected with the cnfY mutant strain, no bacterial microcolonies 
(diffuse patches of bacteria) could be detected under the light microscope with the H & E 
staining three or six days post infection. However, in prepared cryosections with 
fluorescent YP147 (ΔcnfY) bacteria harbouring a constitutively expressed dsred2 
reporter gene (pFU228), few microcolonies could also be detected in the spleen three 
days post infection (see Figure S1). Most spleens of YPIII-infected mice in contrast 
contained many bacterial microcolonies, already visible in the H & E stained spleen 
sections six days post infection (see Figure 3.3.5 C). In addition to the higher amounts of 
bacteria, the inflammation in these spleens was more severe in comparison to the 
spleens of YP147 (ΔcnfY)-infected animals and showed areas of multifocal necrosis. 
The bacteria in the spleens of YPIII-infected mice resulted in necrotizing splenitis leading 
to splenic atrophy with marked depletion of the white pulp. However, the spleens of 
YP147 (ΔcnfY)-infected mice only displayed mild hyperplasia of the white pulp and an 
influx of red blood cells (erythropiesis) (see Figure 3.3.5 C). Nevertheless, necrotic areas 
could also be detected in the livers infected with YPIII (data not shown). 
In summary, CNFY leads to a severe, wide-spread inflammation in the gut particularly in 
the ileum. This enables the bacteria to effectively colonize the spleen, and causes 
necrosis in the systemic organs spleen and liver. 
3.3.3 CNFY triggers the release of multiple proinflammatory cytokines 
Due to the inflammatory response visible in the histopathological analysis, the serum 
cytokine response triggered upon an infection of mice with YPIII or YP147 (ΔcnfY) in 
comparison to untreated mice, was measured. Hence, groups of 5 BALB/c mice were 
infected orally with 2 x 108 bacteria, heart blood was taken, the serum prepared, and the 
level of released cytokines (eotaxin, G-CSF, GM-CSF, IFN-γ, IL-10, IL-12 (p40), IL-12 
(p70), IL-13, IL-15, IL-17, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IP-10, KC-
like, LIF, LIX, M-CSF, MCP-1, MIG, MIP-1α, MIP-1β, MIP-2, RANTES, TNF-α and 
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VEGF) was measured by an immunology multiplex assay, measured with the Luminex 
detection system. 
Figure 3.3.6 represents the released proinflammatory cytokines in the serum, which 
showed different levels upon infection with the two strains (eotaxin, tumor necrosis 
factor-α (TNF-α), macrophage inflammatory protein-1β (MIP-1β), interleukin 6 (IL-6), 
granulocyte macrophage colony-stimulating factor (GM-CSF), and IL-12 (p40)).  
The secretion was generally higher upon infection with the wild-type strain YPIII, 
indicating a severe inflammation when CNFY is present, thus supporting the 
histopathological data (see above). The GM-CSF median concentration in the serum of 
YPIII-infected mice was 1.1 times higher compared to YP147 (∆cnfY)-infected animals. 
This cytokine is secreted by different immune cells, e.g. macrophages or NK cells and 
increases the inflammation by stimulating the production of further immune cells (e.g. 
neutrophils) and the maturation of monocytes to macrophages and DCs (Shi et al., 
2006). The IL-12 (p40) median concentration in the serum of YPIII-infected mice was 1.5 
times higher in comparison to YP147 (∆cnfY)-infected animals. IL-12 (p40) is a subunit 
of IL-12 and mainly produced by DCs and macrophages. It induces the production of 
cytokines from NK cells and T cells, enhances the cytotoxic activity of NK cells, and 
stimulates cytotoxic T cell proliferation (Trinchieri, 1995). The median concentration of 
TNF-α in the serum of YPIII-infected mice was also 1.5 times higher when compared to 
YP147 (∆cnfY)-infected animals. TNF-α is primarily produced by macrophages, but also 
by T cells and results in the activation of neutrophils and further proinflammatory 
responses (Gifford & Flick, 1987).  
The median concentration of the chemokine eotaxin was 2 times higher in the serum of 
YPIII-infected mice in comparison to YP147 (∆cnfY)-infected animals. Different cell 
types, but mainly fibroblasts produce eotaxin in response to allergic stimuli or parasites, 
leading to the recruitment of eosinophils (Griffiths-Johnson et al., 1993; Jose et al., 
1994). The median concentration of MIP-1β in the serum of YPIII-infected mice was also 
increased twofoldly in comparison to YP147 (∆cnfY)-infected animals. MIP-1β is a 
chemokine secreted by macrophages, which activates inflammatory responses, resulting 
in the secretion of IL-6 or TNF-α (Sherry et al., 1988). However, the most significant 
changes were detected in the concentration measured for the IL-6. A median 
concentration in the serum of YPIII-infected mice, which was 4 times higher in 
comparison to YP147 (∆cnfY)-infected animals could be detected. IL-6 plays a cruicial 
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role in the transition from innate to adaptive immune response and is mainly produced 
by macrophages, but also by T cells and endothelial cells (Jones, 2005).  
In summary, these data suggest that CNFY leads to the secretion of proinflammatory 
cytokines and induces an increased inflammation in the host. 
 
 
Figure 3.3.6: CNFY induces higher proinflammatory cytokine levels in the serum of infected mice.  
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Groups of 5 BALB/c mice were infected orally with 2 x 108 bacteria of Y. pseudotuberculosis YPIII or 
YP147 (∆cnfY). Three days after infection, mice were sacrificed and serum prepared. A quantitative 
cytokine (eotaxin, TNF-α, MIP-1β, IL-6, GM-CSF, and IL-12 (p40)) analysis was performed. Scatter dot 
plots show the median of two independent experiments. For statistical analysis, a Mann-Whitney test was 
applied to determine significant differences in the serum cytokine levels between YPIII-infected, YP147 
(∆cnfY)-infected or uninfected mice. Asterisks indicate the significances, with * (P<0.05), ** (P<0.01) and 
*** (P<0.001). 
 
3.3.4 CNFY modulates the host immune response 
The differences in the colonizing abilities of the strains in the MLNs, spleen and liver and 
the harsh influx of proinflammatory cytokines due to the infection with YPIII led to the 
assumption that the triggered immune response in the lymphatic tissues PP, MLNs, and 
spleen could differ. These experiments have been performed in cooperation with Jörn 
Pezoldt of the group „Experimental Immunology“ led by Prof. Dr. Jochen Hühn, of the 
Helmholtz Centre for Infection Research. Due to preliminary data for infection periods of 
three and six days (data not shown), a period of three days was chosen for the analysis. 
These preliminary data suggested that the immune response is already altered at the 
shorter time point at which the bacterial loads are still quite similar. Furthermore, the 
health status of mice infected for six days is already severely reduced.  
Hence, groups of 5 - 6 BALB/c mice were infected orally with approximately 2 x 108 
bacteria of Y. pseudotuberculosis per mouse. After three days, the PP, MLNs or spleens 
were isolated, the prepared cell suspensions stained with fluorescently labeled 
antibodies for different immune cells (neutrophils, macrophages/monocytes, dendritic 
cells, CD3+ T cells, CD4+ T cells, CD8+ T cells, and B cells) and analyzed by multi-colour 
flow cytometry. Two different panels of antibodies were used to identify the different cell 
populations (see Figure S2).  
Figure 3.3.7 shows the amounts of isolated neutrophils (CD11b+Ly6G+), 
macrophages/monocytes (CD11b+Ly6G-), DCs (CD11c+), NK cells (NKp46+), B cells 
(CD19+), and T cells (CD3+) of the different tissues. The innate immune response in the 
PP was triggered upon infection with both strains, but almost no change in the adaptive 
immune response was detectable (see Figure 3.3.7 A). Despite the unchanged 
colonizing abilities of the two strains in the PP, the measured quantities of infiltrated 
neutrophils differed significantly. The infection with YPIII led to a 100-fold higher amount 
of neutrophils, whereas the infection with YP147 (∆cnfY) only induced a 40-fold higher 
influx in comparison to the steady state level of neutrophils in the PP of untreated mice. 
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Within three days, the numbers of the cnfY mutant strain began to decrease in the 
MLNs, whereas the wild-type strain was able to replicate. Figure 3.3.7 B shows the 
corresponding immune response in the MLNs. An overall increase of innate as well as 
adaptive immune cells was detected due to the infections. However, no drastic 
differences between the strains were visible. Nevertheless, slightly higher amounts of 
macrophages/monocytes upon infection with YPIII and of T cells upon infection with 
YP147 (∆cnfY) were detected. 
The colonization of the spleen up to day three post infection does not differ significantly 
between the two strains, yet the immune cell contents show drastic differences (see 
Figure 3.3.7 C). Already after three days, all tested immune cell populations were 
significantly decreased upon infection with YPIII, in accordance with the shrinking of the 
spleen and the necrotic spots in the histopathological analysis. The most significant 
reduction was visible in the innate immune cell contents. Particularly macrophages, 
monocytes, and NK cells, were significantly reduced (approximately 15-fold) in 
comparison to the cell populations in the spleens of untreated animals. This effect was 
less pronounced in the neutrophil, DC, T cell, and B cell populations. 
On the other hand, a significant increase of the immune cells predominantly of 
neutrophils and macrophages/monocytes, was detectable in mice infected with the cnfY 
mutant. These data are also consistent with the differences in the spleen weight, the 
histopathological analysis, and the fast clearance of the mutant strain of this tissue after 
triggering the immune response. Necrosis in the spleen induced by YPIII infection and 
splenomegaly induced by YP147 (∆cnfY) infection, resulted in significant differences in 
the overall cell counts for this organ between the groups. Hence, the percentages of 
populations also for PP and MLNs were determined to test a possible effect of CNFY on 
the steady-state level of a specific cell population. CNFY seems not to affect the steady-
state level of the cell populations in the PP and MLNs (see Figure S3 A + B). However, a 
significant expansion of neutrophils and macrophages/monocytes could be detected in 
the YP147 (∆cnfY)-infected spleens (see Figure S3 C). 
Taken together, the measured immune response in the PP and MLNs, the 
histopathological data of the gut, and the increased secretion of proinflammatory 
cytokines in the serum suggest that CNFY leads to an enhanced inflammatory response. 
Furthermore, the measured immune response and the histopathological data of the 
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spleen strongly suggest that CNFY reduces an influx and/or leads to a rapid cell death of 
the infiltrating immune cells. 
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Figure 3.3.7: CNFY modulates the host immune response and leads to depletion of immune cells.  
Groups of 5 - 6 BALB/c mice were infected orally with 2 x 108 bacteria of Y. pseudotuberculosis YPIII or 
YP147 (∆cnfY). Three days after infection, mice were sacrificed and organs (PP, MLNs, and spleen) 
B cells
uninfected YPIII YP147 ( cnfY)
0.0
5.0 1006
1.0 1007
1.5 1007
*** ***
**
C
D
19
+ c
el
ls
/s
pl
ee
n
Natural killer cells
uninfected YPIII YP147 ( cnfY)
0
1 1004
2 1004
3 1004
4 1004
5 1004
5.0 1005
1.0 1006
1.5 1006
N
Kp
46
+ c
el
ls
/s
pl
ee
n
***
***
T cells
uninfected YPIII YP147 ( cnfY)
0.0
5.0 1006
1.0 1007
1.5 1007
*** ***
C
D
3+
ce
lls
/s
pl
ee
n
Neutrophils
uninfected YPIII YP147 ( cnfY)
0
1 1005
2 1005
3 1005
4 1005
5 1005
2 1006
4 1006
6 1006
C
D
11
b+
Ly
6G
+ c
el
ls
/s
pl
ee
n
*
***
***
Dendritic cells
uninfected YPIII YP147 ( cnfY)
0.0
5.0 1004
1.0 1005
1.5 1005
2.0 1005
C
D
11
c+
ce
lls
/s
pl
ee
n
**
**
***
Macrophages/Monocytes
uninfected YPIII YP147 ( cnfY)
0
1 1005
2 1005
3 1005
4 1005
5 1005
1 1006
2 1006
3 1006
4 1006
C
D
11
b+
Ly
6G
- c
el
ls
/s
pl
ee
n
***
***
***
C Spleen
Results 
 
 95 
isolated. Prepared cell suspensions were stained with fluorescently labeled antibodies to detect the 
different immune cells with flow cytometry: neutrophils (CD11b+/Ly6G+), macrophages/monocytes 
(CD11b+Ly6G-), DCs (CD11c+), NK cells (NKp46+), B cells (CD19+), and T cells (CD3+). Data plotted on the 
y axis indicate the cell numbers isolated from uninfected, YPIII-infected of YP147 (∆cnfY)-infected organs. 
Scatter dot plots show the median of two independent experiments for (A) PP, (B) MLNs, and (C) spleen. 
For statistical analysis, a Mann-Whitney test was applied to determine significant differences in the 
numbers of indicated cell types in the whole organ between YPIII-infected, YP147 (∆cnfY)-infected or 
uninfected mice. Asterisks indicate the significances, with * (P<0.05), ** (P<0.01) and *** (P<0.001). 
 
3.3.5 CNFY influence on Yop delivery 
Previous infection experiments showed that loss of CNFY leads to a clearance of the 
bacteria from the MLNs, spleen, and liver and avirulence of Y. pseudotuberculosis YPIII. 
Similar effects after oral mouse infections have been reported for YPIII (1) without the 
virulence plasmid and thus without the T3SS and the Yop effector proteins, (2) with 
multiple yop gene deletions, and (3) without the transcriptional regulator LcrF, a regulator 
of the T3SS and the Yop effector proteins (Böhme et al., 2012; Logsdon & Mecsas, 
2003). Furthermore, a Y. pestis yopM mutant strain induced an influx of neutrophils into 
the spleens of infected mice, whereas the wild-type strain caused a decrease of this cell 
type, similar to the effects observed in this study (Kerschen et al., 2004; Ye et al., 2009). 
Moreover, the Yop effector protein YopJ was demonstrated to induce the cell death of 
professional phagocytes (Monack et al., 1997; Zheng et al., 2011). 
These data suggested an interaction or control of the CNFY toxin with the Yop 
machinery during the course of infection. Furthermore, it was recently shown that Rho 
activation leads to enhanced Yop delivery (Mejía et al., 2008). Therefore, it was 
hypothesized that the CNFY toxin might influence Yop translocation into the innate 
immune cells by activation of the small Rho-GTPases (Blumenthal et al., 2007; 
Hoffmann et al., 2004).  
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3.3.5.1 CNFY enhances the Yop delivery into eukaryotic cells 
Due to the known impact of CNFY on the actin cytoskeleton and the Rho-GTPases of 
human epithelial cells (see 3.2), these cells were tested for the Yop delivery. Generally, 
the Yop secretion in vitro under secretion inducing conditions did not differ between the 
wild-type and the cnfY mutant strain (data not shown). 
In order to test the Yop delivery by Y. pseudotuberculosis YPIII into eukaryotic cells, 
different strains harbouring a YopE-β-lactamase reporter fusion were employed (Harmon 
et al., 2010). These strains were YP173 (YPIII-ETEM), YP174 (YP101 (ΔyscS)-ETEM), 
and YP217 (YP147 (ΔcnfY)-ETEM). Tested cells were stained with the dye CCF4-AM, 
consisting of coumarin and fluorescein conjugated by a lactam ring. This dye is trapped 
inside the living cells by estarases and fluoresces green after excitation. After 
translocation of the YopE β-lactamase fusion protein, the β-lactam ring of the dye is 
cleaved resulting in a fluorescent shift from green to blue, which allows the detection of 
Yop translocated cells (Gao et al., 2003; Zlokarnik et al., 1998). 
Two approaches were followed to detect the stained translocated cells in vitro, (1) 
visualization and counting with the fluorescent microscope and (2) analysis of 
translocated cells by flow cytometry. To test the Yop delivery into eukaryotic cells, the 
cells were either pretreated with the recombinant CNFY toxin (25 nM) or the same 
amount of PBS for three hours. Cells were subsequently infected with an MOI 10 of the 
strains YPIII/YP147 (∆cnfY) (both without the Yop-β-lactamase reporter fusion as 
negative controls), YP173 (YPIII-ETEM), YP174 (YP101 (∆yscS)-ETEM) (without 
functional T3SS; additional negative control), and YP217 (YP147 (∆cnfY)-ETEM) grown 
at 37°C overnight to achieve a high production of CNFY.  
No blue cells were detectable in the control groups: untreated, YPIII, YP147 (∆cnfY) or 
YP174 (YP101 (∆yscS)-ETEM) treated cells. However, a high amount of cells infected 
with YP173 (YPIII-ETEM) without CNFY pretreatment appeared blue, indicating high 
translocation rates of the YopE-β-lactamase reporter fusion (see Figure 3.3.8 A, B). In 
contrast, an infection with YP217 (YP147 (∆cnfY)-ETEM) led to significantly reduced 
levels of Yop delivery, indicating an impact of CNFY on Yop delivery. Additional 
pretreatment of the cells with recombinant CNFY led to an even higher translocation rate 
after infection with both strains. Nevertheless, a significantly higher amount of blue cells 
was still detectable due to infection with YP173 (YPIII-ETEM), compared to YP217 
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(YP147 (∆cnfY)-ETEM). In conclusion, Yop translocation into eukaryotic cells is 
enhanced by the CNFY activity. 
 
Figure 3.3.8: CNFY enhances Yop delivery into human epithelial cells.  
Bacteria were pregrown for infection overnight at 37°C to induce the CNFY secretion. The human epithelial 
cells HEp-2 were treated with 25 nM recombinant CNFY or the same amount of PBS for 3 h prior infection 
for 1 h with Y. pseudotuberculosis YPIII-ETEM (YP173), YP147 (∆cnfY)-ETEM (YP217), YPIII, YP101 
(∆yscS)-ETEM (YP174) or YP147 (∆cnfY), using an MOI of 10. Cells were labeled with the dye CCF4-AM 
and analyzed: (A) Fluorescent microscopy of the HEp-2 cells. All living cells appear green fluorescent, all 
Yop translocated cells appear blue fluorescent after excitation. Microscopic pictures are representative for 
three independent experiments of 3 wells. White bars indicate 20 µm. + CNFY indicates preincubation with 
the toxin. (B) Flow cytometry of the HEp-2 cells. Scatter dot plot represents the median of two independent 
experiments with 5 - 6 samples. For statistical analysis, a Mann-Whitney test was applied to determine 
significant differences in the numbers of translocated cells between YPIII-ETEM- and YP147 (∆cnfY)-
ETEM-infected cells with or without CNFY pretreatment. Asterisks indicate the significances, with *** 
(P<0.001). ETEM: yopE-bla-expressed β-lactamase. 
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3.3.5.1.1 Activation of Rho is crucial for enhanced Yop delivery 
The innate immune cells are known to be the main targets of the T3SS and the Yop 
effector proteins in vivo (Durand et al., 2010). Hence, murine macrophages (J774A.1 
and RAW246.7) were tested for the effect of CNFY on Yop delivery. Cells were 
pretreated two hours with recombinant CNFY (3 µg/ml (25 nM)) or the same amount of 
PBS. The subsequent infection was performed with an MOI of 10 with the strain YP173 
(YPIII-ETEM) grown overnight at 37°C to increase the expression of CNFY. Blue and 
green cells were counted from fluorescent microscopic pictures. CNFY had a boosting 
effect on the Yop delivery also on the phagocytes, indicating a possible impact of CNFY 
on the innate immune cells in vivo (see Figure 3.3.9).  
In addition, the Rho-GTPase responsible for the higher translocation rate induced by 
CNFY was determined. Previous publications showed that activation of Rac1 by YadA or 
invasin is required for the Yersinia uptake into epithelial cells (Wong & Isberg, 2005). 
However, the bacterial internalization as well as the Rac1 activation was not necessary 
to promote the Yop translocation into HeLa cells by Y. pseudotuberculosis (Mejía et al., 
2008). These data prompted the hypothesis that CNFY might induce the enhanced Yop 
delivery especially via RhoA activation. Hence, Rho-GTPase interacting bacterial toxins 
were used to specifically inhibit the different GTPases. For this purpose J774A.1 or 
RAW264.7 macrophages were pretreated two hours with (1) the C3 toxin (0.5 µg/ml, 
1 µgml) of C. botulinum an ADP-ribosylating protein that specifically inhibits RhoA, B and 
C or (2) the toxin B (85 ng/ml, 250 ng/ml) from variant C. difficile serotype F strain 1470 
(TcdBF), which specifically inhibits Rac, but not RhoA/B/C (Aktories & Hall, 1989; 
Huelsenbeck et al., 2007b).  
The toxin treated cells displayed typical actin cytoskeletal rearrangements and 
morphological changes, with no associated cell death (data not shown). Figure 3.3.9 
shows the translocation rate into the macrophages after treatment with the different 
toxins. The RhoA/B/C inhibitor C3 led to a significantly diminished Yop translocation into 
the macrophages already at the lowest toxin concentration, particularly in the J774A.1 
macrophages. However, even at high concentrations the Rac inhibitory toxin TcdBF had 
no effect on the amount of blue cells.  
Taken together, these data indicate that the toxin CNFY enhances the Yop delivery into 
murine macrophages. The process leading to this boost seems to be mainly dependent 
on RhoA activation in the professional phagocytes, rather than Rac1.  
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Figure 3.3.9: CNFY enhanced Yop delivery into murine macrophages is dependent on RhoA 
activation.  
Bacteria were pregrown for infection overnight at 37°C to induce the CNFY secretion. The murine 
macrophages J774A.1 and RAW264.7 were untreated or treated with Rho-GTPase modifying toxins: 
recombinant CNFY (3 µg/ml (25 nM)), toxin C3 of C. botulinum (0.5 µg/ml/ 1 µg/ml) or toxin TcdBF of 
C. difficile (85 ng/ml/ 250 ng/ml) for 2 h prior infection for 1 h with Y. pseudotuberculosis YPIII-ETEM 
(YP173), YPIII or YP101 (∆yscS)-ETEM (YP174), using an MOI of 10. Cells were labeled with the dye 
CCF4-AM and analyzed for percentage of blue (translocated) cells among green (living) cells. Scatter dot 
plot represents the median of three independent experiments with 3 samples. For statistical analysis, a 
Mann-Whitney test was applied to determine significant differences in the numbers of translocated cells 
between cells without pretreatment and toxin (CNFY, C3 or TcdBF)-treated cells. Asterisks indicate the 
significances, with ** (P<0,01) and *** (P<0.001).  
 
3.3.5.2 YopE is not strong enough to counteract CNFY 
It is known that YopE of Y. pseudotuberculosis YPIII is a GTPase-activating protein 
(GAP) mainly targeting Rac1 and RhoA. Thus, it can be considered a counterplayer of 
CNFY. The function of YopE seems to be important for the regulation of Yop 
translocation and modulation of host defences (Aili et al., 2002, 2006; Black & Bliska, 
2000; Songsungthong et al., 2010).  
This raised the question whether YopE and CNFY interact or compete in Rho-GTPase 
activation and Yop delivery. To test the ability of YopE to counteract the activity of CNFY, 
a yopE mutant strain was constructed. This strain was tested for its influence on 
RhoA/Rac1-GTP levels and for differences in the Yop translocation into murine 
macrophages with or without CNFY pretreatment.  
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For this purpose, murine macrophages were treated with recombinant CNFY (25 nM) or 
the same amount of PBS for three hours and subsequently infected with an MOI of 100 
with Y. pseudotuberculosis wild-type YPIII or the yopE mutant YP275 or left uninfected. 
The bacteria were grown at 37°C overnight to induce a high amount of CNFY and to 
mimic the situation prior to host cell contact. 
The uninfected cells without CNFY pretreatment showed low activation levels of the 
tested GTPases (GTP-bound) (see Figure 3.3.10 A). Upon treatment with the toxin, a 
higher amount of activated RhoA/Rac1 could be detected as indicated by the ratio of 
GTP-bound to GDP-bound forms. As indicated by the RhoA-GTP/RhoA ratio, 
macrophages infected with a yopE mutant strain with or without CNFY pretreatment 
show a slightly increased level of the GTP-bound form in comparison to wild-type-
infected cells. However, Rac1-GTP levels seem to be unaffected or only minimally 
affected by the translocation of YopE. 
Since RhoA was demonstrated to be mainly responsible for the CNFY-induced 
enhanced Yop delivery and YopE is supposed to counteract the activation, the ability of 
YopE to act against CNFY in terms of Yop translocation was evaluated. In order to test 
this, murine macrophages were pretreated with recombinant CNFY (25 nM) or the same 
amount of PBS for three hours and infected with the bacteria YPIII or YP275 (∆yopE) 
grown at 37°C overnight (MOI 100). The translocated Yop proteins were detected with  
an anti-serum directed against all Yop proteins. The ratios of the respective Yop to the 
actin control were calculated. As a negative control, cells were infected with a yscS 
mutant strain (YP101), unable to form a functional T3SS. However, loss of YopE had no 
or only a slight stimulatory effect on the translocation of YopD and YopH independently 
of the pretreatment with CNFY (see Figure 3.3.10 B). Thus, the intracellular GAP activity 
of YopE seems to be insufficient to efficiently counteract CNFY under the tested 
conditions, as indicated by the slightly higher activation of the GTPases and the higher 
amount of translocated Yop proteins when YopE is absent. 
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Figure 3.3.10: Deletion of YopE induces slightly higher amounts of RhoA/Rac1-GTP and leads to a 
minimal increase in Yop delivery.  
Murine macrophages RAW264.7 were incubated with 25 nM recombinant CNFY or the same amount of 
PBS for 3 h prior to infection with an MOI 100. Bacteria were pregrown for infection at 37°C overnight. (A) 
Infection for 20 min was performed with Y. pseudotuberculosis strains YPIII or YP275 (∆yopE) and PBS as 
negative control. Cells were lyzed and aliquots taken for western blot analysis. The rest of the samples was 
used to isolate the activated GTPases Rac1-GTP or RhoA-GTP using PAK1- or rhotekin-coupled beads, 
respectively. Using specific antibodies against RhoA (24 kDa) and Rac1 (21 kDa), the activated form and 
total amount of the proteins in the lysates could be detected. (B) Infection was performed for 1 h with 
Y. pseudotuberculosis YPIII, YP275 (∆yopE) or YP101 (∆yscS). Cells were lyzed and taken for western 
blot analysis, using an antiserum directed against all secreted Yops (α-Yop). Strain YP101 (∆yscS) 
represents the negative control to rule out permeabilization of the membrane in the detergent solubility 
assay. A western blot analysis with a specific antibody directed against actin was used as loading control. 
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3.3.5.3 CNFY enhances Yop delivery in vivo 
Due to the significant differences in the Yop translocation efficiency between the 
Y. pseudotuberculosis wild-type strain and a cnfY mutant strain in vitro, further in vivo 
analyses were performed. Former publications already reported that 
Y. pseudotuberculosis selectively targets the Yop injection into professional phagocytes 
of the PP, MLNs and spleen during the oral infection route (Durand et al., 2010).  
The following experiments were performed in cooperation with Dr. Devesha Kulkarni, 
formerly in the group „Experimental Immunology“ led by Prof. Dr. Jochen Hühn, of the 
Helmholtz Centre for Infection Research. 
To analyze a possible influence of CNFY on the YopE-β-lactamase delivery during the 
infection process, groups of 6 - 8 BALB/c mice were infected orally with 2 x 109 bacteria 
of the strains YP173 (YPIII-ETEM) or YP217 (YP147 (∆cnfY)-ETEM), and as negative 
controls with the strains YPIII and YP174 (YP101 (∆yscS)-ETEM). Three days post 
infection, the mice were sacrificed, PP, MLNs and spleen isolated and the cells of single 
suspensions stained with fluorescently conjugated antibodies and the dye CCF4-AM. 
Before the staining, aliquots were removed for detection of the bacterial load in the 
different organs. The stained cells were acquired using a multi-colour flow cytometer and 
the Yop translocation into the different immune cell subsets (Gr1+CD11b+ neutrophils, 
CD11+ macrophages, CD11c+ DCs, NKp46+ NK cells, CD19+ B cells and CD3+ T cells) 
was analyzed (see Figure S4). 
The percentage of translocated (blue) cells among all living (green) cells was calculated. 
The PP contained overall the highest rate of translocated cells of the tested lymphatic 
tissues. The PP of mice infected with the strain YP173 (YPIII-ETEM) contained 4.5% of 
blue cells among the living cells (see Figure S5 A). In contrast to that, the PP of YP217 
(YP147 (∆cnfY)-ETEM)-infected mice only contained around 1.5% of blue cells among 
the living ones.  
Because of the differences between the strains in bacterial colonization of the different 
organs, the data were additionally normalized to the bacterial load in the different 
organ/tissue (see Figure 3.3.11). The normalization is based on the assumption that the 
bacteria are infecting the different cells with the same MOI, but this is unknown. 
However, the cnfY mutant strain is significantly less able to translocate the Yop proteins 
into the cells of the PP, MLNs and spleen (see Figure 3.3.11 A; Figure S5 A). 
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These data indicate that CNFY enhances the Yop delivery also in vivo, yet the question 
remained if one cell subset is affected more frequently in the MLNs and spleen. 
Generally, the Yop proteins of Y. pseudotuberculosis targeted all the analyzed immune 
cells with a higher efficiency in the presence of CNFY (see Figure 3.3.11 B, Figure S5 B). 
Nevertheless, neutrophils in the MLNs and spleen showed a higher percentage of 
translocated cells, indicating a more frequently targeting of this cell type by the T3SS in 
these tissues. However, also macrophages, DCs and NK cells showed distinct 
blue/translocated populations, particularly in comparison to the T cells in both organs 
and the B cells in the spleen. These findings are in full agreement with former studies, 
which showed that YopH of Y. pseudotuberculosis IP2666 was concentrated in 
neutrophils, macrophages and DCs of the MLNs and spleen (Durand et al., 2010). 
The most significant reduction of Yop translocation was found for the cells of the MLNs 
in the absence of CNFY (except for NK cells). However, significantly less translocation 
due to the loss of CNFY was also detectable for neutrophils, B cells, and T cells in the 
spleen (see Figure 3.3.11 B). Additionally, lower percentages of Yop translocated cells 
were measured for macrophages and NK cells in the absence of CNFY (see Figure S5 
B). However, a slight reduction of the translocation rates due to the loss of cnfY was 
visible with all the tested cell subsets.  
Considering that Y. pseudotuberculosis induces host cell death (Bergsbaken & 
Cookson, 2007) and CNFY in particular seems to be involved in formation of necrotic 
spots in the spleen (see 3.3.2), it can be speculated that the amount of Yop translocated 
immune cells is probably higher in the presence of CNFY. In summary, CNFY enhances 
Yop delivery into host immune cells in vivo, in particular into professional phagocytes 
and thereby plays a significant role during infection of Y. pseudotuberculosis YPIII. 
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Figure 3.3.11: Deletion of cnfY diminishes Yop delivery predominantly into neutrophils, 
macrophages and DCs in PP, MLNs and spleen in vivo.  
Groups of 6 - 8 BALB/c mice were infected orally with 2 x 109 bacteria of Y. pseudotuberculosis YPIII-
ETEM (YP173), YP147 (∆cnfY)-ETEM (YP217), YPIII or YP101 (∆yscS)-ETEM (YP174). Three days after 
infection, mice were sacrificed and the organs (PP, MLNs, and spleen) isolated. Prepared cell suspensions 
were stained with fluorescently labeled antibodies to detect the different immune cells with flow cytometry: 
neutrophils (Gr1+/CD11b+), macrophages (CD11b+), DCs (CD11c+), NK cells (NKp46+), B cells (CD19+), 
and T cells (CD3+). Subsequently, cells were additionally dyed using CCF4-AM. The percentage of blue 
cells was analyzed by multi-colour flow cytometry of two independent experiments (see also Figure S5). 
Bacterial loads of the organs of 8 mice have been determined in parallel. These data were used for 
normalization to determine the Yop translocation efficiency. (A) Yop translocation efficiency into living cells 
of PP, MLNs, and spleen of mice infected with YPIII-ETEM (YP173) or YP147 (∆cnfY)-ETEM (YP217) is 
illustrated. (B) Yop translocation efficiency into different living immune cell subsets of MLNs and spleen of 
mice infected with YPIII-ETEM (YP173) or YP147 (∆cnfY)-ETEM (YP217) is illustrated. For statistical 
analysis, a Mann-Whitney test was applied to determine significant differences in translocation efficiency in 
(A) the different organs and (B) cell types between YPIII-ETEM (YP173)- and YP147 (∆cnfY)-ETEM 
(YP217)-infected mice. Asterisks indicate the significances, with * (P<0.05), ** (P<0.01) and *** (P<0.001). 
 
3.3.6 Yop delivery-independent CNFY function 
To test whether CNFY has an impact on the virulence of Y. pseudotuberculosis YPIII 
besides its influence on Yop delivery, further analyses were performed. For this purpose, 
a yscS single and a yscS cnfY double mutant strain were used. These strains lack the 
ability to translocate the Yop effector proteins due to the loss of the essential T3SS 
injectisome component YscS. Hence, an additional function of CNFY independently of 
the T3SS and the Yop effector proteins could be displayed with these strains. In order to 
test potential differences, the bacterial loads in the organs, the histopathology of the 
infected tissues, and the triggered immune response were analyzed three days post 
infection. This time-point was chosen to ensure bacterial colonization, considering that a 
mutant without the T3SS lacks the main defence mechanism against the host immune 
system and is rapidly eradicated. 
3.3.6.1 Additional loss of cnfY in a yscS mutant leads to a efficient 
colonization of the gut 
Organ burden experiments have been performed for the analysis of the bacterial loads 
in the different organs important in the enteropathogenic Yersinia infection route. Former 
studies already revealed that the pathogenicity of the Yersinia species is massively 
diminished without the virulence plasmid and thus the T3SS and the Yop effector 
proteins. These mutant bacteria are no longer able to reach the systemic organs liver 
and spleen (Cornelis et al., 1998; Straley et al., 1993). 
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In order to test the bacterial colonization of the organs three days post infection, groups 
of 5 BALB/c mice were infected orally with 2 x 108 bacteria of the strains YPIII, YP147 
(∆cnfY), YP101 (∆yscS) or YP298 (∆yscS ∆cnfY). The mice were sacrificed, the organs 
(small intestine, PP, caecum, colon, MLNs, spleen, and liver) isolated, and the organ 
homogenates plated to determine the colony forming units (CFU) per gram tissue. 
Figure 3.3.12 shows the bacterial loads of the different organs. The data for the systemic 
organs spleen and liver are not plotted because no bacteria of the strains YP101 
(∆yscS) and YP298 (∆yscS ∆cnfY) could be reisolated (data not shown). Similar 
amounts of all strains could be detected in the MLNs, whereas high variations between 
the strains were visible in the different intestinal tissues. Both bacterial strains without 
YscS are not able to colonize the gut as efficiently as the wild-type and the cnfY mutant 
bacteria. Interestingly, the double mutant strain YP298 (∆yscS ∆cnfY) is significantly 
more able to colonize especially the small intestine, caecum, and colon compared to the 
yscS single mutant strain. To exclude growth deficiencies/differences between the 
different strains, growth of the strains was monitored at 25°C and 37°C, but no 
differences in the bacterial growth in vitro were detectable (data not shown). These data 
indicate that the functional CNFY toxin in the absence/loss of the T3SS function is 
disadvantageous for the pathogen. Expression of a non-functional CNFY toxin or 
deletions in the gene could be beneficial for Y. pseudotuberculosis to prevent 
inflammation and tissue damage. 
In summary, the bacteria without a functional T3SS are less able to colonize the 
intestinal parts, show only slight differences in the colonization of the MLNs, and are not 
able to reach the underlying organs spleen and liver. Further, secretion of the CNFY 
toxin seems to reduce colonization of the bacteria in the intestinal tissues in the absence 
of a functional T3SS. In the MLNs, however, the additional loss of CNFY to YscS does 
not alter the colonizing ability of the bacteria. 
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Figure 3.3.12: Deletion of yscS reduces colonization of intestinal tissues, whereby a yscS cnfY 
double mutant strain more efficiently colonizes the intestinal tract than a yscS single mutant. 
Groups of 5 BALB/c mice were infected orally with 2 x 108 bacteria of Y. pseudotuberculosis YPIII, YP101 
(∆yscS), YP147 (∆cnfY) or YP298 (∆yscS ∆cnfY). Three days after infection, mice were sacrificed and the 
organs (small intestine, PP, caecum, colon, MLNs, spleen, and liver) were isolated. Homogenized organs 
were plated and the bacterial load (CFU) per gram tissue determined. The figure displays results of two 
independent experiments. For statistical analysis, a Mann-Whitney test was applied to determine significant 
differences in bacterial colonization of the organs between YPIII-, YP101 (∆yscS)-, YP147 (∆cnfY)-, and 
YP298 (∆yscS ∆cnfY)-infected mice. Asterisks in tables below the graphs indicate the significances, with * 
(P<0.05), ** (P<0.01) and *** (P<0.001). n.s.: no significance 
 
3.3.6.2 CNFY causes slight inflammation in the intestine independent of the 
Yop machinery 
The organ burden experiments revealed differences in the colonizing abilities between 
the tested strains YP101 (∆yscS) and YP298 (∆yscS ∆cnfY) (see 3.3.6.1). Interestingly, 
the additional loss of cnfY in the yscS mutant led to higher bacterial colonization rates in 
the intestinal parts. To further analyze the infection, a histopathological analysis was 
performed by Dr. Marina C. Pils of the „Mouse Pathology, Animal Experimental Unit“ of 
the Helmholtz Centre for Infection Research. 
Hence, groups of 4 BALB/c mice were infected orally with 2 x 108 bacteria, YPIII, YP147 
(∆cnfY), YP101 (∆yscS) or YP298 (∆yscS ∆cnfY) for three days. Subsequently, the mice 
were sacrificed, the organs isolated, embedded in formaldehyde, the sections stained 
with H & E, and evaluated blindly. Only minor differences in the histopathology of the 
different tissues between YP101 (∆yscS)- and YP298 (∆yscS ∆cnfY)-infected mice could 
be detected in the intestine, particularly in the ileum and caecum already three days after 
infection.  
Figure 3.3.13 shows representative pictures of the ileum of infected mice. The YPIII 
infection caused a severe diffuse ileitis already visible after three days of infection, which 
was observed before in mice infected for six days (see 3.3.2 for details). The infection 
with the cnfY mutant strain caused a moderate granulomatous ulcerative ileitis and 
inflammation (neutrophilic invasion) in the PP, restricted to focal areas (observed before 
after six days of infection; see 3.3.2 for details). 
However, the yscS mutant strain induced only mild epithelial hyperplasia in the intestinal 
epithelium (extension of villi), whereas no alterations could be observed after infection 
with the double mutant strain YP298 (∆yscS ∆cnfY) when compared with uninfected 
mice (see Figure 3.3.13, scale). In summary, CNFY causes a slight inflammation in the 
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intestine. However, the inflammation is much less severe compared to strains 
expressing a functional T3SS machinery.  
 
Figure 3.3.13: CNFY induces slight inflammation in the ileum independent of the T3SS.  
Groups of 4 BALB/c mice were infected orally with 2 x 108 bacteria of Y. pseudotuberculosis YPIII, YP147 
(∆cnfY), YP101 (∆yscS) or YP298 (∆yscS ∆cnfY). Mice were sacrificed three days post infection, the ileum 
isolated and sections stained with H & E. The figure shows representative light microscopic pictures of an 
ileum of a YPIII- , YP147 (∆cnfY)-, YP101 (∆yscS)- or YP298 (∆yscS ∆cnfY)-infected or uninfected animal. 
YPIII induced severe diffuse neutrophilic ileitis. YP147 (∆cnfY) induced a moderate focal ileitis and 
epithelial hyperplasia. YP101 (∆yscS) induced mild to moderate epithelial hyperplasia. YP298 (∆yscS 
∆cnfY) induced no alteration of the ileum. Black bar represents 50 µm. M: muscularis mucosa; Scale: villi 
length of uninfected control. 
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3.3.6.3 Loss of cnfY in a ΔyscS mutant causes no significant alteration of 
the immune response  
Loss of cnfY in an yscS mutant strain led to slightly, but not significantly higher 
colonization rates of this mutant strain in the PP, but no alteration in colonization of the 
MLNs. The growth curves in vitro showed no differences in the growth of the bacterial 
strains, which suggested a change in the triggered immune response especially in the 
PP. Potential differences in the immune responses exclusively attributed to CNFY should 
be analyzed. The PP, MLNs, and spleen were examined because these lymphatic 
tissues are the main sites for initiation of an immune response against enteric Yersinia 
infections. 
Hence, groups of 5 BALB/c mice were infected orally with 2 x 108 bacteria, YPIII, YP147 
(∆cnfY), YP101 (∆yscS) or YP298 (∆yscS ∆cnfY) for three days. The mice were 
sacrificed, the organs PP, MLNs and spleen isolated, and single cell suspensions 
prepared. Cells were stained with fluorescently labeled antibodies to stain the different 
immune cells (neutrophils, macrophages, DCs, monocytes, NK cells, CD3+ T cells, CD4+ 
T cells, CD8+ T cells, and CD19+ B cells) and analyzed by multi-colour flow cytometry 
(see Figure S6 B). Figure 3.3.14 shows the amounts of isolated neutrophils 
(CD11b+Ly6G+), macrophages (F4/80hi), DCs (CD11c+), and monocytes (Ly6C+CD11b+) 
of the different tissues. 
The strains YPIII and YP147 (∆cnfY) were able to colonize the PP more efficiently in 
comparison to the strains YP101 (∆yscS) or YP298 (∆yscS ∆cnfY). The double mutant 
could even be detected with slightly, but not significant higher amounts than the yscS 
single mutant (see Figure 3.3.12). However, the triggered innate immune response 
showed no differences as a result to the infection with the two yscS mutant strains 
YP101 (∆yscS) or YP298 (∆yscS ∆cnfY) in the PP (see Figure 3.3.14 A). A slight influx 
of neutrophils and monocytes could be detected in response to the infection with the 
yscS single and yscS cnfY double mutant strains, yet the influx of these cell types upon 
infection with the cnfY mutant strain was significantly higher. However, the highest influx 
of innate immune cells was detectable after infection with the wild-type strain harbouring 
both, YscS and CNFY. 
The bacterial numbers in the MLNs did differ only minorly between the four strains (see 
Figure 3.3.12). However, the infection with the wild-type strain caused generally a higher 
influx of all tested innate immune cells into the MLNs (see Figure 3.3.14 B). The loss of 
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cnfY, yscS or both yscS and cnfY led to significantly reduced amounts of neutrophils, 
macrophages, DCs, and monocytes. Again, no significant differences in the amounts of 
the tested immune cells were measured between an yscS and a yscS cnfY double 
mutant strain. Nevertheless, the innate immune response to a mutant strain without 
yscS or both yscS and cnfY does not or only slightly differ from the response caused by 
the infection with YP147 (∆cnfY), indicating that the functional T3SS machinery and 
CNFY combined lead to a changed immune response in the MLNs. 
In general, only slightly higher amounts of neutrophils and macrophages could be 
detected upon infection with the cnfY mutant, the yscS mutant or the yscS cnfY double 
mutant strain in comparison to the amounts in the MLNs of untreated mice. These data 
indicate that all the analyzed mutant strains are less attacked by the immune system in 
the MLNs compared to YPIII. It can be assumed that neither CNFY nor YscS (the Yop 
delivery) are exclusively responsible for the induction of the immune response in the 
MLNs, and a fine-tuned concerted function is needed to trigger Yop translocation and 
resulting effects on the immune system. 
YP101 (∆yscS) and YP298 (∆yscS ∆cnfY) bacteria could not be reisolated out of the 
spleens of infected mice (see Figure 3.3.12). In agreement with this result, no significant 
differences in the immune reaction could be detected between the strains. However, 
overall slightly lower amounts of neutrophils, macrophages and monocytes and an even 
significant lower amount of DCs could be detected upon infection with YP298 (∆yscS 
∆cnfY) in contrast to an YP101 (∆yscS) infection. The YP147 (∆cnfY) bacteria in contrast 
are able to colonize the spleen up to day three and induce a harsh influx predominantly 
of neutrophils and monocytes. In the wild-type the amounts are diminished, indicating 
that the combined activity of YscS and CNFY is needed. In summary, YscS but not CNFY 
is needed for the initial colonization of the spleen, but the concerted activity of YscS and 
CNFY seems to be important for defending the bacteria against the host immune system 
to remain in this tissue, probably by enhancing the Yop delivery machinery. 
Taken together, these data indicate that the major influence of CNFY in vivo appears to 
be the enhancement of Yop delivery. 
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Figure 3.3.14: Additional loss of cnfY in a ∆yscS mutant does not change the triggered immune 
response.  
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Groups of 5 BALB/c mice were infected orally with 2 x 108 bacteria of Y. pseudotuberculosis YPIII, YP101 
(∆yscS), YP147 (∆cnfY) or YP298 (∆yscS ∆cnfY). Three days after infection, mice were sacrificed and 
organs (PP, MLNs, and spleen) were isolated. Prepared cell suspensions were stained with fluorescently 
labeled antibodies to detect the different immune cells with flow cytometry: neutrophils (CD11b+/Ly6G+), 
macrophages (F4/80hi), DCs (CD11c+), and monocytes (Ly6C+CD11b+). Data plotted on the y axis indicate 
the cell numbers isolated from uninfected, YPIII-, YP101 (∆yscS)-, YP147 (∆cnfY)-, and YP298 (∆yscS 
∆cnfY)-infected organs. Scatter dot plots show the median of two independent experiments for (A) PP, (B) 
MLNs, and (C) spleen. For statistical analysis, a Mann-Whitney test was applied to determine significant 
differences in the numbers of indicated cell types in the whole organ between YPIII-, YP101 (∆yscS)-, 
YP147 (∆cnfY)-, YP298 (∆yscS ∆cnfY)-infected or uninfected mice. Asterisks in the tables below the 
graphs indicate the significances, with * (P<0.05), ** (P<0.01) and *** (P<0.001). 
 
3.3.6.4 Proteins of the virulence plasmid decrease the membrane integrity 
Previous studies of the CNFY homolog of E. coli, CNF1 revealed a strong increase of the 
membrane permeability of epithelial cells due to RhoA activation by CNF1 (Schlegel et 
al., 2011). Since CNFY is known to mainly activate RhoA in epithelial cells (Hoffmann et 
al., 2004), the influence of CNFY on membrane permeability was tested. 
For this purpose, Caco-2 cells were cultivated on a membrane until a polarized 
monolayer was formed (see 2.2.2.8). The cell monolayer was infected apically with 3 x 
106 bacteria of YPIII, YP147 (∆cnfY), YP12 pYV- or YP150 pYV- (∆cnfY) for 8 hours. 
Every hour and prior to infection, the trans epithelial electrical resistance (TEER) and 
thus the membrane integrity was determined. After 8 hours, the pH increased in the 
presence of bacteria, making a reliable measurement impossible. 
As visible in Figure 3.3.15 A, the strains containing the virulence plasmid YPIII and 
YP147 (∆cnfY) and thus a functional Yop delivery machinery, caused a fast destruction 
of the epithelial membrane, starting already two hours post infection. The monolayers 
infected with the strains YP12 pYV- or YP150 pYV- (∆cnfY) lacking the virulence plasmid 
stayed intact over 8 hours. These data suggest that the factors encoded on the virulence 
plasmid of Y. pseudotuberculosis YPIII diminish the membrane integrity. 
To test whether CNFY acts independently of other bacterial factors (e.g. the Yops), the 
recombinant toxin (50 nM) was used to intoxicate the cells basolaterally. The TEER was 
measured prior treatment and every second hour up to 22 hours (see Figure 3.3.15 B). 
At a TEER value lower than 80% of the starting point, the membrane becomes leaky 
(permeability threshold) and is termed as permeable. These data show a slight impact of 
CNFY on the membrane permeability, starting after four hours. However, this impact is 
not as significant as the one of the virulence plasmid-encoded factors. 
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In summary, CNFY seems to decrease the membrane integrity when applied in high 
concentrations. However, the T3SS and Yop effector proteins seem to play a 
predominant role in disrupting the membrane function. 
 
Figure 3.3.15: Proteins of the virulence plasmid lead to destruction of an epithelial membrane, 
whereas CNFY only causes a slight increase in membrane permeability.  
Caco-2 cells were cultivated on a membrane till a dense monolayer was formed. (A) Bacteria were grown 
overnight at 25°C. Cells on the membrane stayed uninfected or were infected apical with approximately 3 x 
106 bacteria of Y. pseudotuberculosis YPIII, YP12 pYV-, YP147 (∆cnfY) or YP150 pYV- (∆cnfY). Graph 
represents data of three independent experiments with each 2 wells normalized to time point 0. The trans 
epithelial electrical resistance (TEER) was measured 8 hours every hour. (B) Cells were treated 
basolaterally with 50 nM recombinant CNFY or the same amount of PBS over 22 hours. Graph represents 
data of three independent experiments with each 2 wells normalized to time point 0. TEER was measured 
every second hour. Green line indicates at which point the epithelial membrane starts being permeable. 
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3.4 CNFY leads to long-term changes of the host immune system 
Previous data suggested that the cnfY mutant strain is able to colonize the caecum and 
to some extent also the PP over long periods after an oral infection (14, 28 and 80 days; 
data not shown). In order to test if avirulent Yersinia mutant strains (YP12 pYV-, YP147 
(∆cnfY) or YP150 pYV- (∆cnfY)) possess different colonization abilities and induce 
different immune responses, long-term infections were performed for 28 days. Such 
experiments should allow to determine a possible effect of CNFY, independently from the 
virulence plasmid (no Yop machinery). Since YPIII-infected mice would not survive long-
term infections, the wild-type strain was not included in this experiment. The immune 
response in the PP, MLNs, and spleen was measured because these are the lymphatic 
tissues in which an immune response against Yersinia is expected. 
Groups of 5 BALB/c mice were infected orally with 2 x 108 bacteria. At day 28, the mice 
were sacrificed, the organs (small intestine, PP, caecum, colon, MLNs, spleen, and liver) 
were isolated and single cell suspensions were prepared of PP, MLNs and spleen and 
aliquots were taken to determine the bacterial load. Furthermore, single cell suspensions 
were stained with fluorescently labeled antibodies to detect different immune cells 
(neutrophils, macrophages, DCs, monocytes, NK cells, CD3+ T cells, CD4+ T cells, CD8+ 
T cells, and CD19+ B cells) and analyzed with multi-colour flow cytometry (see Figure 
S6). 
Neither YP12 pYV- nor YP150 pYV- (∆cnfY) bacteria could be reisolated of the examined 
tissues, maybe due to the high detection limit. However, the cnfY mutant strain could be 
detected in the caecum in 7 out of 9 mice (see Figure 3.4.1 A). The spleen weights of 
untreated mice still differed slightly from YP12 pYV--infected and significantly from the 
YP147 (∆cnfY)- and YP150 pYV- (∆cnfY)-infected mice, thus indicating long-lasting 
changes in this organ (see Figure 3.4.1 B). 
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Figure 3.4.1: Only the cnfY mutant strain could be reisolated of the caecum 28 days post infection, 
yet the spleen weights still differ after infection with YP12 pYV-, YP147 (∆cnfY) or YP150 pYV- 
(∆cnfY).  
Groups of 5 BALB/c mice were infected orally with 2 x 108 bacteria of Y. pseudotuberculosis YP12 pYV-, 
YP147 (∆cnfY) or YP150 pYV- (∆cnfY) or the same amount of PBS. 28 days after infection, mice were 
sacrificed and the organs were isolated. An YPIII-infection control was not included since mice would not 
survive a long-term infection. (A) Homogenized organs were plated and the bacterial load (CFU) per gram 
of the tissue determined. The figure displays the results of two independent experiments of the caecum. No 
bacteria could be reisolated of the other tested organs (small intestine, PP, colon, MLNs, spleen, and liver). 
(B) Spleen weights were determined in two independent experiments. For statistical analysis, a Mann-
Whitney test was applied to determine significant differences in (A) bacterial colonization in the caecum and 
(B) spleen weights between YP12 pYV--, YP147 (∆cnfY)-, YP150 pYV- (∆cnfY)-infected or uninfected mice. 
Asterisks indicate the significances, with ** (P<0.01) and *** (P<0.001). 
 
Figure 3.4.2 represents the flow cytometry analysis of the organs PP, MLNs and spleen 
for the immune cells neutrophils (CD11b+Ly6G+), macrophages (F4/80hi), DCs (CD11c+), 
monocytes (Ly6C+CD11b+), NK cells (NKp46+), T cells (CD3+), and B cells (CD19+). 
Analysis of the immune cell composition of the PP highlighted an ongoing immune 
response after infection with the three different strains in comparison to uninfected PP 
(see Figure 3.4.2 A). Significant differences could be measured for the DCs, monocytes, 
NK cells, T cells, and B cells without detectable bacterial numbers in this organ. 
Also the MLNs showed differences in their immune cell composition after a long-term 
infection without measurable bacterial numbers. Significantly higher amounts of 
neutrophils, monocytes, NK cells, and B cells could be detected upon infection with 
YP12 pYV- and YP147 (∆cnfY) (see Figure 3.4.2 B). In addition, significantly higher 
amounts of macrophages and DCs could be detected upon infection with YP12 pYV-, 
indicating an even stronger immune response due to infection with YP12 pYV- than with 
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YP147 (∆cnfY). However, a long-term infection with the strain YP150 pYV- (∆cnfY) only 
led to increased levels of NK cells, T cells, and B cells in comparison to the levels in 
uninfected MLNs, and thus a very mild remodulation of the immune compartment. In 
summary, no bacteria could be detected in the MLNs after a long-term infection with the 
three strains. Yet, significantly increased amounts of most tested immune cells could be 
measured 28 days after infection with YP12 pYV- - the strain harbouring the toxin - when 
compared to uninfected MLNs. 
As indicated by the differences in the spleen weights the mutant strains seem to have 
different impacts on the spleen (see Figure 3.4.1 B). However, an infection with the 
strains YP147 (∆cnfY) and YP150 pYV- (∆cnfY) did not or only slightly alter the immune 
cell contents in the spleen (see Figure 3.4.2 C). An infection with the strain YP12 pYV- in 
contrast led to significantly lower amounts of all tested immune cells, except for T cells 
and B cells in comparison to the contents of uninfected, YP147 (∆cnfY)- or YP150 pYV- 
(∆cnfY)-infected spleens. These data strongly indicate that CNFY affects innate immune 
cell contents in the spleen independent of the T3SS machinery. 
In summary, these strains (YP12 pYV-, YP147 (∆cnfY), YP150 pYV- (∆cnfY)) affect the 
immune system of the host over long periods after an infection without detectable 
bacterial numbers in the intestinal tissues (except for the caecum of YP147 (∆cnfY)-
infected mice), MLNs, and organs. Additionally, CNFY seems to be able to diminish the 
immune cell numbers in the spleen, independently from the virulence plasmid.  
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Figure 3.4.2: CNFY induced reduction of immune cell numbers in the spleen is independently from 
the virulence plasmid and still detectable 28 days post infection. 
Groups of 5 BALB/c mice were infected orally with 2 x 108 bacteria of Y. pseudotuberculosis YP12 pYV-, 
YP147 (∆cnfY) or YP150 pYV- (∆cnfY) or the same amount of PBS. 28 days after infection, mice were 
sacrificed and organs (PP, MLNs, and spleen) were isolated. Prepared cell suspensions were stained with 
fluorescently labeled antibodies to detect the different immune cells with flow cytometry: neutrophils 
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(CD11b+/Ly6G+), macrophages (F4/80hi), DCs (CD11c+), monocytes (Ly6C+CD11b+), NK cells (NKp46+), 
T cells (CD3+), and B cells (CD19+). Data plotted on the y axis indicate the cell numbers isolated from 
uninfected, YP12 pYV--, YP147 (∆cnfY)- or YP150 pYV- (∆cnfY)-infected organs. Scatter dot plots show the 
median of two independent experiments for (A) PP, (B) MLNs, and (C) spleen. For statistical analysis, a 
Mann-Whitney test was applied to determine significant differences in the numbers of indicated cell types in 
the whole organ between YP12 pYV--, YP147 (∆cnfY)-, YP150 pYV- (∆cnfY)-infected or uninfected mice. 
Asterisks indicate the significances, with * (P<0.05), ** (P<0.01) and *** (P<0.001). 
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4 Discussion 
The small Rho-GTPases are involved in different cellular processes, like the cell cycle 
progression, genetic information processing, organization of the cytoskeleton, and 
different host defence mechanisms (Etienne-Manneville & Hall, 2002; Lemonnier et al., 
2007). Particularly the actin cytoskeleton plays a crucial role in bacterial pathogenesis, 
e.g. phagocytosis of pathogens. Different bacteria have evolved toxins and effector 
proteins targeting the small Rho-GTPases which enable them (1) to prevent their 
phagocytosis by macrophages, (2) to induce their phagocytosis into non-phagocytic cells 
or (3) to disrupt the epithelial barrier to reach the underlying tissue (Bhavsar et al., 2007; 
Cossart & Toledo-Arana, 2008; Gouin et al., 2005). 
This study investigates the function of the Rho-GTPase-activating toxin CNFY, produced 
by the clinical isolate Y. pseudotuberculosis YPIII (Lockman et al., 2002). The molecular 
mechanism by which the toxin modulates cellular pathways and the cell morphology has 
already been addressed by several studies. However, the CNFY role in the pathogenesis 
of Y. pseudotuberculosis has not yet been dissected. To shed light upon this topic, the 
regulation of the cnfY expression, the molecular function, and particularly the impact of a 
cnfY deletion on the virulence of YPIII in a mouse gastrointestinal infection model were 
investigated. 
4.1 CNFY is present at infection relevant conditions 
The significance of CNFY for the pathogenesis of Y. pseudotuberculosis YPIII was 
initially studied by the expression and secretion profile of the toxin in vitro as well as in 
vivo. Not much was known about the expression conditions of cnfY. It was previously 
shown that cnfY expression is not regulated by temperature, the growth phase or 
calcium (Lockman et al., 2002). However, this study tested broth supernatant and 
bacteria-free lysates on epithelial cells for CNFY activity by monitoring the formation of 
multinucleated, giant cells. 
Here, promoter fusions (PcnfY::lacZ) were used to measure the expression of the toxin, 
which give more detailed information about the expression conditions. It could be 
demonstrated that cnfY is predominantly expressed at 37°C during late stationary 
growth phase in nutrient rich media. Hence, the expression is temperature-, growth 
phase-, and nutrient-dependent, i.e. cnfY is expressed under similar conditions to other 
virulence genes, e.g. the virulence-plasmid encoded yops or yadA (Cornelis & Wolf-
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Watz, 1997). This supported the assumption that CNFY could be an additional virulence 
factor for Y. pseudotuberculosis YPIII, since 37°C and a nutrient rich environment are 
conditions found in the intestinal tract of the host. Furthermore, the expression in vitro as 
well as in vivo in all tested organs of the infection route was distinct and leads to the 
assumption that the toxin is active throughout the whole infection process in the different 
organs. Additionally, the high secretion level of CNFY at 37°C suggests that a high 
concentration of the toxin is needed in the infection process for an adequate effect in the 
host.  
Additionally, the cnfY expression has been tested in dependence of different global 
virulence regulators crucial for temperature- or nutrient-dependent regulation of virulence 
gene expression in Y. pseudotuberculosis. The cnfY expression was independent of the 
ferric uptake regulator (Fur), indicating that CNFY synthesis does not depend on the iron 
concentration in the surrounding of the bacteria. Oppositely, Crp (cAMP receptor protein) 
activated the cnfY expression at the tested conditions, as cnfY is significantly less 
expressed in a crp mutant strain at 37°C in nutrient rich medium. The Crp protein 
controls the transcription of a variety of genes, e.g. invA of Y. pseudotuberculosis, and 
operons of the family Enterobacteriaceae, depending on carbon sources in the 
surrounding (Saier, 1998; Zheng et al. 2004; Heroven et al. 2012). Hence, Crp probably 
regulates the cnfY expression in response of the nutrients in the surrounding.  
Previous data also revealed that cnfY expression is controlled by the Yersinia 
modulator A (YmoA) (J. Schweer, Master-thesis). The nucleoid-associated protein 
YmoA is an important modulator involved in different thermo-regulated virulence gene 
expressions, linking early and late virulence phases (Cornelis et al., 1991). The 
expression of cnfY was repressed by YmoA at 25°C, particularly in the stationary 
growth phase, similarly to other late virulence genes like the yops (Böhme, 2010; 
Cornelis et al., 1991), indicating that cnfY is co-expressed with the yops in the late 
virulence phase in vivo.  
Since different virulence-relevant factors are often regulated and encoded by the 
Yersinia virulence plasmid pYV (yadA, yops, and T3SS), the influence of pYV on the 
expression and secretion of CNFY was tested. The data showed neither a virulence 
plasmid-dependent expression, nor secretion of the toxin. Hence, the plasmid encoded 
global virulence regulator LcrF, crucial for yop expression (Böhme et al., 2012; Lambert 
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de Rouvroit et al., 1992), plays no role in regulation of the toxin expression at the tested 
conditions.  
Furthermore, the CNFY secretion is independent of the virulence plasmid-encoded 
T3SS. The homologous toxin CNF1 of E. coli, was shown to be secreted by outer 
membrane vesicles (OMVs) (Davis et al., 2006). This could also be the case for CNFY, 
enabling the toxin to be transported over long distances in the host - independent of the 
bacteria - to prime the eukaryotic cells before these cells encounter the yersiniae. 
Nevertheless, a recent work by Kolodziejek et al. indicated that Y. pseudotuberculosis 
might not produce OMVs, whereas Y. pestis was shown to secrete membrane vesicles 
at the experimental conditions (Kolodziejek et al., 2013). These data and the sequence-
identity to cnf1 of only around 65% - also in the signal peptide region - suggest an OMV-
independent secretion mechanism for CNFY. Moreover, the CNFY toxin does not 
harbour a conserved signal sequence at its N-terminus, suggesting a secretion 
mechanism different from other well described mechanisms. 
A recent study of the typhoid toxin from Salmonella Typhi - also an A-B toxin - described 
a bacteriophage endolysin-like N-acetyl-β-D-muramidase, now termed as typhoid toxin 
secretion A (TtsA), which is essential for secretion of the typoid toxin (Hodak & Galán, 
2013). Endolysins are used by bacteriophages for lysis of the bacterial host to release 
the replicated phages. These peptides are secreted through the inner bacterial 
membrane and are able to cleave the peptidoglycan of the host (Borysowski et al., 2006; 
Young, 2002). The secretion of the endolysins is established by holins, small pore 
forming membrane proteins (Young, 1992, 2002). TtsA contains unique amino acids at 
the predicted peptidoglycan-binding domain and thus is probably a secretion mechanism 
newly evolved from bacteria (Hodak & Galán, 2013). Database research at the National 
Center for Biotechnology Information (NCBI) revealed that also Y. pseudotuberculosis 
YPIII harbours homologous proteins to bacteriophage holins and endolysins in its 
genome. It can be speculated that the CNFY toxin is secreted via a similar pathway as 
the typhoid toxin of S. Typhi.  
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4.2 CNFY constitutively activates the small Rho-GTPases Rac1, 
Cdc42, and RhoA and causes inflammation 
The Rho-GTPases are known to be the target of different virulence factors of pathogenic 
bacteria. Over 30 bacterial molecules directly or indirectly interacting with the GTPases 
were described (Symons & Settleman, 2000). All these factors help to ensure a 
successful infection of the pathogen. The CNFY toxin of Y. pseudotuberculosis YPIII is a 
Rho-GTPase constitutively activating toxin. In the present study, it was shown that 
intoxication of macrophages and epithelial cells with CNFY under the tested conditions 
led to the activation of the three small Rho-GTPases Rac1, RhoA, and Cdc42, whereby 
the macrophages were more susceptible to the treatment than the epithelial cells. The 
activation in macrophages was accompanied by high contents of actin stress fibres, 
formation of filopodia, and lamellipodia, and additionally the formation of giant, 
multinucleated cells. Previous studies with epithelial cells already demonstrated that 
CNF intoxication leads to the inhibition of cytokinesis, mainly by activation of RhoA 
(Falzano et al., 2006; Huelsenbeck et al., 2009). Thus, the cells lose their ability to 
divide, whereas mitosis continues (Caprioli et al., 1984; Knust et al., 2009).  
It was described previously that CNFY is able to interact with the three GTPases Rac1, 
Cdc42, and RhoA. Yet, it was shown to predominantly activate RhoA in intoxicated 
epithelial cells (Hoffmann et al., 2004; Lockman et al., 2002). However, a recent study 
also observed CNFY-mediated activation of Rac1 and Cdc42 additionally to RhoA, 
consistent with the data presented in this study (Wolters et al., 2013). Explanations for 
these variations in activation of the GTPases could be the intoxication periods, the toxin 
concentrations, and/or the employed cell lines in which CNFs may display different 
selectivity (e.g. different cellular receptors) and/or efficiency. As demonstrated for 
macrophages and epithelial cells, eukaryotic cells display a different susceptibility to the 
toxin treatment. Nevertheless, the Rho-GTPase activation pattern induced by CNFY 
changes over time with a generally more distinct RhoA activation level over Rac1 and 
Cdc42 two hours after toxin addition (Wolters et al., 2013). Taken together these data 
suggest that CNFY might induce RhoA predominantly at early time points and/or with low 
toxin concentrations, which are probably found in the host (see also 4.4).  
Since these three GTPases are known to influence the activation state among each 
other, most probably depending on the requirement, the initial RhoA activation could 
also result in activation/blocking of the other GTPases. The exploitation of this interaction 
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between the GTPases by enteropathogenic yersiniae was described before. For 
instance, the activation of Rac1 by invasin is needed for the β1-integrin mediated 
invasion of Yersinia, which in turn inhibits RhoA activation. This interaction is needed, 
because RhoA was shown to block the β1-integrin-mediated invasion (Alrutz et al., 2001; 
Wong et al., 2006). 
CNFY-induced changes in the activation pattern of the GTPases with different 
concentrations, incubation periods, and susceptibilities of the cells could be an 
advantage for the bacteria in the host, e.g. to induce/inhibit their cellular uptake. 
Previous studies demonstrated that phagocytes preferentially take up opsonised 
particles mostly by RhoA-, but also Rac-, and Cdc42-dependent pathways (Caron & 
Hall, 1998; Cox et al., 1997), which might also be activated by CNFY. Additionally, CNF1 
was shown to exploit the ubiquitin-proteasome machinery to eliminate the constitutively 
active GTPases and thus facilitate the invasion of the bacteria into the host cells (Doye 
et al., 2002). Furthermore, it has been reported that YPIII can initially survive in 
macrophages (Grabenstein et al., 2004), prompting the hypothesis that the bacteria 
might use these phagocytes as vehicles to reach underlying tissues without being 
attacked by the immune system. This suggests a possible advantage for those bacteria 
carrying the Rho-GTPase activating CNFY toxin to induce their cellular uptake to reach 
the underlying tissue. 
4.3 CNFY is crucial for virulence of Y. pseudotuberculosis YPIII 
The high expression levels of cnfY and its regulation by known virulence regulators 
suggested a function for CNFY during the course of infection. The role of CNFY was 
tested in the mouse model with an isogenic cnfY mutant strain. With the loss of cnfY, the 
bacterium Y. pseudotuberculosis was unable to cause a severe disease. Similar effects 
were published for uropathogenic E. coli strains, showing attenuated virulence in urinary 
tract infections with the loss of CNF1 in a mouse model (Rippere-Lampe et al., 2001a).  
Additionally, a homolog to the catalytic domain of CNF1 and thus also of CNFY, the toxin 
BPSL1549 (now termed Burkholderia lethal factor 1) of B. pseudomallei, is crucial for the 
virulence of this bacterium in a mouse model. This factor is a cytotoxin, which 
deamidates the glutamine of a translational factor and thereby inhibits translation (Cruz-
Migoni et al., 2011). These data display the importance of each individual bacterial toxin 
for their parental strain, as the deletion of one factor renders the bacterium avirulent. In 
general, such a dramatic influence on virulence by the loss of one single gene has only 
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been observed for important virulence genes or regulators of Yersinia: (1) with the 
absence of the global yop expression regulator LcrF (Böhme et al., 2012) or (2) when 
different yop genes are deleted (Logsdon & Mecsas, 2003). 
It is relevant to note that YopT (Viboud & Bliska, 2001), and the response regulator 
PhoP (Grabenstein et al., 2004) are not expressed in the CNFY+ Y. pseudotuberculosis 
strain YPIII, indicating that different strains may exert virulence through alternative 
mechanisms. The cnfY gene is only active in few Y. pseudotuberculosis strains. Large 
deletions over the whole gene in other Y. pseudotuberculosis as well as Y. pestis strains 
are frequently found. As the toxin is flanked by a transposase it can be assumed that this 
gene has been acquired from other bacterial strains (Lockman et al., 2002). Presumably 
the strains with deletions in the cnfY gene did not utilise the gene and/or had even a 
disadvantage in their colonisation/persistence in the host by the toxin.  
Yet, the clinical Y. pseudotuberculosis isolate YPIII was shown to be strongly attenuated 
in its virulence without the toxin. Due to mutations in the phoP gene, this strain is not 
able to replicate in macrophages (Grabenstein et al., 2004). Other Y. pseudotbuerculosis 
strains display a strongly attenuated virulence upon inactivation of PhoP (Fisher et al., 
2007; Grabenstein et al., 2004; Oyston et al., 2000). However, YPIII retains its virulence 
despite an unfunctional PhoP, which might be attributed to the activity of CNFY. 
Furthermore, a phoP+ mutant of YPIII used in this study was also shown to lose its 
virulence without the functional cnfY, indicating a significant role for CNFY during 
Y. pseudotuberculosis YPIII infection independent of PhoP.  
One strain harbouring both the cnfY gene and the functional phoP was already 
identified, namely Y. pseudotuberculosis IP2666 (Pujol & Bliska, 2003). This strain was 
shown to be able to replicate within macrophages (Grabenstein et al., 2004). 
Additionally, it was demonstrated that the wild-type strain IP2666 seems to be slightly 
more virulent than the wild-type strain YPIII (McCoy et al., 2010). Thus, it can be 
hypothesized that the presence of both functional genes might be an advantage for this 
strain. However, this hypothesis is rather speculative as the two Y. pseudotuberculosis 
strains probably display several other differences. 
Studies addressing the dissemination ability of Y. pseudotuberculosis YPIII to deeper 
tissues revealed a strong impact of the toxin in the colonization of the MLNs, spleen, and 
liver. The cnfY mutant bacteria were still able to reach the underlying tissue, but could 
not persist for longer than three to five days after infection. This phenomenon was also 
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observed with different yop single mutant strains, e.g. yopE or yopH (Logsdon & 
Mecsas, 2003), indicating a similar function for CNFY in defending the bacteria against 
the immune system. The wild-type bacteria in contrast were able to replicate and led 
ultimately to the death of infected animals. 
Moreover, compared to YPIII the cnfY mutant strain did not induce the same release of 
proinflammatory cytokines into the serum of infected animals, resulting in a significantly 
lower inflammatory response. Particularly eotaxin, a chemokine involved in processes of 
allergic inflammation, was secreted in significantly higher amounts upon infection with 
YPIII, compared to the YP147 (∆cnfY) infection. This cytokine was demonstrated to 
prime the production of reactive oxygen species (ROS) from eosinophils (Honda & 
Chihara, 1999), a process associated with cell- or tissue-damage (Bergamini et al., 
2004). Interestingly, this reaction was inhibited by the pertussis toxin of Bordetella 
pertussis, an A-B toxin blocking the activation of GTPases probably involved in the 
eosinophil activation signal transduction (Honda & Chihara, 1999). Hence, this toxin 
exerts counteracting activities to CNFY.  
Data of this work showed that Y. pseudotuberculosis wild-type, which was demonstrated 
to be able to persist in the systemic organs, induces eotaxin secretion into the serum. 
Furthermore, recruitment of eosinophils into the gastrointestinal tract and PP by eotaxin 
was described (Mishra et al., 2000). It can be assumed that YPIII primes the production 
of ROS by eosinophils, leading to subsequent dramatic tissue damage in the infected 
animals probably mainly in the intestine. Further, CNFY could enhance the production of 
ROS by activating GTPases involved in signaling pathways of the eosinophil activation. 
This hypothesis is in accordance with the histopathological analysis and the immune cell 
composition in the different infected tissues. These revealed a strong CNFY involvement 
in the acute inflammatory response and host tissue damage during infection. Former 
studies of cnf1 uropathogenic E. coli deletion mutant strains revealed similar effects after 
mouse infection, using urinary tract and prostatitis infection models by subcutaneous 
injection (Rippere-Lampe et al., 2001a, b). It was shown that CNF1 leads to highly 
inflamed bladders or prostates of the animals. 
Notably the caecum and ileum of infected mice displayed severe signs of diffuse 
inflammation due to CNFY with disrupted villi, thickened lamina propria, and resulting 
shortened gut lengths. With the loss of CNFY the intestinal inflammation of mice was 
restricted to small foci and reversible, whereas with CNFY the inflammation is more 
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generalized. Similar impacts on the intestine of mice have been found with S. enterica 
serovar Typhimurium (S. Typhimurium) infections, revealing an advantage for these 
bacteria in the inflamed gut to compete with the intestinal microbiota, thus enhancing the 
growth of Salmonella in the gut lumen (Stecher et al., 2007; Winter et al., 2010). 
S. Typhimurium was demonstrated to being able to metabolize ethanolamine, provided 
by the host, which enables the bacterium to avoid competition with the microbiota, 
regarding nutrients (Thiennimitr et al., 2011). Yersinia might also be able to metabolize 
substances produced in the inflamed gut, which the bacteria of the microbiota can not 
metabolize. 
Additionally, it was shown that S. Typhimurium exploits the inflammatory response 
(primarily of neutrophils), which results in disruption of the microbiota and the intestinal 
barrier, to reach the underlying tissues (Winter et al., 2010). Hence, it can be 
hypothesized that the CNFY induced intestinal inflammation promotes the migration of 
the yersiniae through the gut by the disruption of the intestinal barrier. 
The decreased immune cell content in the Y. pseudotuberculosis wild-type infected 
spleens compared to the cnfY mutant suggests an induction of apoptosis of immune 
cells in the presence of the toxin CNFY: the histopathologic evaluation underlined this 
assumption, as the necrotic spots in this organ were not seen after infection with the 
cnfY mutant strain. In YPIII infected spleens, cell death led to atrophy of the organ, 
displayed by shrinking and less red coloring, whereas infection with the cnfY mutant led 
to hyperplasia of the white pulp (contains mainly lymphocytes) indicating a triggered 
immune response, which is also displayed by splenomegaly.  
4.4 CNFY functions as a Yop delivery enhancer 
Professional phagocytes are preferentially targeted by the Yop effector proteins of 
Yersinia (Durand et al., 2010). Since these cell types were shown to be mostly affected 
by CNFY, testing the differences in Yop delivery rates into the immune cells caused by 
CNFY presence was consequential. Furthermore, it was observed that a selective 
modulation of RhoA activity by Y. pseudotuberculosis (e.g. by the binding of InvA to the 
β1-integrins or signals triggered by the YopB/D translocon) leads to cellular changes, 
controlling the T3SS pore formation and Yop translocation (Mejía et al., 2008). 
As discussed above, the CNFY intoxication of eukaryotic cell lines predominantly induces 
the activation of RhoA. Overall significantly higher translocation rates due to CNFY could 
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be detected in tested epithelial cells and macrophages. This is consistent with a recently 
published study in which CNFY preincubation enhances the Yop delivery of a CNFY-
negative Y. enterocolitica strain (Wolters et al., 2013). Wolters et al. were able to 
demonstrate that mostly CNFY-induced Rac1 activation is responsible for higher Yop 
translocation by Y. enterocolitica (CNFY- strain). 
Contrary to that, CNFY induced Yop translocation by Y. pseudotuberculosis into 
macrophages was diminished after treatment with the Rho inhibitor C3-transferase of 
C. botulinum, yet was unaffected by the Rac1 inhibitor TcdBF of C. difficile even at high 
concentrations in this study. This demonstrated that the activation of RhoA by CNFY is 
essential to enhance Yop translocation of Y. pseudotuberculosis into macrophages. This 
is consistent with the study of Mejía et al., which showed that mostly RhoA controls the 
pore formation of the T3SS (Mejía et al., 2008). These discrepancies in between the 
study of Wolters et al. and this current study regarding the impact of the different 
GTPases on Yop delivery could be due to differences in the experimental setups, likely 
the differences between the species Y. pseudotuberculosis and Y. enterocolitica. 
Factors causing these discrepancies might be differences in the YadA/InvA-promoted 
signaling events, in Yop protein abundance (e.g. the RhoA-inactivating YopT does not 
exist in YPIII), and in the regulation of Yop delivery by Rho-GTPases. 
Furthermore, CNFY influence on Yop translocation rates was observed for all cells of the 
lymphatic tissues PP, MLNs, and spleen in vivo. Less Yop delivery into the different 
immune cells - mostly into phagocytes - was measured after infection with the cnfY 
mutant strain, especially in the MLNs. Translocation rates into the splenocytes would 
probably differ more significantly between YPIII- and YP147 (∆cnfY)-infected animals. 
However, it was shown that the YPIII infection causes necrosis and particularly reduced 
amounts of phagocytic cells in the spleen, resulting in overall lower numbers of living 
cells. As professional phagocytes are preferentially attacked by the Yop proteins 
(Durand et al., 2010) and some of these proteins cause cellular death (see 4.4.1) 
(Viboud & Bliska, 2005) identification of less Yop translocated cells could result since 
only living cells were analyzed. Taken together, CNFY enhances Yop translocation by 
activation of Rho-GTPases, which is crucial for defence of Y. pseudotuberculosis YPIII 
against the immune system in this mouse infection model. 
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4.4.1 CNFY causes inflammation and increased cellular death 
Gastrointestinal infections with enteropathogenic Yersinia lead to a biphasic 
inflammatory process. Initially, the bacteria are able to replicate, adhere to, and 
transmigrate through the gut epithelial layer accompanied only by a slight antibacterial 
defence response with little inflammation, e.g. IL-8 expression by epithelial cells. 
Subsequently, an acute influx and activation of phagocytes, cytokine production and 
tissue damage occurs (Autenrieth et al., 1993b; Dube et al., 2001, 2004). The invading 
yersiniae are recognized at first due to their LPS by Toll-like receptor 4 (TLR4) of naïve 
host macrophages. This initiates the production of proinflammatory cytokines by 
activation of the mitogen-activated protein kinase (MAPK) and NF-κB (Haase et al., 
2003; Zhang & Bliska, 2003). YopJ was shown to inhibit the activation of MAPK and NF-
κB after translocation into the eukaryotic cell, inducing an apoptotic signaling pathway, 
which includes the activation of initiator caspase-8 and the executioner caspase-3, -7, 
and -9 (Bergsbaken & Cookson, 2009; Philip & Brodsky, 2012; Zhang et al., 2005).  
A yopJ mutant strain was observed to be deficient in spreading from PP to other 
lymphoid tissues (Monack et al., 1998) similar to the effect of a cnfY deletion mutant. 
Hence, both YopJ and CNFY are needed for the efficient systemic dissemination after 
oral infection. Moreover, the wild-type Yersinia infection was shown to induce apoptosis 
of macrophages in the spleen (Monack et al., 1998). YopJ seems to be mainly 
responsible for elimination of the immune cells in this organ and thereby decreases the 
triggered immune response against Yersinia. However, since CNFY enhances Yop 
delivery predominantly into the innate immune cells, a higher amount of YopJ is also 
released into the cells and probably causes increased apoptosis. This effect is 
presumably displayed by the shrinking of the spleen and the decreased immune cell 
contents after infection with YPIII. Apoptotic macrophages are eliminated by other 
phagocytes, triggering the production of anti-inflammatory cytokines like IL-10 and TGF-
β (Fink & Cookson, 2005; Savill et al., 2002).  
Since CNFY seems to enhance the apoptotic cell death of macrophages, the bacteria 
might be less attacked by these cells and subsequently are able to replicate 
uncontrollably. This would result in even higher CNFY secretion, higher Yop 
translocation, and thus increased amounts of apoptotic cells. Generally, the apoptotic 
cell death is non-inflammatory, yet it is probably not completely immunologically silent 
particularly not if the amount of apoptotic cells increases significantly, e.g. phagocytosis 
Discussion 
 
 134 
of apoptotic cells can prime other immunological responses like the activation of 
cytotoxic CD8+ T cells (Philip & Brodsky, 2012). During the process of the Yersinia 
infection, the contents of activated macrophages increase, whereas the contents of 
naïve macrophages decrease. Moreover, the infection induces cell death of naïve 
macrophages by apoptotic pathways, while it induces cell death of mature macrophages 
by proinflammatory pyroptosis (Bergsbaken & Cookson, 2007). Pyroptosis occurs due to 
activation of a multiprotein complex, the inflammasome, a platform for the 
autoprocessing and activation of the cysteine protease caspase-1. Yersinia was shown 
to induce caspase-1 activation and thus initiates pyroptosis by LPS, the T3SS, and the 
translocated YopJ (Brodsky et al., 2010; Philip & Brodsky, 2012; Zheng et al., 2011). 
The activation of caspase-1 induces the secretion of proinflammatory cytokines like IL-
1α, IL-1β, and IL-18, which causes the cell death (Bergsbaken & Cookson, 2007). 
The induction of the proinflammatory cell death (pyroptosis) is associated with the later 
infection phase of Yersinia. It is indeed very likely that CNFY promotes cell death of 
activated phagocytes by pyroptosis in the spleen. In this study, necrotic spots were 
observed in spleens of YPIII-, but not of ∆cnfY-infected animals six days after infection. 
Additionally, the wild-type strain induced a harsh release of proinflammatory cytokines 
(TNF-α, IL-6, GM-CSF, and IL-12 (p40)) into the serum and caused severe inflammation 
of the intestine, especially the ileum and caecum. Moreover, CNFY was shown to 
manipulate the immune cell contents in the spleen. Particularly macrophage-,  
monocyte-, and neutrophil-amounts were significantly diminished three days post 
infection. On the other hand, an infection with the cnfY mutant strain resulted in a harsh 
influx of phagocytes into the spleen (in comparison to spleens of uninfected mice) and 
induces only minor inflammation, which strongly suggests that the increased 
translocation of YopJ into phagocytes in the presence of CNFY stimulates 
proinflammatory cell death in the spleen during later stages of the infection. 
Particularly striking was the effect of CNFY on the NK cell contents in the spleen, which 
were significantly decreased when compared to the amounts in uninfected spleens. This 
reduction could either be caused by induced cell death or by migration of the NK cells 
from the spleen into other tissues. A deletion mutant of cnfY in contrast led to no or even 
slightly increased amounts of these cells in the spleen when compared to uninfected 
mice. Furthermore, no differences in the amounts of NK cells could be detected in the 
PP and MLNs between YPIII- and ∆cnfY-infected animals. Hence, CNFY seems to 
contribute to NK cell reduction in the spleen at this stage of the infection, by enhancing 
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cell death. A similar effect was observed with a yopM deficient Y. pestis mutant, which 
failed to decrease the global NK cell levels, whereas the wild-type strain led to a 
depletion of these cells (Kerschen et al., 2004). Hence, CNFY seems to enhance the NK 
cell depletion by inducing a higher YopM translocation. These data propose that CNFY 
secretion results in death of immune cells allowing an uncontrollably replication of the 
bacteria, which in turn secrete higher CNFY amounts. 
The secreted toxin leads to the activation of the small Rho-GTPases as mentioned 
above. It was recently reported that the effector SopE of Salmonella, which also 
activates Rac1 and Cdc42, triggered the NOD1 pathway (Keestra et al., 2013). NOD1 is 
a pattern recognition receptor sensing cytosolic microbial products (similar to NOD2), 
which monitors the activation states of the three small Rho-GTPases RhoA, Rac1, and 
Cdc42. Hence, the activation of the GTPases induced NOD1 signaling pathways, 
resulting in the RIP2-mediated triggering of the nuclear factor κB (NF-κB)-dependent 
proinflammatory responses (Keestra et al., 2013). Additional to that, all three Rho-
GTPases were previously shown to activate the NF-κB pathway, but particularly CNF1-
activated Rac1 has been reported to induce the NF-κB activation (Boyer et al., 2004). 
CNF1 leads to the clustering of the NF-κB inhibitor IκBα and components of the IκBα 
E3-ubiquitin ligase into formed membrane ruffles. This indicates a similar effect for 
CNFY, leading to even higher inflammatory responses, activation of phagocytes, and 
tissue damage. This would in turn presumably enable the bacteria to spread to the 
underlying tissues and additionally lead to the release of nutrients through the cell death.  
4.4.2 YopE exerts counteracting effects to CNFY 
Since CNFY was shown to enhance the Yop delivery by activating the small Rho-
GTPases, also Yop proteins with counteracting effects on the GTPases are translocated 
more frequently (YopE, YopA/O, and YopT). Particularly YopE, a GTPase-activating 
protein (GAP), leading to the inactivation of the GTPases, seems to act as a 
counterplayer for CNFY. YopE was previously shown to inhibit the Yop delivery by 
inactivation of RhoA and Rac1. Additionally, a yopE mutant strain was observed to 
cause increased translocation rates into epithelial cells compared to the wild-type (Aili et 
al., 2002, 2006, 2008; Songsungthong et al., 2010; Wong & Isberg, 2005). Thus, YopE 
acts as a regulator for the Yop delivery, like an intracellular control system, which 
measures and adjusts the amount of translocated Yop proteins during infection. A study 
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of the effector YopJ demonstrated the importance for a tight regulation of the Yop 
delivery in the oral mouse infection: a higher YopJ translocation results in raised 
cytotoxicity rates of phagocytes, yet leads to a decreased virulence of 
Y. pseudotuberculosis, as does the complete loss of YopJ (Brodsky & Medzhitov, 2008). 
The YopJ hyper-secretion or deletion resulted in reduced proinflammatory cytokine 
levels in the serum of infected mice (e.g. TNF-α or IL-6), similar to the effect of an 
infection with the cnfY mutant strain observed in this study. It was hypothesized that the 
secretion of proinflammatory cytokines induced by the wild-type bacteria promotes tissue 
damage, which in turn would enable the bacteria to spread to deeper tissues (Brodsky & 
Medzhitov, 2008). Since the mutant strains did not induce the same inflammatory 
response like the wild-type, this could result in disadvantages in dissemination of the 
bacteria. 
In this study it was demonstrated that the absence of yopE in a Y. pseudotuberculosis 
infection did not or only slightly increased the Rac1- or RhoA-GTP levels or the amount 
of translocated Yop proteins into murine macrophages with or without CNFY 
pretreatment. This indicates that although YopE possesses counteracting activities 
compared to CNFY, it is not strong enough to antagonize CNFY intracellularly in murine 
macrophages at the tested conditions in vitro. A recently published study is supporting 
this observation, as it shows that none of the Rho-GTPase interacting Yop effector 
proteins (YopE, YopO, and YopT) were able to reduce the effect of CNFY on Yop 
delivery of Y. enterocolitica into human epithelial cells (Wolters et al., 2013).  
However, the Yop secretion is dependent on contact with eukaryotic host cells in vivo 
and calcium depletion in vitro (Forsberg et al., 1987, 1994; Goguen et al., 1984; 
Pettersson et al., 1996). Since CNFY was shown to be secreted at infection relevant 
conditions, it can be assumed that CNFY is priming the eukaryotic cells - most likely the 
professional phagocytes - by constitutively activating the Rho-GTPases, resulting in 
higher Yop delivery rates. However, it can be hypothesized that if sufficient counteracting 
Yop effectors (especially YopE) are translocated, the translocation is diminished, most 
likely to prevent proinflammatory cell death and thus the triggering of an increased 
inflammatory response (Aili et al., 2008). Nevertheless, counteraction of CNFY by other 
cell functions cannot be excluded, e.g. the enhancement of deamidation and subsequent 
ubiquitin-dependent degradation of the activated GTPases, as it was observed after 
CNF1 intoxication (Doye et al., 2002). 
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4.4.3 Schematic model of CNFY-enhanced Yop delivery  
The results of this study highlight for the first time a dominant role of CNFY during the 
course of an oral Y. pseudotuberculosis YPIII infection. Based on these data, a basic 
model of the CNFY-enhanced Yop delivery can be proposed (see Figure 4.4.1).  
To the current knowledge, CNFY is starting a cascade, resulting in the proinflammatory 
cell death pyroptosis and additional proinflammatory responses. In the first step during 
the early phase of the infection process, the secreted toxin is endocytosed by infiltrating 
innate immune cells (e.g. neutrophils, macrophages, DCs). The catalytic domain of 
CNFY is secreted into the cytosol of the phagocytes in a pH-dependent manner and 
activates the Rho-GTPases, in particular RhoA, by deamidation. The constitutive 
activation of the GTPases induces actin-polymerization, leading to enhanced Yop 
delivery into the host cell. The translocated Yop effector proteins counteract the innate 
and adaptive immune responses by inhibition of the invading immune cells and the 
subsequent induction of apoptosis. In parallel, the bacteria can replicate uncontrollably, 
leading to the secretion of even higher CNFY amounts. The resulting enhanced 
activation of the Rho-GTPases triggers proinflammatory responses like the NOD1-RIP2 
(NF-κB) signaling pathway. Hence, the Yersinia infection increases the numbers of 
activated macrophages. The interaction of the bacteria with these cells results in the 
proinflammatory cell death pyroptosis, inducing a strong inflammation and necrosis of 
the infected tissues during later phases of the infection. 
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Figure 4.4.1: Proposed model of CNFY-enhanced Yop delivery.  
(A) Adhesion of Y. pseudotuberculosis to macrophages induces activation of RhoA, resulting in actin 
polymerization, which in turn leads to Yop delivery into the phagocyte by the T3SS. The translocated Yop 
effector proteins inhibit the phagocytosis and induce YopJ-mediated apoptotic cell death. (B) CNFY-
producing Y. pseudotuberculosis strains secrete the toxin prior or parallel to the interaction with the 
macrophage. CNFY is internalized, most likely by receptor-mediated endocytosis, into early endosomes. 
Due to acidification of the early endosomes, maturation to late endosomes occurs. The catalytic domain of 
CNFY is translocated across the membrane of the endosome via its translocation domain. The toxin 
deamidates the small Rho-GTPases RhoA over Rac1, and Cdc42 and renders them constitutively active. 
The activation results in enhanced Yop delivery and subsequent cell death. The Rho-GTPase activation 
was demonstrated to promote pore formation of the T3SS, probably leading to caspase-1 activation 
(Brodsky et al., 2010; Mejía et al., 2008). Additionally, the induced cell death may lead to increased 
proinflammatory immune responses, resulting in raised levels of activated macrophages and the Yersinia-
triggered activation of caspase-1 (Bergsbaken & Cookson, 2007). This activation induces the release of 
proinflammatory cytokines and the proinflammatory cell death pyroptosis. Meanwhile, the bacteria replicate 
and the CNFY levels increase, resulting in enhanced activation of the Rho-GTPases and thus increased 
inflammatory pyroptosis. 
 
4.5 CNFY exerts a minor impact on the epithelial layer 
permeability 
An important factor for the host to prevent penetration or dissemination of bacteria is the 
maintenance of the intestinal epithelial barrier function. Different actin cytoskeleton-
modifying bacterial toxins are known to destroy this barrier, like the GTPase inactivating 
(glycosylation) toxin A of C. difficile, which causes severe inflammatory enterocolitis and 
diarrhea (Hecht et al., 1988; Shen, 2012; Triadafilopoulos et al., 1987). Similar effects 
were observed in the histopathological analysis of the small intestine after YPIII 
infections in this study.  
The intoxication of a monolayer with the CNF1 toxin of E. coli leads to the disruption of 
the barrier function mostly by the constitutive activation of RhoA, which affects the tight 
junction integrity (Schlegel et al., 2011). Since CNFY was shown to predominantly 
activate RhoA, it was assumed that this toxin exerts an even stronger impact on the cell-
cell contact of the monolayer than CNF1, thus enabling the bacteria to pass through the 
epithelial layer without the M-cells (paracytosis). Additionally, CNFY was demonstrated to 
decrease the endothelial barrier integrity (Baumer et al., 2008), possibly enabling the 
bacteria to cross the endothelial layer of the blood vessels. However, incubation of an 
epithelial monolayer of Caco-2 cells with the CNFY toxin revealed only a slight increase 
in permeability, shown by the measurement of the trans epithelial electrical resistance 
(TEER). This barrier breakdown was not as harsh as the disruption caused by the 
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proteins of the virulence plasmid (coding for T3SS and the Yop effector proteins), 
indicating a significant role for these proteins to facilitate the transmigration of the 
yersiniae across membranes in the host. Consistent with this assumption, it was recently 
shown that the virulence plasmid and particularly YopJ are needed to disrupt the 
intestinal barrier integrity in vivo. YopJ was shown to be able to subvert the 
NOD2/RICK/TAK1 pathway, activate caspase-1, and induce the secretion of IL-1β in the 
PP, thus increasing the epithelial barrier permeability (Jung et al., 2012; Meinzer et al., 
2012). These results strongly suggest that CNFY induces the disruption of the intestinal 
epithelial membrane by enhancing the delivery of YopJ. This would promote the 
dissemination of Yersinia by exploiting the mucosal inflammatory response. 
4.6 CNFY activity is detrimental to Y. pseudotuberculosis without 
activated T3SS 
To detect an additional function of CNFY besides the enhancement of Yop delivery 
during the course of infection, mutant strains without a functional T3SS were tested for 
colonizing abilities, histopathological changes, and the host immune response in both, 
the presence and absence of CNFY.  
It was observed that a functional T3SS of Y. pseudotuberculosis YPIII is crucial to 
efficiently colonize the gastrointestinal tract, as the bacteria without a functional T3SS 
are significantly less able to colonize. This is consistent with previous studies 
demonstrating that mutations in different genes encoding components of the T3SS lead 
to non-efficient colonization of the gastrointestinal tract (Mecsas et al., 2001). The 
mutant strains without the functional T3SS colonized the MLNs with equal amounts as 
the wild-type strain. It was described before that Y. pseudotuberculosis has a tropism for 
B cell and T cell zones in the MLNs, which seems to protect wild-type bacteria as well as 
T3SS mutant bacteria from the infiltrating phagocytes (Balada-Llasat & Mecsas, 2006). 
However, three days post infection the exclusive loss of either the functional T3SS 
(∆yscS) or cnfY had no significant impact on the colonization of the MLNs by the 
bacteria in comparison to the colonization by the wild-type. Yet, decreased amounts of 
neutrophils and monocytes were detected after infection with either the cnfY or the yscS 
mutant strain in comparison to the amounts in the MLNs of YPIII-infected animals. This 
leads to the assumption that neither CNFY nor the Yop machinery alone induce the 
increase of immune cells normally detected in the YPIII infection. Hence, it can be 
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hypothesized that the concerted presence of the Yop machinery and CNFY (e.g. by 
enhancing the Yop delivery) is responsible for the higher contents of neutrophils and 
monocytes in the MLNs. Yet, the cnfY mutant strain is in the long-term probably more 
efficient in defending the immune system, due to the Yop proteins that are translocated. 
Moreover, the yscS mutant strain failed to reach the systemic organs spleen and liver, 
indicating that the Yop machinery is essential for Y. pseudotuberculosis YPIII to spread. 
Contrary to that, the cnfY mutant strain was able to colonize the spleen and liver, but 
was cleared rapidly. Hence, the Yop machinery is crucial to reach the systemic organs, 
whereas the Yop translocation enhancement of CNFY is presumably essential for 
Y. pseudotuberculosis YPIII to efficiently colonize these organs. 
Interestingly, the double mutant strain without cnfY and yscS was able to colonize the 
gastrointestinal tract better than the yscS single mutant strain, particularly the small 
intestine and the caecum. Thus, CNFY seems to be a disadvantage for those bacteria 
without a functional T3SS or under conditions in which the T3SS is not fully active. 
Former studies showed a decreased ability of single yop mutant strains to colonize the 
intestine and PP when co-infected with the wild-type strain, compared to single 
infections of the mutants (Logsdon & Mecsas, 2003, 2006). Regarding the yop mutant 
strains, their reduced ability to colonize is due to the inflammation of the gastrointestinal 
tract induced by the co-infected wild-type. Hence, immune cells (e.g. neutrophils) 
infiltrate and lead to the reduction of the mutant bacteria, as these bacteria are less 
able/unable to withstand the immune response.  
Since CNFY was shown before to be immunogenic (Mou et al., 2012), it can be assumed 
that this toxin is leading to an infiltration of innate immune cells into the intestine. This 
attraction of immune cells would eradicate the bacteria, as the functional T3SS is 
missing. Additionally, CNF1 of E. coli has been shown to activate NF-κB by the 
constitutively activation of Rac1, which is causing inflammation (Boyer et al., 2004). 
CNFY could induce similar effects, since it was also shown to activate Rac1. Hence, 
CNFY could induce inflammatory responses by activating NF-κB pathways. This 
assumption was supported by the histopathological analysis, which displayed that the 
ileum of mice infected with the mutant without a functional T3SS, but CNFY showed sites 
of inflammation, whereas the ileum of mice infected with the double mutant strain (YscS-, 
CNFY-) was not inflamed and appeared like the uninfected control group. This supports 
the hypothesis that CNFY induces inflammation in the host’s intestine, resulting in a 
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faster eradication of the single mutant strain without a functional T3SS compared to the 
double mutant strain without the toxin and the T3SS.  
Slightly higher amounts of the double mutant bacteria without the functional T3SS and 
CNFY in comparison to the single mutant without a functional T3SS were reisolated of 
the PP. However, the differences in inflammation seen in the histopathological analysis 
of the ileum were not displayed in the analysis of the immune response in the PP. No 
significant differences in the recruitment of immune cells could be detected upon 
infection. Reasons therefore could be that the (1) differences are too minor to detect or 
(2) the time point of investigation three days after infection is too early.  
4.6.1 CNFY causes long-lasting modulation of the immune cell 
contents in the spleen 
The detected bacterial loads of the cnfY mutant strain in the different organs indicated 
the necessity of CNFY for the effective colonization of the underlying tissues MLNs, 
spleen, and liver by Y. pseudotuberculosis YPIII. However, no difference could be 
detected between YPIII and a cnfY mutant in the colonization of the gut and gut-related 
tissues up to seven days after infection. So far, not much is known about persistence 
and long-term influence on the immune system after infection of mice with avirulent/low 
virulent Yersinia strains. A long-range infection with a cnfY mutant strain, a pYV-negative 
strain (e.g. without the T3SS and the Yop effector proteins), and a cnfY, pYV-negative 
mutant strain was performed in this study to measure a possible exclusive long-term 
effect of CNFY.  
The cnfY mutant strain could be reisolated of the caecum (not of the other tissues) of 
infected mice 28 days post infection. The pYV-negative mutant strains - with or without 
cnfY - were initially able to colonize, but could not persist over 28 days in the caecum. 
Hence, not cnfY but the virulence plasmid encoded genes are crucial for the persistence 
of the bacteria in detectable amounts over long time periods in the host’s intestine.  
Increased levels of the immune cells DCs, monocytes, NK cells, T cells, and B cells 
could be measured in the PP of mice infected with the different strains (pYV- CNFY+, 
pYV+ CNFY- and pYV- CNFY-) in comparison to uninfected mice. Yet, the measured 
immune responses showed no significant differences among the strains. These data 
indicated an ongoing immune reaction even though no bacteria were detectable in this 
tissue.  
Discussion 
 
 143 
However, the infection with the different avirulent/low virulent Yersinia strains resulted in 
different immune responses in the MLNs and spleens of the infected mice over a long 
period of infection. The MLNs contained slightly increased amounts of the immune cells 
upon infection with all tested strains (pYV- CNFY+, pYV+ CNFY- and pYV- CNFY-) when 
compared to uninfected MLNs. However, the increase of the immune cells (neutrophils, 
macrophages, DCs, monocytes, NK cells, and B cells) was most significant in the 
presence of CNFY and absence of the T3SS/Yop machinery. This leads to the 
hypothesis that CNFY could be immunogenic and has a long-term influence on the 
immune system independent of the T3SS machinery. The hypothesis is supported by a 
study, where the CNFY toxin of Y. pseudotuberculosis was administered subcutaneously 
to vaccinate mice. This vaccination entails immunity against a subsequent 
Y. pseudotuberculosis aerosol mouse infection (Mou et al., 2012). 
Since the splenic structure is mostly altered over long time periods, the spleen weights 
were recorded 28 days post infection to detect possible changes caused by necrosis or 
infiltrating immune cells. Significant differences in the spleen weights of uninfected and 
infected animals could be detected in the long-term infection. These data showed that 
the infection of mice with the strain harbouring CNFY but not pYV caused slightly 
reduced spleen weights, whereas the infection with the strain harbouring pYV but not 
CNFY caused significantly increased spleen weights, when compared to the spleen 
weights of uninfected mice. The spleen weights of mice infected with the double mutant, 
without pYV and CNFY, were significantly increased when compared to mice infected 
with the mutant harbouring CNFY, but not the Yop machinery. These effects could either 
be due to (1) long-term changes of the splenic structure by the secreted toxin or 
effectors, (2) an initially/ongoing infiltration of immune cells or (3) a bacterial colonization 
of the spleen below the detection limit.  
Most strikingly, CNFY seems to diminish the amount of immune cells in the spleen, as 
the infection with the strain carrying cnfY but not the virulence plasmid resulted in 
significantly reduced immune cells (neutrophils, macrophages, DCs, monocytes, NK 
cells, and B cells) 28 days post infection. This effect was not detected upon infection with 
the strains without the toxin, no matter whether the virulence plasmid (CNFY- pYV+/-) was 
present, proposing that the toxin caused the decreased amount of immune cells. 
Moreover, F4/80hi macrophages are resident macrophages of the spleen (Lloyd et al., 
2008), thus CNFY seems to eliminate the immune cells independently from the Yop 
machinery. Furthermore, the virulence plasmid of Y. pseudotuberculosis is crucial to 
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infect the systemic organs spleen and liver in the oral infection process (Balada-Llasat & 
Mecsas, 2006). Hence, the bacteria with CNFY, but without pYV are not able to reach 
the spleen, yet were shown to decrease the amount of residential immune cells in this 
organ, indicating that CNFY reaches the spleen independently from the presence of the 
bacteria. 
The toxin circulation could be via the blood, as it is described for other secreted bacterial 
toxins like the tetanus toxin of C. tetani (Schiavo et al., 2000). As described above, the 
toxin is secreted by an unknown mechanism and is able to increase the endothelial 
barrier permeability (Baumer et al., 2008), which could enable the toxin to enter the 
blood stream and circulate to the different tissues. It can be further hypothesized that the 
toxin induces the production of ROS, resulting in tissue damage. Additionally, data of this 
work indicate that CNFY is able to eliminate immune cells without the Yop delivery 
machinery. Since the homologous toxin CNF1 of E. coli was shown to induce necrosis of 
rabbit skin when injected subcutaneously (Caprioli et al., 1983), CNFY could have a 
similar effect in the spleen.  
The loss of cnfY was shown to cause an influx of immune cells into the spleen of the 
infected animals, resulting in splenomegaly, which was still measurable after 28 days of 
infection. Another avirulent enteropathogenic Yersinia strain also induces splenomegaly 
upon infection (Ruiz-Bravo et al., 2001). Further, it causes increased levels of CD3+ 
T cells, CD4+ helper T cells, CD8+ cytotoxic T cells, and CD11b+ phagocytic cells in the 
spleen, although the mice were not colonized, except for the feces. The phenomenon of 
fecal excretion without detectable bacteria colonization was described before for 
avirulent/low virulent enteropathogenic Yersinia strains (Kaneko & Hashimoto, 1983; 
Ricciardi et al., 1978). This prolonged bacteria shedding could be due to residing 
bacteria in the intestinal lumen like shown for L. monocytogenes, which is residing in the 
mucus (Travier et al., 2013). Hence, these residing bacteria could constantly stimulate 
the immune system, indicating a similar effect for the cnfY mutant strain, which is 
persisting in the caecum at least up to 28 days.  
The infection with the avirulent Y. enterocolitica strain resulted in a resistance against a 
subsequent Listeria monocytogenes infection (Ruiz-Bravo et al., 2001). Furthermore, 
another low virulent Y. pseudotuberculosis strain (IP32680, originated from hare 
infection), which was able to persist at least 14 days in the PP, the feces, and the MLNs 
of infected mice also induces immunity against Y. pestis infections (Blisnick et al., 2008). 
Discussion 
 
 145 
Moreover, a CNFY+ Y. pseudotuberculosis strain (IP2666) without the virulence plasmid 
is able to induce 100% immunity against an oral Y. pseudotuberculosis infection, 
whereas it induces only 50% immunity against an intraperitoneal or intranasal infection 
with Y. pseudotuberculosis, when administered six weeks prior infection (Balada-Llasat 
et al., 2007). Hence, it can be hypothesized that the tested avirulent/low virulent 
Y. pseudotuberculosis strains of this study (pYV- CNFY+, pYV+ CNFY- and pYV- CNFY-) 
could presumably also be applied as live attenuated vaccines as these were 
demonstrated to have long-term effects on the immune system. 
However, the strain without the virulence plasmid, which secretes CNFY is probably not 
the best choice for a live attenuated vaccine, as it was shown to diminish the immune 
cell contents in the spleen. A cnfY mutant with the virulence plasmid also is probably not 
the best alternative because it still causes mild symptoms of disease at the early 
infection and is able to persist over long periods in the host. The latter could cause a 
chronic infection or ongoing reinfections. Taken together, the best option for a live 
attenuated vaccine against more virulent pathogens is probably the strain lacking both, 
the cnfY gene and pYV. This strain was shown to trigger the immune response in the PP 
and MLNs without causing symptoms of disease and to be unable to efficiently persist in 
the tissues as no detectable amounts of bacteria where found after long periods of 
infection. 
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5 Outlook 
CNFY was demonstrated to be an important virulence factor for Y. pseudotuberculosis 
YPIII, as it diminishes the immune cell amounts in the spleen by enhancing the 
translocation of Yop effector proteins into professional phagocytes and to a lesser extent 
also independent of the virulence plasmid and the bacteria. 
Further experiments could focus on the aspect of CNFY-induced inflammation. Extensive 
studies on the activation of the inflammasome and the induced signaling pathways could 
be conducted. In addition, intra-peritoneal or subcutaneous injection of the purified CNFY 
toxin would provide information about the transport mechanism of the toxin in the host 
and the consequences of intoxication - regardless of the Yop machinery and presence of 
the bacteria - for a better understanding of the mode of action of this toxin. 
Histopathological and immune response analyses of intoxicated mice should be 
performed.  
Moreover, regulation of the cnfY expression, as well as the secretion mechanism of the 
toxin needs to be unravelled. Another important task for later studies would be to identify 
the cellular receptor of CNFY on the eukaryotic cells, in order to detect those cells 
preferably approached by the toxin.  
Furthermore, the effects of long-term changes of the immune response caused by 
infections with different avirulent/low virulent Y. pseudotuberculosis strains (pYV-, ∆cnfY 
or ∆cnfY pYV-) could be evaluated. These strains might be suitable to apply as live 
attenuated vaccines. A subsequent reinfection with Y. pseudotuberculosis or other 
pathogenic bacteria would reveal if immunity was achieved. Furthermore, mechanisms 
of persistence and induction of chronic infection with long-term effects (e.g. arthritis) 
would be interesting to analyze.  
A comparison regarding the cnfY expression pattern, and impact on the virulence of 
different Y. pseudotuberculosis wild-type strains (CNFY+/CNFY- & PhoP+/PhoP-) could 
provide some indications about advantages/disadvantages for the bacteria by 
harbouring the functional toxin gene. Mimicking a naturally occurring horizontal gene-
transfer by bacteria, the cnfY gene could be integrated into the genome of other CNFY-
negative pathogens. Possible effects for the pathogens could be examined, like an 
enhanced virulence and thus potentially resulting consequences for the population if a 
gene-transfer would occur naturally.  
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6 Summary 
Several bacteria express various toxins to manipulate eukaryotic cells to their 
advantage. Some Y. pseudotuberculosis isolates produce the cytotoxic necrotizing 
factor CNFY, which constitutively activates small Rho-GTPases, important molecular 
switches regulating different cellular functions. However, the role of CNFY in host-
pathogen interaction during infection was unknown. 
Data of this study demonstrated that the cnfY gene of Y. pseudotuberculosis is 
temperature-, growth-phase-, and nutrient-dependently regulated and highly expressed 
in all lymphatic tissues of orally infected mice. Additionally, CNFY is secreted and 
induces rearrangements of the actin cytoskeleton and the formation of giant, 
multinucleated cells by activation of the GTPases RhoA, Rac1, and Cdc42 in epithelial 
cells and macrophages.  
Moreover, the deletion of cnfY leads to an avirulent phenotype of Y. pseudotuberculosis. 
The cnfY mutant strain reaches the underlying tissues MLNs, spleen, and liver, but the 
infection is rapidly cleared three to five days post infection. Presence of CNFY stimulates 
an acute inflammatory response and induces the formation of necrotic areas in the 
lymphatic tissues. The secretion of CNFY resulted in a strong reduction of professional 
phagocytes and NK cells, especially in the spleen, whereas the loss of CNFY caused a 
strong influx of these cells, accompanied by rapid killing of the bacteria. Further, CNFY 
was shown to enhance Yop delivery, mostly by RhoA activation, into eukaryotic cells in 
vitro and during the course of infection. This resulted in an increased ability of the 
bacteria to defend themselve against the host immune system. Moreover, CNFY seems 
to play an additional role during late stages of the infection, as the toxin is sufficient to 
reduce immune cell contents in the spleen independent of the virulence plasmid even 
when the number of residing bacteria is very low.  
In summary, the data of this study identified CNFY as an important Rho-GTPase-
activating toxin, crucial for virulence of Y. pseudotuberculosis YPIII. This toxin is 
essential for the establishment of a successful infection and determines the severity of 
the associated disease by modulating the inflammatory response. 
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Figure S1: Microcolonies of Y. pseudotuberculosis in the spleen. 
Groups of 3 BALB/c mice were infected orally with 2 x 108 bacteria of Y. pseudotuberculosis YPIII of YP147 
(∆cnfY), harbouring the plasmid pFU228 (PgapA::dsRed2). Three days post infection, the mice were 
sacrificed and the spleen isolated. Cryosections (6 µm) have been prepared and analyzed by fluorescence 
microscopy. Sections were screened for bacteria expressing the reporter protein DsRed2. White bars 
indicate 20 µm. 
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Figure S2: Gating strategies for immune cell contents in PP, MLNs, and spleen after infection with 
Y. pseudotuberculosis YPIII or YP147 (∆cnfY). 
Exemplary gating strategies of splenocytes from YP147 (∆cnfY)-infected mice at day three post infection. 
(A) Lymphoid panel: T cells (CD19-CD3+), B cells (CD19+CD3-), NK cells (CD19-CD3-NKp46+). (B) Myeloid 
panel: neutrophils (CD49b-CD19-CD3-Ly-6G+CD11b+), DCs (CD49b-CD19-CD3-Ly-6G-CD11b-Ly-6C-
CD11c+), macrophages/monocytes (CD49b-CD19-CD3-Ly-6G-CD11c-CD11b+). 
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Figure S3: CNFY modulates the host immune response in the infected mice.  
Groups of 5 - 6 BALB/c mice were infected orally with 2 x 108 bacteria of Y. pseudotuberculosis YPIII or 
YP147 (∆cnfY). Three days after infection, mice were sacrificed and organs (PP, MLNs, and spleen) 
isolated. Prepared cell suspensions were stained with fluorescently labeled antibodies to detect the 
different immune cells with flow cytometry: neutrophils (CD11b+/Ly6G+), macrophages/monocytes 
(CD11b+Ly6G-), DCs (CD11c+), NK cells (NKp46+), B cells (CD19+), and T cells (CD3+). Data plotted on the 
y axis indicate the percentages of the different immune cells isolated from uninfected, YPIII-infected or 
YP147 (∆cnfY)-infected organs as the absolute cell amounts in the organs could differ due to tissue 
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damage or splenomegaly. Scatter dot plots show the median of two independent experiments for (A) PP, 
(B) MLNs, and (C) spleen. For statistical analysis, a Mann-Whitney test was applied to determine 
significant differences in the numbers of indicated cell types in the whole organ between YPIII-infected, 
YP147 (∆cnfY)-infected or uninfected mice. Asterisks indicate the significances, with * (P<0.05), ** (P<0.01) 
and *** (P<0.001).  
 
 
 
Figure S4: Gating strategies for the analysis of CNFY impact on Yop delivery. 
Exemplary gating strategies of MLNs cells of YPIII-ETEM infected mice at day three post infection. Isolated 
cells were stained with fluorescently labeled antibodies and additional subjected to CCF4-AM treatment. 
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Living cells are „green“, Yop translocated cells are „blue“. (A) T cells (CD19-CD3+), B cells (CD19+CD3-), 
neutrophils (CD19-CD3-Ly-6G+CD11b+), DCs (CD19-CD3-CD11c+), macrophages/monocytes (CD49b-
CD19-CD3-Ly-6G-CD11b+) (B) NK cells (CD19-CD3-NKp46+). 
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Figure S5: Deletion of cnfY diminishes Yop delivery predominantly into neutrophils, macrophages 
and DCs in MLNs and spleen in vivo.  
Groups of 6 - 8 BALB/c mice were infected orally with 2 x 109 bacteria of Y. pseudotuberculosis YPIII-
ETEM (YP173), YP147 (∆cnfY)-ETEM (YP217), YPIII or YP101 (∆yscS)-ETEM (YP174). Three days after 
infection, mice were sacrificed and the organs (PP, MLNs, and spleen) isolated. Prepared cell suspensions 
were stained with fluorescently labeled antibodies to detect the different immune cells with flow cytometry: 
neutrophils (Gr1+/CD11b+), macrophages (CD11b+), DCs (CD11c+), NK cells (NKp46+), B cells (CD19+), 
and T cells (CD3+). Subsequently, cells were additionally dyed using CCF4-AM. The percentage of blue 
cells was analyzed by multi-colour flow cytometry of two independent experiments. (A) Percentages of blue 
(translocated) cells among living cells of PP, MLNs, and spleen of mice infected with YPIII-ETEM (YP173) 
or YP147 (∆cnfY)-ETEM (YP217) are illustrated. (B) Percentages of blue (translocated) cells among 
different living immune cell subsets of MLNs and spleen of mice infected with YPIII-ETEM (YP173) or 
YP147 (∆cnfY)-ETEM (YP217) are illustrated. For statistical analysis, a Mann-Whitney test was applied to 
determine significant differences in translocation in (A) the different organs and (B) cell types between 
YPIII-ETEM (YP173)- and YP147 (∆cnfY)-ETEM (YP217)-infected mice. Asterisks indicate the 
significances, with * (P<0.05), ** (P<0.01) and *** (P<0.001). 
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Figure S6: Gating strategies for immune cell contents in PP, MLNs, and spleen after infection with 
different Y. pseudotuberculosis strains. 
Exemplary gating strategies of splenocytes from uninfected mice at day three post infection. (A) Lymphoid 
panel: T cells (CD19-CD3+), T helper cells (CD3+CD4+), cytotoxic T cells (CD3+CD8+) B cells (CD19+CD3-), 
NK cells (CD19-CD3-NKp46+). (B) Myeloid panel: neutrophils (Lin-Ly-6G+CD11b+), macrophages (Lin-Ly-
6G-pDC-F4/80hi), DCs (Lin-Ly-6G-pDC-F4/80-CD11c+), monocytes (Lin-Ly-6G-pDC-F4/80-CD11c-CD11b+Ly-
6C+). Lin (lineage) = CD3+CD19+CD49b+; pDC (plasmacytoid dendritic cells) = Ly-6C+B220+. 
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